

STN Columbus

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/Capplus enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/Capplus Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/Capplus enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/Capplus enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 27 CA/Capplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20 JUN 29 STN Viewer now available
NEWS 21 JUN 29 STN Express, Version 8.2, now available
NEWS 22 JUL 02 LEMBASE coverage updated
NEWS 23 JUL 02 LMEDLINE coverage updated
NEWS 24 JUL 02 SCISEARCH enhanced with complete author names
NEWS 25 JUL 02 CHEMCATS accession numbers revised
NEWS 26 JUL 02 CA/Capplus enhanced with utility model patents from China
NEWS 27 JUL 16 Capplus enhanced with French and German abstracts
NEWS 28 JUL 18 CA/Capplus patent coverage enhanced
NEWS 29 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 30 JUL 30 USGENE now available on STN

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 00:27:02 ON 06 AUG 2007

=> file medline
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 00:27:15 ON 06 AUG 2007

FILE LAST UPDATED: 5 Aug 2007 (20070805/UP). FILE COVERS 1950 TO DATE.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s sulfonamide?
L1      27268 SULFONAMIDE?

=> s (diabete?)
L2      252380 (DIABETE?)

=> s (obesity or obese or weight reduct? or weight gain)
      97704 OBESITY
      39234 OBESE
      591509 WEIGHT
      615438 REDUCT?
      4406 WEIGHT REDUCT?
      (WEIGHT(W)REDUCT?)
      591509 WEIGHT
      89472 GAIN
      32433 WEIGHT GAIN
      (WEIGHT(W)GAIN)
L3      136295 (OBESITY OR OBESE OR WEIGHT REDUCT? OR WEIGHT GAIN)

=> s l1 and l2
L4      658 L1 AND L2

=> s l1 and l3
L5      121 L1 AND L3
```

```
=> s l4 650-658
MISSING OPERATOR L4 650-658
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
```

```
=> d l4 650-658
```

```
L4      ANSWER 650 OF 658      MEDLINE on STN
Full Text
AN      56058908      MEDLINE
DN      PubMed ID: 13306553
TI      ORALLY given antidiabetic sulfonamide compounds.
AU      Anonymous
SO      Journal of the American Medical Association, (1956 Apr 14) Vol. 160, No.
      15, pp. 1320-1.
      Journal code: 7507176. ISSN: 0002-9955.
DT      Journal; Article; (JOURNAL ARTICLE)
LA      English
FS      OLDMEDLINE; NONMEDLINE
OS      CLML5630-14763
EM      200305
ED      Entered STN: Feb 2004
      Last Updated on STN: Feb 2004
      Entered Medline: 1 May 2003

L4      ANSWER 651 OF 658      MEDLINE on STN
Full Text
AN      56058895      MEDLINE
DN      PubMed ID: 13306540
TI      Clinical experiences with carbutamide, an orally given hypoglycemic agent;
      preliminary report.
AU      RIDOLFO A S; KIRTLEY W R
SO      Journal of the American Medical Association, (1956 Apr 14) Vol. 160, No.
      15, pp. 1285-8.
      Journal code: 7507176. ISSN: 0002-9955.
DT      Journal; Article; (JOURNAL ARTICLE)
LA      English
FS      OLDMEDLINE; NONMEDLINE
OS      CLML5630-14750
EM      200305
ED      Entered STN: Feb 2004
      Last Updated on STN: Feb 2004
      Entered Medline: 1 May 2003
```

L4 ANSWER 652 OF 658 MEDLINE on STN

Full Text

AN 56056667 MEDLINE
DN PubMed ID: 13304316
TI SULPHONAMIDE compounds for **diabetes**.
AU Anonymous
SO British medical journal, (1956 Mar 31) Vol. 1, No. 4969, pp. 733-4.
Journal code: 0372673. ISSN: 0007-1447.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5630-12522
EM 200305
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2003

L4 ANSWER 653 OF 658 MEDLINE on STN

Full Text

AN 56049164 MEDLINE
DN PubMed ID: 13296878
TI Hypoglycemic effects of 1-butyl-3-p-toluene sulfonylurea given orally in human diabetic subjects; a preliminary report.
AU MILLER M; CRAIG J W
SO Metabolism: clinical and experimental, (1956 Mar) Vol. 5, No. 2, pp. 162-4.
Journal code: 0375267. ISSN: 0026-0495.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5630-5019
EM 200305
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2003

L4 ANSWER 654 OF 658 MEDLINE on STN

Full Text

AN 56049118 MEDLINE
DN PubMed ID: 13296832
TI [New possibilities in the therapy of **diabetes**; critical report on an oral antidiabetic drug].
Neue Moglichkeiten in der **Diabetestherapie**; kritischer Bericht uber ein orales Antidiabeticum.
AU STEIGERWALDT F
SO Medizinische Monatsschrift, (1955 Dec) Vol. 9, No. 12, pp. 793-5.
Journal code: 0375265. ISSN: 0025-8474.
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS OLDMEDLINE; NONMEDLINE
OS CLML5630-4973
EM 200305
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2003

L4 ANSWER 655 OF 658 MEDLINE on STN

Full Text

AN 56013651 MEDLINE
DN PubMed ID: 13261733
TI [An effective peroral anti-diabetic drug (BZ 55)].
Uber ein wirksames perorales Anti-diabeticum (BZ 55).
AU BERTRAM F; BENDFELDT E; OTTO H
SO Deutsche medizinische Wochenschrift (1946), (1955 Oct 7) Vol. 80, No. 40, pp. 1455-60.
Journal code: 0006723. ISSN: 0012-0472.
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS OLDMEDLINE; NONMEDLINE
OS CLML5629-13651
EM 200305
ED Entered STN: Feb 2004

Last Updated on STN: Feb 2004
Entered Medline: 1 May 2003

L4 ANSWER 656 OF 658 MEDLINE on STN

Full Text

AN 56013649 MEDLINE
DN PubMed ID: 13261731
TI [A new anti-**diabetes** principle; results of clinical research].
Ein neues antidiabetisches Prinzip; Ergebnisse klinischer Untersuchungen.
AU FRANKE H; FUCHS J
SO Deutsche medizinische Wochenschrift (1946), (1955 Oct 7) Vol. 80, No. 40,
pp. 1449-52.
Journal code: 0006723. ISSN: 0012-0472.
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS OLDMEDLINE; NONMEDLINE
OS CLML5629-13649
EM 200305
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2003

L4 ANSWER 657 OF 658 MEDLINE on STN

Full Text

AN 53097475 MEDLINE
DN PubMed ID: 13072458
TI [Antidiuretic effect in **diabetes** insipidus after p-carboxy-benzolsulfo-
di-n-butylamide (longacid)].
Antidiuretischer Effekt bei **Diabetes** insipidus nach p-Carboxy-
benzolsulfo-di-n-butylamid (Longacid).
AU BACHMANN H
SO Munchener medizinische Wochenschrift (1950), (1953 May 15) Vol. 95, No.
20, pp. 582-4.
Journal code: 7801802. ISSN: 0027-2973.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5324-43162-189-631
EM 200305
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2003

L4 ANSWER 658 OF 658 MEDLINE on STN

Full Text

AN 51089159 MEDLINE
DN PubMed ID: 14859609
TI [**Sulfonamides** and experimental **diabetes**].
Sulfamides et **diabete** experimental.
AU MENDES ALVES M A
SO Comptes rendus des seances de la Societe de biologie et de ses filiales,
(1951 Apr) Vol. 145, No. 7-8, pp. 604-6.
Journal code: 7505439. ISSN: 0037-9026.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5120-93113-262-341
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

=> d l4 an ti so ab kwic 658

L4 ANSWER 658 OF 658 MEDLINE on STN

Full Text

AN 51089159 MEDLINE
TI [**Sulfonamides** and experimental **diabetes**].
Sulfamides et **diabete** experimental.
SO Comptes rendus des seances de la Societe de biologie et de ses filiales,
(1951 Apr) Vol. 145, No. 7-8, pp. 604-6.

Journal code: 7505439. ISSN: 0037-9026.
 TI [Sulfonamides and experimental diabetes].
 Sulfamides et diabete experimental.
 ST diabetes mellitus; sulfonamides
 CT *Diabetes Mellitus
 *Sulfonamides
 CN 0 (Sulfonamides)

=> d 14 640-650

L4 ANSWER 640 OF 658 MEDLINE on STN

Full Text

AN 56079336 MEDLINE
 DN PubMed ID: 13326744
 TI [Clinical experience with the oral antidiabetic remedy invenol].
 Klinische Erfahrungen mit dem peroralen Antidiabeticum Invenol.
 AU SCHNEEWEISS J; GASSMANN W; BUDING A
 SO rztliche Wochenschrift, (1956 Mar 23) Vol. 11, No. 12, pp. 266-8.
 Journal code: 14640350R. ISSN: 0365-6403.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5630-35191
 EM 200305
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2003

L4 ANSWER 641 OF 658 MEDLINE on STN

Full Text

AN 56075452 MEDLINE
 DN PubMed ID: 13322970
 TI Ineffectiveness of sulfonylureas in alloxan diabetic rats.
 AU MIRSKY I A; PERISUTTI G; JINKS R
 SO Proceedings of the Society for Experimental Biology and Medicine. Society
 for Experimental Biology and Medicine (New York, N.Y.), (1956 Mar) Vol.
 91, No. 3, pp. 475-7.
 Journal code: 7505892. ISSN: 0037-9727.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5630-31307
 EM 200305
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2003

L4 ANSWER 642 OF 658 MEDLINE on STN

Full Text

AN 56073966 MEDLINE
 DN PubMed ID: 13321484
 TI [Preliminary experiences with the sulfonamide nadisan in therapy of
 diabetes].
 Vorlaufige Erfahrungen bei der peroralen Behandlung des Diabetes mit dem
 Sulfonamid Nadisan.
 AU BROGLIE M; VOSS G; BERG E G; RUHLING O
 SO Die Medizinische, (1956 Apr 28) No. 17, pp. 656-9.
 Journal code: 18630160R. ISSN: 0342-1147.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5630-29821
 EM 200305
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2003

L4 ANSWER 643 OF 658 MEDLINE on STN

Full Text

AN 56071958 MEDLINE
 DN PubMed ID: 13319476

TI Insulin-sparing **sulfonamides**.
 AU KINSELL L W; BROWN F R Jr; FRISKEY R W; MICHAELS G D
 SO The Journal of clinical endocrinology and metabolism, (1956 Jun) Vol. 16,
 No. 6, pp. 821-9.
 Journal code: 0375362. ISSN: 0021-972X.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5630-27813
 EM 200305
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2003

L4 ANSWER 644 OF 658 MEDLINE on STN
Full Text
 AN 56070088 MEDLINE
 DN PubMed ID: 13317606
 TI [The Langerhans islands of diabetics after treatment with the oral
 antidiabetic, BZ 55].
 Die Langerhansschen Inseln von Diabetikern nach Behandlung mit dem oralen
 Antidiabetikum BZ 55.
 AU FERNER H; RUNGE W
 SO Deutsche medizinische Wochenschrift (1946), (1956 Mar 9) Vol. 81, No. 10,
 pp. 331-3.
 Journal code: 0006723. ISSN: 0012-0472.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5630-25943
 EM 200305
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2003

L4 ANSWER 645 OF 658 MEDLINE on STN
Full Text
 AN 56070077 MEDLINE
 DN PubMed ID: 13317595
 TI [Indications and successes of peroral treatment of **diabetes** mellitus
 with a sulfonylurea derivative; report on 335 cases].
 Indikationen und Erfolge der peroralen Behandlung des **Diabetes** mellitus
 mit einem Sulfonylharnstoffderivat; Bericht uber 335 Falle.
 AU BERTRAM F; BENDFELDT E; OTTO H
 SO Deutsche medizinische Wochenschrift (1946), (1956 Feb 24) Vol. 81, No. 8,
 pp. 274-8.
 Journal code: 0006723. ISSN: 0012-0472.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5630-25932
 EM 200305
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2003

L4 ANSWER 646 OF 658 MEDLINE on STN
Full Text
 AN 56064157 MEDLINE
 DN PubMed ID: 13311777
 TI [BZ-55, a peroral antidiabetic remedy with a possible glucagon-restraining
 effect].
 Om BZ 55, ett peroralt antidiabetikum med sannolikt glukagonhammande
 effekt.
 AU ANDERSSON B
 SO Svenska lakartidningen, (1956 Jan 13) Vol. 53, No. 2, pp. 57-64.
 Journal code: 0030130.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA Swedish
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5630-20012
 EM 200305

ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2003

L4 ANSWER 647 OF 658 MEDLINE on STN

Full Text

AN 56063643 MEDLINE
DN PubMed ID: 13311263
TI [Antidiabetic effect of a new **sulfonamide**].
Sull'azione antidiabetica di un nuovo **s** sulfamidico.
AU TOLOMELLI E; PELLEGRINI R; POPPI A
SO La Riforma medica, (1956 Feb 18) Vol. 70, No. 7, pp. 180-3.
Journal code: 0404345. ISSN: 0035-5259.
DT Journal; Article; (JOURNAL ARTICLE)
LA Italian
FS OLDMEDLINE; NONMEDLINE
OS CLML5630-19498
EM 200305
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2003

L4 ANSWER 648 OF 658 MEDLINE on STN

Full Text

AN 56061357 MEDLINE
DN PubMed ID: 13309002
TI [Treatment of **diabetes** with a new orally administered drug; preliminary report].
Terapia antidiabetica per via orale; nota preventiva su un nuovo medicamento.
AU MASSOBRIO E; BOGLIONE G
SO Minerva medica, (1956 Jan 31) Vol. 47, No. 9, pp. 273-6.
Journal code: 0400732. ISSN: 0026-4806.
DT Journal; Article; (JOURNAL ARTICLE)
LA English; Italian
FS OLDMEDLINE; NONMEDLINE
OS CLML5630-17212
EM 200305
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2003

L4 ANSWER 649 OF 658 MEDLINE on STN

Full Text

AN 56061356 MEDLINE
DN PubMed ID: 13309001
TI [Hypoglycemic effect of various sulfamides administered orally; treatment of **diabetes** mellitus with BZ 55].
Sull'azione ipoglicemizzante di taluni sulfamidici per via orale; a proposito della terapia del **diabete** mellito con il BZ 55.
AU SCALABRINO R; PASQUARIELLO G
SO Minerva medica, (1956 Jan 31) Vol. 47, No. 9, pp. 270-3.
Journal code: 0400732. ISSN: 0026-4806.
DT Journal; Article; (JOURNAL ARTICLE)
LA Italian
FS OLDMEDLINE; NONMEDLINE
OS CLML5630-17211
EM 200305
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2003

L4 ANSWER 650 OF 658 MEDLINE on STN

Full Text

AN 56058908 MEDLINE
DN PubMed ID: 13306553
TI ORALLY given antidiabetic **sulfonamide** compounds.
AU Anonymous
SO Journal of the American Medical Association, (1956 Apr 14) Vol. 160, No. 15, pp. 1320-1.
Journal code: 7507176. ISSN: 0002-9955.
DT Journal; Article; (JOURNAL ARTICLE)

LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5630-14763
EM 200305
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2003

=> d 14 an ti so ab kwic 650

L4 ANSWER 650 OF 658 MEDLINE on STN
Full Text
AN 56058908 MEDLINE
TI ORALLY given antidiabetic **sulfonamide** compounds.
SO Journal of the American Medical Association, (1956 Apr 14) Vol. 160, No. 15, pp. 1320-1.
Journal code: 7507176. ISSN: 0002-9955.
TI ORALLY given antidiabetic **sulfonamide** compounds.
ST **diabetes mellitus - therapy; sulfonamide mixtures - therapeutic use**
CT ***Diabetes Mellitus: TH, therapy**
***Sulfonamides: TU, therapeutic use**
CN 0 (Sulfonamides)

=> d 14 an ti so ab kwic 649

L4 ANSWER 649 OF 658 MEDLINE on STN
Full Text
AN 56061356 MEDLINE
TI [Hypoglycemic effect of various sulfamides administered orally; treatment of **diabetes mellitus** with BZ 55].
Sull'azione ipoglicemizzante di taluni sulfamidici per via orale; a proposito della terapia del **diabete mellito** con il BZ 55.
SO Minerva medica, (1956 Jan 31) Vol. 47, No. 9, pp. 270-3.
Journal code: 0400732. ISSN: 0026-4806.
TI [Hypoglycemic effect of various sulfamides administered orally; treatment of **diabetes mellitus** with BZ 55].
Sull'azione ipoglicemizzante di taluni sulfamidici per via orale; a proposito della terapia del **diabete mellito** con il BZ 55.
ST **diabetes mellitus - therapy; sulfonamides - therapeutic use; urea - derivatives**
CT ***Diabetes Mellitus: TH, therapy**
***Sulfonamides: TU, therapeutic use**
***Urea: AA, analogs & derivatives**
CN 0 (Sulfonamides)

=> d 14 550-558

L4 ANSWER 550 OF 658 MEDLINE on STN
Full Text
AN 57024596 MEDLINE
DN PubMed ID: 13378442
TI [BZ 55 of D 860 as oral antidiabetic].
Zur Frage der Anwendung von BZ 55 oder D 860 als orales Antidiabetikum.
AU MEHNERT B; MEHNERT H
SO Munchener medizinische Wochenschrift (1950), (1956 Sep 28) Vol. 98, No. 39, pp. 1325-8.
Journal code: 7801802. ISSN: 0027-2973.
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS OLDMEDLINE; NONMEDLINE
OS CLML5731-24873
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 551 OF 658 MEDLINE on STN
Full Text
AN 57024221 MEDLINE

DN PubMed ID: 13378067
TI Clinical experience with carbutamide and tolbutamide.
AU COHN C; HEINEMAN A; LEVINE R; WEINSTEIN M
SO Metabolism: clinical and experimental, (1956 Nov) Vol. 5, No. 6 Part 2,
pp. 972-7.
Journal code: 0375267. ISSN: 0026-0495.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5731-24498
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 552 OF 658 MEDLINE on STN

Full Text

AN 57024220 MEDLINE
DN PubMed ID: 13378066
TI Methods of selection of diabetic patients sensitive to sulfonylurea
compounds.
AU DUNCAN G G; JOINER C L; LEE C T
SO Metabolism: clinical and experimental, (1956 Nov) Vol. 5, No. 6 Part 2,
pp. 964-71.
Journal code: 0375267. ISSN: 0026-0495.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5731-24497
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 553 OF 658 MEDLINE on STN

Full Text

AN 57024219 MEDLINE
DN PubMed ID: 13378065
TI Metabolic studies with the arylsulfonylureas.
AU KUHL W J Jr
SO Metabolism: clinical and experimental, (1956 Nov) Vol. 5, No. 6 Part 2,
pp. 953-63.
Journal code: 0375267. ISSN: 0026-0495.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5731-24496
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 554 OF 658 MEDLINE on STN

Full Text

AN 57024218 MEDLINE
DN PubMed ID: 13378064
TI Clinical experience with orinase.
AU DOLGER H
SO Metabolism: clinical and experimental, (1956 Nov) Vol. 5, No. 6 Part 2,
pp. 947-52.
Journal code: 0375267. ISSN: 0026-0495.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5731-24495
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 555 OF 658 MEDLINE on STN

Full Text

AN 57024217 MEDLINE
 DN PubMed ID: 13378063
 TI Clinical experience with orinase.
 AU DUBE A H; FULMER H S; LLOYD C W
 SO Metabolism: clinical and experimental, (1956 Nov) Vol. 5, No. 6 Part 2,
 pp. 940-6.
 Journal code: 0375267. ISSN: 0026-0495.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5731-24494
 EM 200205
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2002

L4 ANSWER 556 OF 658 MEDLINE on STN

Full Text

AN 57024216 MEDLINE
 DN PubMed ID: 13378062
 TI The use of orinase in **diabetes**.
 AU BEASER S B
 SO Metabolism: clinical and experimental, (1956 Nov) Vol. 5, No. 6 Part 2,
 pp. 933-9.
 Journal code: 0375267. ISSN: 0026-0495.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5731-24493
 EM 200205
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2002

L4 ANSWER 557 OF 658 MEDLINE on STN

Full Text

AN 57024215 MEDLINE
 DN PubMed ID: 13378061
 TI Some clinical experiences with the arylsulfonyleureas in the management of
diabetes mellitus.
 AU ERK V; HAAR H; MCGAVACK T H; SEEGER S W
 SO Metabolism: clinical and experimental, (1956 Nov) Vol. 5, No. 6 Part 2,
 pp. 919-32.
 Journal code: 0375267. ISSN: 0026-0495.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5731-24492
 EM 200205
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2002

L4 ANSWER 558 OF 658 MEDLINE on STN

Full Text

AN 57024214 MEDLINE
 DN PubMed ID: 13378060
 TI Experience with orinase in the management of adult **diabetes**.
 AU BRAVERMAN A E; DREY N W; SHERRY S
 SO Metabolism: clinical and experimental, (1956 Nov) Vol. 5, No. 6 Part 2,
 pp. 911-8.
 Journal code: 0375267. ISSN: 0026-0495.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5731-24491
 EM 200205
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2002

=> d 14 400-420

L4 ANSWER 400 OF 658 MEDLINE on STN

Full Text

AN 58025053 MEDLINE
DN PubMed ID: 13482358
TI [Sulfonamides in the treatment of diabetes mellitus].
Sulfonamidi u terapiji dijabetesa melitusa.
AU TRGO A; GJURIC-JAKOPEC Z
SO Lijec nic ki vjesnik, (1957 Mar-Apr) Vol. 79, No. 3-4, pp. 100-9.
Journal code: 0074253. ISSN: 0024-3477.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5833-25303-42
EM 200007
ED Entered STN: 25 Aug 2000
Last Updated on STN: 25 Aug 2000
Entered Medline: 1 Jul 2000

L4 ANSWER 401 OF 658 MEDLINE on STN

Full Text

AN 58010609 MEDLINE
DN PubMed ID: 13467939
TI [Treatment of diabetes with hypoglycemic sulfonamides].
Le traitement du diabete par les sulfonamides hypoglycemiantes.
AU DARNAUD C; DENARD Y; MOREAU G; VOISIN R; COMBES P F
SO Toulouse medical, (1957 Apr) Vol. 58, No. 4, pp. 301-11.
Journal code: 0035523. ISSN: 0372-042X.
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS OLDMEDLINE; NONMEDLINE
OS CLML5833-10611-42
EM 200007
ED Entered STN: 25 Aug 2000
Last Updated on STN: 25 Aug 2000
Entered Medline: 1 Jul 2000

L4 ANSWER 402 OF 658 MEDLINE on STN

Full Text

AN 58009399 MEDLINE
DN PubMed ID: 13466729
TI [Acromegalic diabetes; onychia & paronychia treated by hypoglycemic sulfonamides].
Diabete acromegalique, onyxis et perionyxis traites par sulfamides hypoglycemiants.
AU DENEFF W
SO Revue medicale de Liege, (1957 Sep 15) Vol. 12, No. 18, pp. 499-501.
Journal code: 0404317. ISSN: 0370-629X.
DT (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LA French
FS OLDMEDLINE; NONMEDLINE
OS CLML5833-9399-6-42-154-378
EM 200007
ED Entered STN: 25 Aug 2000
Last Updated on STN: 25 Aug 2000
Entered Medline: 1 Jul 2000

L4 ANSWER 403 OF 658 MEDLINE on STN

Full Text

AN 58009019 MEDLINE
DN PubMed ID: 13466360
TI [General concept concerning the use of oral hypoglycemic sulfonamides in the treatment of diabetes mellitus].
Concepto general acerca del empleo de las sulfamidas hipoglucemiantes por via oral en el tratamiento de la diabetes sacarina.
AU CABARROU A; CAINO H V
SO Revista clinica espanola, (1957 May 31) Vol. 65, No. 4, pp. 265-8.
Journal code: 8608576. ISSN: 0014-2565.
DT Journal; Article; (JOURNAL ARTICLE)
LA Spanish

FS OLDMEDLINE; NONMEDLINE
OS CLML5833-9019-42
EM 200007
ED Entered STN: 25 Aug 2000
Last Updated on STN: 25 Aug 2000
Entered Medline: 1 Jul 2000

L4 ANSWER 404 OF 658 MEDLINE on STN

Full Text

AN 58008761 MEDLINE
DN PubMed ID: 13466102
TI [Clinical aspects and considerations on the treatment of **diabetes** mellitus with **sulfonamides**].
Aspetti e riflessi clinici del trattamento del **diabete** mellito con solfonamidi.
AU CERESA F; VITELLI A
SO Rassegna di fisiopatologia clinica e terapeutica, (1957 May) Vol. 29, No. 5, pp. 555-82.
Journal code: 0401262. ISSN: 0033-9520.
DT Journal; Article; (JOURNAL ARTICLE)
LA Italian
FS OLDMEDLINE; NONMEDLINE
OS CLML5833-8761-41
EM 200007
ED Entered STN: 25 Aug 2000
Last Updated on STN: 25 Aug 2000
Entered Medline: 1 Jul 2000

L4 ANSWER 405 OF 658 MEDLINE on STN

Full Text

AN 58002290 MEDLINE
DN PubMed ID: 13459635
TI [Results of hypoglycemicizing **sulfonamide** therapy of **diabetes** mellitus].
Risultati conseguiti con i sulfamidici ipoglicemizzanti nelle varie forme di **diabete** mellito.
AU BASSI M; DETTI S
SO Archivio di medicina interna, (1956 Sep-Oct) Vol. 8, No. 5, pp. 135-42.
Journal code: 0421741. ISSN: 0004-010X.
DT Journal; Article; (JOURNAL ARTICLE)
LA Italian
FS OLDMEDLINE; NONMEDLINE
OS CLML5833-2290-42
EM 200007
ED Entered STN: 25 Aug 2000
Last Updated on STN: 25 Aug 2000
Entered Medline: 1 Jul 2000

L4 ANSWER 406 OF 658 MEDLINE on STN

Full Text

AN 57103292 MEDLINE
DN PubMed ID: 13456509
TI [Hepatotoxic effect of chronic oral administration of **sulfonamide** in therapy of **diabetes** mellitus].
Zur Frage der Hepatotoxischen Wirkung chronischer sulfonamidgaben im Rahmen der oralen **Diabetestherapie**.
AU QUITZOW G; SPIES R; WUNDRAK-WALDHEIM G
SO Wiener medizinische Wochenschrift (1946), (1957 Jun 1) Vol. 107, No. 22, pp. 464-6.
Journal code: 8708475. ISSN: 0043-5341.
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS OLDMEDLINE; NONMEDLINE
OS CLML5732-54848
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 407 OF 658 MEDLINE on STN

Full Text

AN 57103250 MEDLINE
DN PubMed ID: 13456467

TI [Optic nerve disorders during peroral treatment of **diabetes**].
 Erkrankung der Sehnerven im Verlauf einer peroralen **Diabetesbehandlung**.
 AU PURTSCHER E
 SO Wiener klinische Wochenschrift, (1957 May 10) Vol. 69, No. 19, pp. 340.
 Journal code: 21620870R. ISSN: 0043-5325.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5732-54806
 EM 200205
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2002

L4 ANSWER 408 OF 658 MEDLINE on STN
Full Text
 AN 57102724 MEDLINE
 DN PubMed ID: 13455941
 TI [Effects of oral antidiabetic drugs on blood sugar & blood phosphate
 curves after oral & intravenous glucose administration].
 Virkningerne af perorale antidiabetika på blodsukker- og fosfatkurve efter
 oral og intravenøs glukosebelastning.
 AU JENSEN S E; LUNDBAEK K; MOLLER B; RAFAELSEN O J
 SO Ugeskrift for læger, (1957 Jun 27) Vol. 119, No. 26, pp. 825-9.
 Journal code: 0141730. ISSN: 0041-5782.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA Danish
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5732-54280
 EM 200205
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2002

L4 ANSWER 409 OF 658 MEDLINE on STN
Full Text
 AN 57102723 MEDLINE
 DN PubMed ID: 13455940
 TI [Tolbutamide (rastinon) in oral **diabetes** therapy].
 Peroral **diabetesbehandling** med tolbutamid (rastinon).
 AU IVERSEN M
 SO Ugeskrift for læger, (1957 Jun 27) Vol. 119, No. 26, pp. 819-25.
 Journal code: 0141730. ISSN: 0041-5782.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA Danish
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5732-54279
 EM 200205
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2002

L4 ANSWER 410 OF 658 MEDLINE on STN
Full Text
 AN 57102639 MEDLINE
 DN PubMed ID: 13455856
 TI [Theoretical & practical problems posed by the use of hypoglycemic
sulfonamides].
 Problemes theoriques et pratiques poses par l'emploi des sulfamides
 hypoglycemiants.
 AU COHEN M
 SO La Tunisie medicale, (1957 Feb) Vol. 45, No. 2, pp. 117-9; passim.
 Journal code: 0413766. ISSN: 0041-4131.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English; French
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5732-54195
 EM 200205
 ED Entered STN: Feb 2004
 Last Updated on STN: Feb 2004
 Entered Medline: 1 May 2002

L4 ANSWER 411 OF 658 MEDLINE on STN

Full Text

AN 57102310 MEDLINE
DN PubMed ID: 13455527
TI [Current conclusions regarding tablet therapy of **diabetes**].
Aktuella synpunkter pa tablettbehandling vid sockersjuka.
AU ANDERSSON B
SO Svenska lakartidningen, (1957 Jun 14) Vol. 54, No. 24, pp. 1945-50.
Journal code: 0030130.
DT Journal; Article; (JOURNAL ARTICLE)
LA Swedish
FS OLDMEDLINE; NONMEDLINE
OS CLML5732-53866
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 412 OF 658 MEDLINE on STN

Full Text

AN 57102305 MEDLINE
DN PubMed ID: 13455522
TI [Experience with peroral **diabetes** therapy, with special consideration of
the development of resistance].
Nagra erfarenheter av peroral **diabetesbehandling** med sarskild hansyn
till utvecklingen av senresistens.
AU DOTEVALL G
SO Svenska lakartidningen, (1957 Jun 7) Vol. 54, No. 23, pp. 1881-7.
Journal code: 0030130.
DT Journal; Article; (JOURNAL ARTICLE)
LA Swedish
FS OLDMEDLINE; NONMEDLINE
OS CLML5732-53861
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 413 OF 658 MEDLINE on STN

Full Text

AN 57102228 MEDLINE
DN PubMed ID: 13455446
TI [Results of the treatment of **diabetes** with new **sulfonamide-urea**
preparations].
Opitut ni pri lechenie na diabeta s novite sulfanil-ureini preparati.
AU PUKHLEV A; TIKHOLOV K
SO Suvremenna medit sina, (1957) Vol. 8, No. 1, pp. 21-33.
Journal code: 2984813R. ISSN: 0562-7192.
DT Journal; Article; (JOURNAL ARTICLE)
LA Bulgarian
FS OLDMEDLINE; NONMEDLINE
OS CLML5732-53784
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 414 OF 658 MEDLINE on STN

Full Text

AN 57101998 MEDLINE
DN PubMed ID: 13455216
TI [**Sulfonamides** as hypoglycemia-active drugs].
Sulfamidi kao hipoglikemici.
AU POPOVIC R; ROSIC D; PUTNIK M
SO Srpski arhiv za celokupno lekarstvo, (1957 Feb) Vol. 85, No. 2, pp.
211-27.
Journal code: 0027440. ISSN: 0370-8179.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5732-53554
EM 200205

ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 415 OF 658 MEDLINE on STN

Full Text

AN 57100992 MEDLINE
DN PubMed ID: 13454211
TI [New anti-diabetic **sulfonamides**: personal results].
Les nouveaux sulfamides antidiabetiques: resultats personnels.
AU CHAIA J
SO Revue medicale du Moyen-Orient, (1957 Mar-Apr) Vol. 14, No. 2, pp. 147-9.
Journal code: 20340240R. ISSN: 0370-632X.
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS OLDMEDLINE; NONMEDLINE
OS CLML5732-52548
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 416 OF 658 MEDLINE on STN

Full Text

AN 57100988 MEDLINE
DN PubMed ID: 13454207
TI [New **sulfonamides** with uricosuric, diuretic & antidiabetic action].
Les nouveaux sulfamides a action uricosurique, diuretique et
antidiabetique.
AU HAZARD R
SO Revue medicale du Moyen-Orient, (1957 Mar-Apr) Vol. 14, No. 2, pp. 89-97.
Journal code: 20340240R. ISSN: 0370-632X.
DT Journal; Article; (JOURNAL ARTICLE)
LA English; French
FS OLDMEDLINE; NONMEDLINE
OS CLML5732-52544
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 417 OF 658 MEDLINE on STN

Full Text

AN 57100419 MEDLINE
DN PubMed ID: 13453644
TI Clinical use of oral sulfonylurea compounds in **diabetes** mellitus.
AU COLWELL A R Sr; COLWELL J A
SO Quarterly bulletin. Northwestern University (Evanston, Ill.). Medical
School, (1957) Vol. 31, No. 2, pp. 102-13.
Journal code: 19220080R.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5732-51975
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 418 OF 658 MEDLINE on STN

Full Text

AN 57100348 MEDLINE
DN PubMed ID: 13453573
TI [Experiences & case reports on the therapeutic use of hypoglycemic
sulfonamides; 110 cases].
Esperienze ed osservazioni sull'impiego terapeutico dei sulfamidici
ipoglicemizzanti. I. Osservazioni cliniche su 110 casi.
AU TOPI G C; ALESSANDRINI A; JACOBELLI A; FORCINA G
SO Il Progresso medico, (1957 May 31) Vol. 13, No. 10, pp. 303-11.
Journal code: 2984827R. ISSN: 0370-1514.
DT Journal; Article; (JOURNAL ARTICLE)
LA Italian

FS OLDMEDLINE; NONMEDLINE
OS CLML5732-51904
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 419 OF 658 MEDLINE on STN

Full Text

AN 57099299 MEDLINE
DN PubMed ID: 13452524
TI [Clinical experiences with a new hypoglycemic **sulfonamide** derivative].
Klinikai tapasztalatok egy új vércukorcsökkentő sulfonamidszarmazakkal.
AU TISZAI A; SZUCS Z
SO Orvosi hetilap, (1957 May 26) Vol. 98, No. 21, pp. 546-9.
Journal code: 0376412. ISSN: 0030-6002.
DT Journal; Article; (JOURNAL ARTICLE)
LA German; Hungarian
FS OLDMEDLINE; NONMEDLINE
OS CLML5732-50855
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

L4 ANSWER 420 OF 658 MEDLINE on STN

Full Text

AN 57099298 MEDLINE
DN PubMed ID: 13452523
TI [Oral **sulfonamideurea** therapy in **diabetes** mellitus].
A cukorbetegség orális sulfonamidurea kezelése.
AU KORANYI A; LORINCZ A; KARSAY G; BIKICH G; FENYES I
SO Orvosi hetilap, (1957 May 26) Vol. 98, No. 21, pp. 537-45.
Journal code: 0376412. ISSN: 0030-6002.
DT Journal; Article; (JOURNAL ARTICLE)
LA German; Hungarian
FS OLDMEDLINE; NONMEDLINE
OS CLML5732-50854
EM 200205
ED Entered STN: Feb 2004
Last Updated on STN: Feb 2004
Entered Medline: 1 May 2002

=> d 14 300-320

L4 ANSWER 300 OF 658 MEDLINE on STN

Full Text

AN 69130883 MEDLINE
DN PubMed ID: 5609552
TI [The bingo game of the **diabetes** specialist].
Le jeu de l'oie du diabetologue.
AU Chimenes H
SO Les Cahiers du College de medecine des hopitaux de Paris, (1967 May 30)
Vol. 8, No. 6, pp. 451-2.
Journal code: 7503474. ISSN: 0375-877X.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 196904
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 24 Apr 1969

L4 ANSWER 301 OF 658 MEDLINE on STN

Full Text

AN 69117389 MEDLINE
DN PubMed ID: 5766385
TI Hyperglycemic, nonketotic coma in the patient with burns: factors in
pathogenesis.
AU Oakes D D; Schreibman P H; Hoffman R S; Arky R A

SO Metabolism: clinical and experimental, (1969 Feb) Vol. 18, No. 2, pp. 103-9.
Journal code: 0375267. ISSN: 0026-0495.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 196904
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 9 Apr 1969

L4 ANSWER 302 OF 658 MEDLINE on STN

Full Text

AN 69109602 MEDLINE
DN PubMed ID: 4885099
TI The behaviour of beta-glucuronidase in drug metabolism.
AU Dohrmann R E
SO Arzneimittel-Forschung, (1968 Jul) Vol. 18, No. 7, pp. 854-62. Ref: 37
Journal code: 0372660. ISSN: 0004-4172.
CY GERMANY, WEST: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 196903
ED Entered STN: 1 Jan 1990
Last Updated on STN: 6 Feb 1998
Entered Medline: 28 Mar 1969

L4 ANSWER 303 OF 658 MEDLINE on STN

Full Text

AN 69088558 MEDLINE
DN PubMed ID: 4883853
TI Oral treatment of **diabetes** mellitus.
AU Chhetri M K
SO Journal of the Indian Medical Association, (1968 May 16) Vol. 50, No. 10, pp. 486-8. Ref: 39
Journal code: 7505608. ISSN: 0019-5847.
CY India
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 196903
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 5 Mar 1969

L4 ANSWER 304 OF 658 MEDLINE on STN

Full Text

AN 69088554 MEDLINE
DN PubMed ID: 5704866
TI Treatment of **diabetes** mellitus with glycodiazine.
AU Chhetri M K; Pal K
SO Journal of the Indian Medical Association, (1968 May 16) Vol. 50, No. 10, pp. 476-81.
Journal code: 7505608. ISSN: 0019-5847.
CY India
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 196903
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 5 Mar 1969

L4 ANSWER 305 OF 658 MEDLINE on STN

Full Text

AN 69081272 MEDLINE
DN PubMed ID: 5604109
TI [Clinical experimentation with weak doses of sulfamethopyrazine].

Experimentation clinique de la sulfamethopyrazine a failbes doses.
 AU Plauchu M; Arnaud P; Pousset G
 SO Lyon medical, (1967 Feb 12) Vol. 217, No. 7, pp. 507-9.
 Journal code: 0335015. ISSN: 0024-7790.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 196902
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 20 Feb 1969

L4 ANSWER 306 OF 658 MEDLINE on STN
Full Text
 AN 69066331 MEDLINE
 DN PubMed ID: 5727621
 TI [The clinical metaboli developmental stages of **diabetes** mellitus in
 acromegaly].
 Die klinische-metabolische Entwicklungsstadien des **Diabetes** mellitus
 bei Akromegaliekranen.
 AU Ioanitziu D; Dragomirescu M; Mitrache L; Hann K
 SO Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, (1968
 Aug 15) Vol. 23, No. 16, pp. Suppl:241-3.
 Journal code: 21730470R. ISSN: 0044-2542.
 CY GERMANY, EAST: German Democratic Republic
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 196902
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 7 Feb 1969

L4 ANSWER 307 OF 658 MEDLINE on STN
Full Text
 AN 69035140 MEDLINE
 DN PubMed ID: 5303307
 TI [Generalized nocardiosis. Central nocardia sepsis in a woman with fatal
 outcome].
 Generalisierte Nokardiose. Eine zentrale Nokardia-Sepsis bei einer Frau
 mit todlichem Ausgang.
 AU Stafova J; Motlikova M; Kruml J; Dvorsky K; Viklicky J; Vacek V
 SO Zentralblatt fur allgemeine Pathologie und pathologische Anatomie, (1967)
 Vol. 110, No. 4, pp. 351-6.
 Journal code: 9105593. ISSN: 0044-4030.
 CY Czechoslovakia
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Nursing Journals
 EM 196901
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 8 Jan 1969

L4 ANSWER 308 OF 658 MEDLINE on STN
Full Text
 AN 68396020 MEDLINE
 DN PubMed ID: 5597792
 TI [Clinical experience with B.S. 4469 (benzosulfonamide
 isopropoxypyrimidine)].
 Experiencia clinica con el B.S. 4469 (benzosulfonamida-
 isopropoxipirimidina).
 AU Suarez Pereda I; Puchulu F E; Zavala A V; Rodriguez M F; Busquet I
 SO Prensa medica argentina, (1967 Mar 24) Vol. 54, No. 4, pp. 157-61.
 Journal code: 0204056. ISSN: 0032-745X.
 CY Argentina
 DT Journal; Article; (JOURNAL ARTICLE)
 LA Spanish
 FS Priority Journals
 EM 196810
 ED Entered STN: 1 Jan 1990

Last Updated on STN: 1 Jan 1990
Entered Medline: 17 Oct 1968

L4 ANSWER 309 OF 658 MEDLINE on STN
Full Text
AN 68395312 MEDLINE
DN PubMed ID: 5672068
TI [Peroral therapy of **diabetes** mellitus].
Peroralna terapija dijabetesa melitusa.
AU Sprung M
SO Vojnosanitetski pregled. Military-medical and pharmaceutical review, (1968 Apr) Vol. 25, No. 4, pp. 201-2.
Journal code: 21530700R. ISSN: 0042-8450.
CY Yugoslavia
DT Journal; Article; (JOURNAL ARTICLE)
LA Serbian
FS Priority Journals
EM 196810
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 17 Oct 1968

L4 ANSWER 310 OF 658 MEDLINE on STN
Full Text
AN 68369865 MEDLINE
DN PubMed ID: 4299418
TI [Intravenous tolbutamide test in secondary failure of antidiabetic **sulfonamides**].
L'epreuve au tolbutamide intraveineux au cours des echecs secondaires des sulfamides antidiabetiques.
AU Canivet J; Jacotot B
SO La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, (1968 Apr 8) Vol. 44, No. 17, pp. 1147-51.
Journal code: 9410059.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 196810
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 7 Oct 1968

L4 ANSWER 311 OF 658 MEDLINE on STN
Full Text
AN 68237082 MEDLINE
DN PubMed ID: 4967681
TI [Is there only one type of **diabetes**?].
Gibt es nur eine Zuckerkrankheit?.
AU Lestradet H
SO Munchener medizinische Wochenschrift (1950), (1966 Sep 16) Vol. 108, No. 37, pp. 1790-5.
Journal code: 7801802. ISSN: 0027-2973.
CY GERMANY, WEST: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals
EM 196807
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 4 Jul 1968

L4 ANSWER 312 OF 658 MEDLINE on STN
Full Text
AN 68195643 MEDLINE
DN PubMed ID: 4230739
TI Glymidine in the treatment of **diabetes** mellitus.
AU Burns F H
SO The Medical journal of Australia, (1968 Mar 9) Vol. 1, No. 10, pp. 393-4.
Journal code: 0400714. ISSN: 0025-729X.
CY Australia
DT Journal; Article; (JOURNAL ARTICLE)

LA English
FS Priority Journals
EM 196805
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 27 May 1968

L4 ANSWER 313 OF 658 MEDLINE on STN

Full Text

AN 68049763 MEDLINE
DN PubMed ID: 5985567
TI [How to control a diabetic treated by hypoglycemiant sulfamides].
Comment contrôler und diabetique traite par les sulfamides
hypoglycemiants.
AU Gueniot M
SO Semaine therapeutique, (1966 Apr) Vol. 42, No. 4, pp. 211-2.
Journal code: 0205463. ISSN: 0040-5922.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 196801
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 19 Jan 1968

L4 ANSWER 314 OF 658 MEDLINE on STN

Full Text

AN 67201739 MEDLINE
DN PubMed ID: 4166142
TI [Abnormalities of thyroid function in **diabetes** mellitus. Statistical
study].
Les deviations fonctionnelles thyroïdiennes dans le **diabete** sucre. Etude
statistique.
AU Mirouze J; Jaffiol C; Dicquemare J; Chanaud C
SO Annales d'endocrinologie, (1966 Nov-Dec) Vol. 27, No. 6, pp. 727-37.
Journal code: 0116744. ISSN: 0003-4266.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 196709
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 25 Sep 1967

L4 ANSWER 315 OF 658 MEDLINE on STN

Full Text

AN 67184211 MEDLINE
DN PubMed ID: 6029502
TI Melioidosis.
AU Magee H R; Mitchell R M; Fitzwater J J; Christie D G; Rao A
SO The Medical journal of Australia, (1967 Jun 10) Vol. 1, No. 23, pp.
1180-3.
Journal code: 0400714. ISSN: 0025-729X.
CY Australia
DT (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 196709
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 13 Sep 1967

L4 ANSWER 316 OF 658 MEDLINE on STN

Full Text

AN 67181283 MEDLINE
DN PubMed ID: 5230284
TI Micropuncture experiments with saluretic **sulfonamides**.
AU Ullrich K J; Baumann K; Loeschke K; Rumrich G; Stolte H
SO Annals of the New York Academy of Sciences, (1966 Nov 22) Vol. 139, No. 2,

pp. 416-23.
 Journal code: 7506858. ISSN: 0077-8923.

CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 196709
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 11 Sep 1967

L4 ANSWER 317 OF 658 MEDLINE on STN
Full Text
 AN 67123913 MEDLINE
 DN PubMed ID: 5899812
 TI [2-Benzolsulfonamido-5(beta-methoxy-ethoxy)-pyrimidine (Glycodiazine). II. Metabolism of 2-benzolsulfonamido-5(beta-hydroxy-ethoxy)-pyrimidine, a blood sugar reducing metabolite of glycodiazine in man].
 2-Benzolsulfonamido-5(beta-methoxy-athoxy)-pyrimidin (Glycodiazin). II. Der Stoffwechsel von 2-Benzolsulfonamido-5(beta-hydroxy-athoxy)-pyrimidin, einem blutzuckersenkenden Metaboliten des Glycodiazin, beim Menschen.
 AU Gerhards E; Kolb K H
 SO Arzneimittel-Forschung, (1965 Dec) Vol. 15, No. 12, pp. 1375-9.
 Journal code: 0372660. ISSN: 0004-4172.
 CY GERMANY, WEST: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 196705
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 16 May 1967

L4 ANSWER 318 OF 658 MEDLINE on STN
Full Text
 AN 66110642 MEDLINE
 DN PubMed ID: 5909923
 TI [Results of treatment of adult diabetes mellitus with Metformin-sulfonamide combination (apropos of 197 cases)].
 Resultats du traitement du diabete sucre de l'adulte par l'association Metformin sulfamides (a propos de 197 cas).
 AU Debry G; Laurent J
 SO Journal de medecine de Lyon, (1966 Mar 5) Vol. 47, No. 94, pp. 407-13.
 Journal code: 2985084R. ISSN: 0021-7883.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 196606
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 26 Jun 1966

L4 ANSWER 319 OF 658 MEDLINE on STN
Full Text
 AN 66036050 MEDLINE
 DN PubMed ID: 5840156
 TI [Serum level of pyruvic acid after the administration of some hypoglycemic drugs].
 Zachowanie sie kwasu pirogronowego w surowicy po nietylorych srodkach hipoglikemizujacych.
 AU Wasilewska A
 SO Polski tygodnik lekarski (Warsaw, Poland : 1960), (1965 Jul 5) Vol. 20, No. 27, pp. 1013-4.
 Journal code: 9705468. ISSN: 0032-3756.
 CY Poland
 DT Journal; Article; (JOURNAL ARTICLE)
 LA Polish
 FS Priority Journals
 EM 196601
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990

Entered Medline: 15 Jan 1966

L4 ANSWER 320 OF 658 MEDLINE on STN
Full Text
AN 65136555 MEDLINE
DN PubMed ID: 14331871
TI [HYPOGLYCEMIC SULFONAMIDES IN COMBINED THERAPY OF DIABETES MELLITUS].
GIPOGLIKEMIZIRUISHCHIE SUL'FANILAMIDNYE PREPARATY V KOMPLEKSE LECHENIIA
SAKHARNOGO DIABETA.
AU MNATSAKANOV Ts; BOSTANDZHIAN O Sh
SO Terapevticheskii arkhiv, (1965 Jun) Vol. 37, pp. 47-53.
Journal code: 2984818R. ISSN: 0040-3660.
CY RUSSIA: Russian Federation
DT Journal; Article; (JOURNAL ARTICLE)
LA Russian
FS OLDMEDLINE; NONMEDLINE
EM 199612
ED Entered STN: 16 Jul 1999
Last Updated on STN: 16 Jul 1999
Entered Medline: 1 Dec 1996

=> d l4 an ti so ab kwic 303 304 312

L4 ANSWER 303 OF 658 MEDLINE on STN
Full Text
AN 69088558 MEDLINE
TI Oral treatment of **diabetes** mellitus.
SO Journal of the Indian Medical Association, (1968 May 16) Vol. 50, No. 10,
pp. 486-8. Ref: 39
Journal code: 7505608. ISSN: 0019-5847.
TI Oral treatment of **diabetes** mellitus.
CT Chlorpropamide: AE, adverse effects
Chlorpropamide: TU, therapeutic use
***Diabetes Mellitus: DT, drug therapy**
Humans
Hypoglycemia: CI, chemically induced
Hypoglycemic Agents: AE, adverse effects
*Hypoglycemic Agents: TU, therapeutic use
Metformin: TU, therapeutic use
Phenformin: AE, adverse effects
Phenformin: TU, therapeutic use
***Sulfonamides: TU, therapeutic use**
Tolbutamide: TU, therapeutic use
CN 0 (Hypoglycemic Agents); 0 (Sulfonamides)

L4 ANSWER 304 OF 658 MEDLINE on STN
Full Text
AN 69088554 MEDLINE
TI Treatment of **diabetes** mellitus with glycodiazine.
SO Journal of the Indian Medical Association, (1968 May 16) Vol. 50, No. 10,
pp. 476-81.
Journal code: 7505608. ISSN: 0019-5847.
TI Treatment of **diabetes** mellitus with glycodiazine.
CT Check Tags: Female; Male
Adult
Aged
***Diabetes Mellitus: DT, drug therapy**
Humans
*Hypoglycemic Agents: TU, therapeutic use
Middle Aged
***Sulfonamides: TU, therapeutic use**
CN 0 (Hypoglycemic Agents); 0 (Sulfonamides)

L4 ANSWER 312 OF 658 MEDLINE on STN
Full Text
AN 68195643 MEDLINE
TI Glymidine in the treatment of **diabetes** mellitus.
SO The Medical journal of Australia, (1968 Mar 9) Vol. 1, No. 10, pp. 393-4.
Journal code: 0400714. ISSN: 0025-729X.
TI Glymidine in the treatment of **diabetes** mellitus.
CT Check Tags: Female; Male

Adult
 Aged
 *Diabetes Mellitus: DT, drug therapy
 Drug Eruptions
 Drug Synergism
 Humans
 Hypoglycemic Agents: AD, administration & dosage
 *Hypoglycemic Agents: TU, therapeutic use
 Middle Aged
 Pyrimidines: AE, adverse effects
 Pyrimidines: TU, therapeutic use
 Sulfonamides: AE, adverse effects
 Sulfonamides: TU, therapeutic use
 CN 0 (Hypoglycemic Agents); 0 (Pyrimidines); 0 (Sulfonamides)

=> d 14 280-300

L4 ANSWER 280 OF 658 MEDLINE on STN

Full Text

AN 70065178 MEDLINE
 DN PubMed ID: 5360865
 TI [Physiopathologic basis of oral treatment of diabetes].
 Bases physiopathologiques du traitement oral du diabete.
 AU Vague P
 SO Marseille medical, (1969) Vol. 106, No. 10, pp. 779-81.
 Journal code: 2985228R. ISSN: 0025-4053.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 197002
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 5 Feb 1970

L4 ANSWER 281 OF 658 MEDLINE on STN

Full Text

AN 70052480 MEDLINE
 DN PubMed ID: 5737547
 TI [A new hypoglycemic sulfonamide: AN1324].
 Un nouveau sulfamide hypoglycemiant: Le 1324 AN.
 AU Vignalou J; Beck H
 SO La Presse medicale, (1968 Oct 12) Vol. 76, No. 38, pp. 1827-8.
 Journal code: 0312556. ISSN: 0032-7867.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 197001
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 20 Jan 1970

L4 ANSWER 282 OF 658 MEDLINE on STN

Full Text

AN 70006526 MEDLINE
 DN PubMed ID: 5619705
 TI [Experimentation with glycodiazine in the treatment of diabetes. Apropos
 of 30 cases].
 Experimentation de la glycodiazine dans le traitement du diabete. A
 propos de 30 observations.
 AU Warembourg H; Jaillard J
 SO Lille medical : journal de la Faculte de medecine et de pharmacie de
 l'Universite de Lille, (1967 May) Vol. 12, No. 4, pp. Suppl:516-9.
 Journal code: 8203780. ISSN: 0024-3507.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 196912
 ED Entered STN: 1 Jan 1990

Last Updated on STN: 1 Jan 1990
Entered Medline: 1 Dec 1969

L4 ANSWER 283 OF 658 MEDLINE on STN

Full Text

AN 69298447 MEDLINE
DN PubMed ID: 4898344
TI HB419 (glibenclamide) in the treatment of diabetes mellitus.
AU Schneider T; Lopis S
SO South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
(1969 Aug 9) Vol. 43, No. 32, pp. 981-3.
Journal code: 0404520. ISSN: 0256-9574.
CY South Africa
DT (CLINICAL TRIAL)
(COMPARATIVE STUDY)
(CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 196911
ED Entered STN: 1 Jan 1990
Last Updated on STN: 3 Feb 1997
Entered Medline: 5 Nov 1969

L4 ANSWER 284 OF 658 MEDLINE on STN

Full Text

AN 69295843 MEDLINE
DN PubMed ID: 4898090
TI Preliminary trial of a powerful new sulphonylurea in maturity-onset
diabetes--HB419 (glibenclamide).
AU Jackson W P; Vinik A I
SO South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
(1969 Aug 9) Vol. 43, No. 32, pp. 1002-4.
Journal code: 0404520. ISSN: 0256-9574.
CY South Africa
DT (CLINICAL TRIAL)
(COMPARATIVE STUDY)
(CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 196911
ED Entered STN: 1 Jan 1990
Last Updated on STN: 3 Feb 1997
Entered Medline: 4 Nov 1969

L4 ANSWER 285 OF 658 MEDLINE on STN

Full Text

AN 69285157 MEDLINE
DN PubMed ID: 5809102
TI [Recent data concerning the control of insulin secretion].
Donnees recentes concernant le controle de l'insulino-secretion.
AU Tchobroutsky G
SO La Revue francaise d'endocrinologie clinique, nutrition, et metabolisme,
(1969 May-Jun) Vol. 10, No. 3, pp. 237-42.
Journal code: 0404335. ISSN: 0048-8062.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 196910
ED Entered STN: 1 Jan 1990
Last Updated on STN: 6 Feb 1998
Entered Medline: 23 Oct 1969

L4 ANSWER 286 OF 658 MEDLINE on STN

Full Text

AN 69280746 MEDLINE
DN PubMed ID: 5734171
TI [Biological characteristics of n-salicyl-o-methoxybenzol-sulphamide].
Biologicheskaja kharakteristika N-salikoil-o-metoksibenzol-sul'famida.
AU Ryzhkova T S; Lapynina L A; Dykhanov N N; Sysoeva T F

SO Problemy e ndokrinologii, (1968 Jul-Aug) Vol. 14, No. 4, pp. 112-4.
 Journal code: 0140673. ISSN: 0375-9660.

CY USSR
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 LA Russian
 FS Priority Journals
 EM 196910
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 21 Oct 1969

L4 ANSWER 287 OF 658 MEDLINE on STN
Full Text
 AN 69264179 MEDLINE
 DN PubMed ID: 4308469
 TI [Comparative study of oral treatment in diabetes].
 Etude comparative des traitements oraux du diabete.
 AU Romani J D
 SO La semaine des hopitaux : organe fonde par l'Association d'enseignement
 medical des hopitaux de Paris, (1969 May 26) Vol. 45, No. 25, pp. 1768-76.
 Journal code: 9410059.

CY France
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 196910
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 2 Oct 1969

L4 ANSWER 288 OF 658 MEDLINE on STN
Full Text
 AN 69233097 MEDLINE
 DN PubMed ID: 5793543
 TI [Oral therapy of diabetes].
 Therapeutique orale du diabete.
 AU Anonymous
 SO La Presse medicale, (1969 Jun 25) Vol. 77, No. 31, pp. 1117-20.
 Journal code: 0312556. ISSN: 0032-7867.

CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 196908
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 27 Aug 1969

L4 ANSWER 289 OF 658 MEDLINE on STN
Full Text
 AN 69228666 MEDLINE
 DN PubMed ID: 5791835
 TI [Place of hypoglycemic sulfonamides in treatment of steatosis of
 nutritional origin].
 Place des sulfamides hypoglycemiants dans le traitement des steatoses
 d'origine nutritionnelle.
 AU Dorf G; Tutin M; Bour H; Guy-Grand B
 SO Therapeutique (La Semaine des hopitaux), (1969 May) Vol. 45, No. 5, pp.
 536-7.
 Journal code: 0415606. ISSN: 0040-5922.

CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 196908
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 21 Aug 1969

L4 ANSWER 290 OF 658 MEDLINE on STN

Full Text

AN 69226193 MEDLINE
DN PubMed ID: 5730357
TI [Sterility due to diabetic oligoasthenospermia: its treatment by sulfonamidotherapy. Preliminary note].
La sterilité par oligoasthénospermie du diabétique: son traitement par la sulfamidothérapie. Note préliminaire.
AU Chimenès H
SO Le Diabète, (1968 Oct-Dec) Vol. 16, No. 4, pp. 305-6.
Journal code: 2984746R. ISSN: 0012-1770.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 196908
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 19 Aug 1969

L4 ANSWER 291 OF 658 MEDLINE on STN

Full Text

AN 69215752 MEDLINE
DN PubMed ID: 4239707
TI [Inhibition of ketogenesis in liver tissue by tolbutamide and glycodiazine in vitro].
Die Hemmung der Ketogenese im Lebergewebe durch Tolbutamid und Glykodiazin in vitro.
AU Hasselblatt A
SO Naunyn-Schmiedeberg's Archiv für experimentelle Pathologie und Pharmakologie, (1969) Vol. 262, No. 2, pp. 152-64.
Journal code: 0054224.
CY GERMANY, WEST: Germany, Federal Republic of
DT (IN VITRO)
Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals
EM 196908
ED Entered STN: 1 Jan 1990
Last Updated on STN: 3 Mar 2000
Entered Medline: 7 Aug 1969

L4 ANSWER 292 OF 658 MEDLINE on STN

Full Text

AN 69204520 MEDLINE
DN PubMed ID: 5753330
TI [Contributions to the etiopathogenic and histopathologic study of chronic hepatopathy in diabetes mellitus].
Contributions à l'étude étiopathogénique et histopathologique des hépatopathies chroniques dans le diabète sucré.
AU Mincou J; Cimpeanu S; Radulesco G; Cimpeanu L; Petrovici A
SO Revue internationale d'hépatologie, (1968) Vol. 18, No. 8, pp. 987-1022.
Journal code: 9427142.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 196907
ED Entered STN: 1 Jan 1990
Last Updated on STN: 3 Feb 1997
Entered Medline: 30 Jul 1969

L4 ANSWER 293 OF 658 MEDLINE on STN

Full Text

AN 69188683 MEDLINE
DN PubMed ID: 5713675
TI [Hypoglycemic coma due to antidiabetic sulfonamides. Apropos of 16 cases].
Les comas hypoglycémiques par sulfamides antidiabétiques. A propos de 16 cas.
AU Lauvaux J P; Thys O; Sternon J
SO Acta clinica Belgica, (1968) Vol. 23, No. 3, pp. 153-62.
Journal code: 0370306. ISSN: 0001-5512.

CY Belgium
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 196907
ED Entered STN: 1 Jan 1990
Last Updated on STN: 3 Feb 1997
Entered Medline: 3 Jul 1969

L4 ANSWER 294 OF 658 MEDLINE on STN

Full Text

AN 69178072 MEDLINE
DN PubMed ID: 5721707
TI [Medicamentous hepatitis. The role of hypoglycemic **sulfonamides** (apropos of 2 cases)].
Hepatitis medicamenteuses. Le role des sulfamides hypoglycemiants (a propos de deux observations).
AU Geffroy Y; Segrestin M; Bourreille J; Fablet J; Colin R
SO Actualites hepato-gastro-enterologiques, (1968 Sep-Dec) Vol. 4, No. 5, pp. B175-86.
Journal code: 0264367. ISSN: 0240-8007.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 196906
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 24 Jun 1969

L4 ANSWER 295 OF 658 MEDLINE on STN

Full Text

AN 69176435 MEDLINE
DN PubMed ID: 4889379
TI A clinical trial of glymidine (Gondafon).
AU Mallinson C N; Chlouverakis K; Hardwick C; Mistry S J; Butterfield W H
SO Guy's Hospital reports, (1968) Vol. 117, No. 4, pp. 267-74.
Journal code: 7612021. ISSN: 0017-5889.
CY ENGLAND: United Kingdom
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 196906
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 19 Jun 1969

L4 ANSWER 296 OF 658 MEDLINE on STN

Full Text

AN 69176434 MEDLINE
DN PubMed ID: 5721475
TI The mode of action of glymidine (Gondafon) with some speculations about the molecular and intracellular action of insulinotrophic drugs.
AU Butterfield W J; Mallinson C N; Hicks B H; Whichelow M J
SO Guy's Hospital reports, (1968) Vol. 117, No. 4, pp. 257-66.
Journal code: 7612021. ISSN: 0017-5889.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 196906
ED Entered STN: 1 Jan 1990
Last Updated on STN: 1 Jan 1990
Entered Medline: 19 Jun 1969

L4 ANSWER 297 OF 658 MEDLINE on STN

Full Text

AN 69165429 MEDLINE
DN PubMed ID: 4888765
TI [Use of hypoglycemic **sulfonamides** in the clinic].
Emploi en clinique des **sulfonamides** hypoglycemiants.

AU Martin E
 SO Actualites pharmacologiques, (1968) Vol. 21, pp. 191-212. Ref: 40
 Journal code: 0370407. ISSN: 0567-8854.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA French
 FS Priority Journals
 EM 196906
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 5 Jun 1969

L4 ANSWER 298 OF 658 MEDLINE on STN
Full Text
 AN 69163162 MEDLINE
 DN PubMed ID: 5720293
 TI [Clinical study of a hypoglycemic sulfonamide: 1324 AN (gludias) in
 treatment of **diabetes**].
 Etude clinique d'un sulfamide hypoglycemiant: le 1324 AN dans le
 traitement du **diabete**.
 AU Warembourg H; Jaillard J
 SO Lille medical : journal de la Faculte de medecine et de pharmacie de
 l'Universite de Lille, (1968 Dec) Vol. 13, No. 10, pp. Suppl 7:1065+.
 Journal code: 8203780. ISSN: 0024-3507.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 196906
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 2 Jun 1969

L4 ANSWER 299 OF 658 MEDLINE on STN
Full Text
 AN 69152095 MEDLINE
 DN PubMed ID: 5776706
 TI [Glybenclamide (HB 419): a new oral antidiabetic agent of the sulfonylurea
 group].
 Glybenclamid (HB 419): ein neues orales Antidiabetikum der
 Sulfonylharnstoff-Reihe.
 AU Mehnert H; Karg E
 SO Deutsche medizinische Wochenschrift (1946), (1969 Apr 18) Vol. 94, No. 16,
 pp. 819-24.
 Journal code: 0006723. ISSN: 0012-0472.
 CY GERMANY, WEST: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 196905
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990
 Entered Medline: 15 May 1969

L4 ANSWER 300 OF 658 MEDLINE on STN
Full Text
 AN 69130883 MEDLINE
 DN PubMed ID: 5609552
 TI [The bingo game of the **diabetes** specialist].
 Le jeu de l'oie du diabetologue.
 AU Chimenes H
 SO Les Cahiers du College de medecine des hopitaux de Paris, (1967 May 30)
 Vol. 8, No. 6, pp. 451-2.
 Journal code: 7503474. ISSN: 0375-877X.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 196904
 ED Entered STN: 1 Jan 1990
 Last Updated on STN: 1 Jan 1990

Entered Medline: 24 Apr 1969

=> d 14 200-240

L4 ANSWER 200 OF 658 MEDLINE on STN

Full Text

AN 78226142 MEDLINE

DN PubMed ID: 353789

TI [State of the islands of Langerhans in various animal species after administration of 8-(arensulfonylamino)-quinolines].
Sostoianie ostrovkov Langergansa u zhivotnykh raznykh vidov pri vvedenii 8-(arensul'fonilamino)-khinolinov.

AU Eshchenko V A

SO Problemy e ndokrinologii, (1978 May-Jun) Vol. 24, No. 3, pp. 103-7.
Journal code: 0140673. ISSN: 0375-9660.

CY USSR

DT (COMPARATIVE STUDY)

(ENGLISH ABSTRACT)

Journal; Article; (JOURNAL ARTICLE)

LA Russian

FS Priority Journals

EM 197809

ED Entered STN: 14 Mar 1990

Last Updated on STN: 3 Feb 1997

Entered Medline: 29 Sep 1978

L4 ANSWER 201 OF 658 MEDLINE on STN

Full Text

AN 78009962 MEDLINE

DN PubMed ID: 904548

TI [Secondary failures in modern therapy of **diabetes** mellitus with blood glucose lowering **sulfonamides** (author's transl)].
Neue Untersuchungen zum Sekundarversagen der Therapie mit blutglucosesenkenden Sulfonamidderivaten.

AU Haupt E; Laube F; Loy H; Schoffling K

SO Medizinische Klinik (1947), (1977 Sep 23) Vol. 72, No. 38, pp. 1529-36.
Journal code: 0376637. ISSN: 0025-8458.

CY GERMANY, WEST: Germany, Federal Republic of

DT (ENGLISH ABSTRACT)

Journal; Article; (JOURNAL ARTICLE)

LA German

FS Priority Journals

EM 197711

ED Entered STN: 14 Mar 1990

Last Updated on STN: 14 Mar 1990

Entered Medline: 25 Nov 1977

L4 ANSWER 202 OF 658 MEDLINE on STN

Full Text

AN 77232303 MEDLINE

DN PubMed ID: 407433

TI [Cost-benefit analyses of the employment of assistant dieticians by medical practitioners. 1st report: Basic considerations, calculatory basis, analysis of a policlinical research study and preliminary assessment of an in-practice project (author's transl)].
Kosten-Nutzen-Analyse zur Beschäftigung von Diatassistentinnen in der ärztlichen Praxis. I. Mitteilung: Überlegungen, Berechnungsgrundlagen, Auswertung einer poliklinischen Studie sowie vorläufige Beurteilung eines Praxisprojekts.

AU Petzoldt R; Haupt E; Schoffling K

SO Medizinische Klinik (1947), (1977 Jul 8) Vol. 72, No. 27, pp. 1177-82.
Journal code: 0376637. ISSN: 0025-8458.

CY GERMANY, WEST: Germany, Federal Republic of

DT (ENGLISH ABSTRACT)

Journal; Article; (JOURNAL ARTICLE)

LA German

FS Priority Journals

EM 197709

ED Entered STN: 14 Mar 1990

Last Updated on STN: 14 Mar 1990

Entered Medline: 17 Sep 1977

L4 ANSWER 203 OF 658 MEDLINE on STN
Full Text
 AN 77120106 MEDLINE
 DN PubMed ID: 1071098
 TI Death caused by intravenous anesthetics; thoracic pain caused by synthetic penicillin; and liver diseases induced by Glybuzole sometimes used in combination with clindamycin for the treatment of diabetes by dentists in the form of self medication.
 AU Tamura T
 SO Nippon Shika Ishikai zasshi, (1976) Vol. 29, No. 9, pp. 961-6.
 Journal code: 7505756. ISSN: 0047-1763.
 CY Japan
 DT Journal; Article; (JOURNAL ARTICLE)
 LA Japanese
 FS Dental Journals
 EM 197704
 ED Entered STN: 13 Mar 1990
 Last Updated on STN: 13 Mar 1990
 Entered Medline: 15 Apr 1977

L4 ANSWER 204 OF 658 MEDLINE on STN
Full Text
 AN 77080911 MEDLINE
 DN PubMed ID: 63991
 TI [The importance of clinical observations for medical research].
 Die Bedeutung der Klinik fur die medizinisch Forschung.
 AU Koller F
 SO Schweizerische medizinische Wochenschrift, (1976 Oct 30) Vol. 106, No. 44,
 pp. 1489-98. Ref: 84
 Journal code: 0404401. ISSN: 0036-7672.
 CY Switzerland
 DT (CLINICAL TRIAL)
 (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA German
 FS Priority Journals
 EM 197702
 ED Entered STN: 13 Mar 1990
 Last Updated on STN: 13 Mar 1990
 Entered Medline: 16 Feb 1977

L4 ANSWER 205 OF 658 MEDLINE on STN
Full Text
 AN 77036005 MEDLINE
 DN PubMed ID: 10553
 TI [Drug-induced hypoglycemia in diabetic patients].
 Les hypoglycemies induites par les medicaments chez le diabetique.
 AU Gay G; Debry G
 SO La Nouvelle presse medicale, (1976 Oct 9) Vol. 5, No. 9 Oct 76, pp.
 2156-8.
 Journal code: 0312552. ISSN: 0301-1518.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 197612
 ED Entered STN: 13 Mar 1990
 Last Updated on STN: 6 Feb 1995
 Entered Medline: 30 Dec 1976

L4 ANSWER 206 OF 658 MEDLINE on STN
Full Text
 AN 76278148 MEDLINE
 DN PubMed ID: 134717
 TI Comparative study of the hypoglycaemic and antilipolytic effects of four antidiabetic agents administered i.v.
 AU Guirgis F K; Ghanem M H; Abdel-Hay M M
 SO Arzneimittel-Forschung, (1976) Vol. 26, No. 3, pp. 435-7.
 Journal code: 0372660. ISSN: 0004-4172.
 CY GERMANY, WEST: Germany, Federal Republic of

DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 197610
 ED Entered STN: 13 Mar 1990
 Last Updated on STN: 13 Mar 1990
 Entered Medline: 20 Oct 1976

L4 ANSWER 207 OF 658 MEDLINE on STN
Full Text
 AN 76252973 MEDLINE
 DN PubMed ID: 782478
 TI [Clinical trial of the antibacterial combination sulfamoxole/trimethoprim
 (CN 3123)/Sixth communication: Results of compatibility of CN 3123
 (author's transl)].
 Klinische Prufung der antibakteriellen Kombination Sulfamoxol/Trimethoprim
 (CN 3123). 6. Mitteilung: Ergebnisse zur Vertraglichkeit von CN 3123.
 AU Etzel M; Wesenberg W
 SO Arzneimittel-Forschung, (1976) Vol. 26, No. 42, pp. 678-83.
 Journal code: 0372660. ISSN: 0004-4172.
 CY GERMANY, WEST: Germany, Federal Republic of
 DT (CLINICAL TRIAL)
 (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 197609
 ED Entered STN: 13 Mar 1990
 Last Updated on STN: 13 Mar 1990
 Entered Medline: 25 Sep 1976

L4 ANSWER 208 OF 658 MEDLINE on STN
Full Text
 AN 76242150 MEDLINE
 DN PubMed ID: 950904
 TI [Combination of oral hypoglycemic agents].
 Association d'hypoglycemiants per oraux.
 AU Decoulx M
 SO Lille medical : journal de la Faculte de medecine et de pharmacie de
 l'Universite de Lille, (1976) Vol. 21 spec no, pp. 263-5.
 Journal code: 8203780. ISSN: 0024-3507.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 197610
 ED Entered STN: 13 Mar 1990
 Last Updated on STN: 13 Mar 1990
 Entered Medline: 2 Oct 1976

L4 ANSWER 209 OF 658 MEDLINE on STN
Full Text
 AN 76242135 MEDLINE
 DN PubMed ID: 950893
 TI [Hypoglycemic sulfamides].
 Sulfamides hypoglycemiants.
 AU Martin-Linquette A
 SO Lille medical : journal de la Faculte de medecine et de pharmacie de
 l'Universite de Lille, (1976 Apr) Vol. 21, No. 4, pp. 369-73.
 Journal code: 8203780. ISSN: 0024-3507.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 197610
 ED Entered STN: 13 Mar 1990
 Last Updated on STN: 13 Mar 1990
 Entered Medline: 2 Oct 1976

L4 ANSWER 210 OF 658 MEDLINE on STN
Full Text

AN 76231851 MEDLINE
 DN PubMed ID: 947213
 TI Metabolism, kinetics and metabolic activity of the beta-cytotropic antidiabetic 4-(5-isobutylpyrimidinyl-2)-sulphamylphenylacetic acid-3-chloro-6-methoxyanilide sodium (glydanile sodium) in man after oral and intravenous administration.
 AU Gerhards E; Berger D; Peters S
 SO Arzneimittelforschung, (1976 Feb) Vol. 26, No. 2, pp. 278-86.
 Journal code: 0372660. ISSN: 0004-4172.
 CY GERMANY, WEST: Germany, Federal Republic of
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 197609
 ED Entered STN: 13 Mar 1990
 Last Updated on STN: 3 Feb 1997
 Entered Medline: 2 Sep 1976

L4 ANSWER 211 OF 658 MEDLINE on STN
Full Text

AN 76197245 MEDLINE
 DN PubMed ID: 818620
 TI [Hypoglycemic complications of oral drug therapy of diabetes mellitus. 21 cases].
 Les accidents hypoglycémiques des thérapeutiques orales du diabète. 21 cas.
 AU De Vigan C; Delporte M P; Thomas M; Perrault M
 SO La Nouvelle presse medicale, (1976 Apr 3) Vol. 5, No. 14, pp. 906-10.
 Journal code: 0312552. ISSN: 0301-1518.
 CY France
 DT (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 197608
 ED Entered STN: 13 Mar 1990
 Last Updated on STN: 13 Mar 1990
 Entered Medline: 2 Aug 1976

L4 ANSWER 212 OF 658 MEDLINE on STN
Full Text

AN 76195525 MEDLINE
 DN PubMed ID: 818477
 TI Pathophysiologic and pharmacologic alterations in the release and action of ADH.
 AU Moses A M; Miller M; Streeten D H
 SO Metabolism: clinical and experimental, (1976 Jun) Vol. 25, No. 6, pp. 697-721.
 Journal code: 0375267. ISSN: 0026-0495.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
 LA English
 FS Priority Journals
 EM 197608
 ED Entered STN: 13 Mar 1990
 Last Updated on STN: 3 Mar 2000
 Entered Medline: 2 Aug 1976

L4 ANSWER 213 OF 658 MEDLINE on STN
Full Text

AN 76093575 MEDLINE
 DN PubMed ID: 1205443
 TI [Diabetes therapy; 2. Diet, drug therapy (Sulfonamide derivatives, biguanides, insulin)].
 Diabetes-Therapie Folge 2: Diät, medikamentöse Therapie (Sulfonamid-Derivate, Biguanide, Insulin).
 AU Forster H
 SO Fortschritte der Medizin, (1975 Sep 18) Vol. 93, No. 26, pp. 1195-200.
 Journal code: 2984763R. ISSN: 0015-8178.

CY GERMANY, WEST: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals
EM 197603
ED Entered STN: 13 Mar 1990
Last Updated on STN: 13 Mar 1990
Entered Medline: 30 Mar 1976

L4 ANSWER 214 OF 658 MEDLINE on STN

Full Text

AN 76010626 MEDLINE
DN PubMed ID: 808721
TI [Twenty years of oral diabetic therapy (author's transl)].
Zwanzig Jahre orale Diabetestherapie.
AU Mehnert H; Dietze G; Haslbeck
SO MMW, Munchener medizinische Wochenschrift, (1975 Jul 18) Vol. 117, No. 29-30, pp. 1221-8.
Journal code: 7801805. ISSN: 0341-3098.
CY GERMANY, WEST: Germany, Federal Republic of
DT (ENGLISH ABSTRACT)
Historical
Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals; History of Medicine
EM 197512
ED Entered STN: 13 Mar 1990
Last Updated on STN: 13 Mar 1990
Entered Medline: 4 Dec 1975

L4 ANSWER 215 OF 658 MEDLINE on STN

Full Text

AN 76009969 MEDLINE
DN PubMed ID: 1160599
TI [Modern drug therapy of diabetes mellitus].
Moderne medikamentöse Behandlung des Diabetes mellitus.
AU Mehnert H
SO Die Medizinische Welt, (1975 Sep 5) Vol. 26, No. 36, pp. 1571-6.
Journal code: 0376641. ISSN: 0025-8512.
CY GERMANY, WEST: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals
EM 197512
ED Entered STN: 13 Mar 1990
Last Updated on STN: 13 Mar 1990
Entered Medline: 5 Dec 1975

L4 ANSWER 216 OF 658 MEDLINE on STN

Full Text

AN 76002116 MEDLINE
DN PubMed ID: 4465060
TI [Hyperlipemias in diabetics].
Les hyperlipidemies des diabetiques.
AU Mirouze J; Carty M E
SO Coeur et medecine interne, (1974 Oct-Dec) Vol. 13, No. 4, pp. 613-26.
Journal code: 0373165. ISSN: 0010-0234.
CY France
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 197512
ED Entered STN: 13 Mar 1990
Last Updated on STN: 13 Mar 1990
Entered Medline: 4 Dec 1975

L4 ANSWER 217 OF 658 MEDLINE on STN

Full Text

AN 75215156 MEDLINE
DN PubMed ID: 1152377
TI [Complex treatment of patients with diabetes mellitus with diabetic

retinopathy].
O kompleksnom lechenii bol'nykh sakharnym diabetom s diabeticheskoi
retinopatiei.

AU Vasiukova E A; Margolis M G
SO Klinicheskaja meditsina, (1975 Apr) Vol. 53, No. 4, pp. 78-82.
Journal code: 2985204R. ISSN: 0023-2149.

CY USSR
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)

LA Russian
FS Priority Journals
EM 197510
ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 30 Oct 1975

L4 ANSWER 218 OF 658 MEDLINE on STN
Full Text

AN 75185962 MEDLINE
DN PubMed ID: 1095262
TI Effect of equivalent antihypertensive doses of mefruside and
cyclopentiazide on serum electrolytes, uric acid and glucose tolerance in
hypertensive patients.

AU Waal-Manning H J
SO Clinical and experimental pharmacology & physiology, (1975 Mar-Apr) Vol.
2, No. 2, pp. 141-6.
Journal code: 0425076. ISSN: 0305-1870.

CY ENGLAND: United Kingdom
DT (CLINICAL TRIAL)
(COMPARATIVE STUDY)
(CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)

LA English
FS Priority Journals
EM 197510
ED Entered STN: 10 Mar 1990
Last Updated on STN: 6 Feb 1998
Entered Medline: 11 Oct 1975

L4 ANSWER 219 OF 658 MEDLINE on STN
Full Text

AN 75167356 MEDLINE
DN PubMed ID: 124241
TI Pancreatic islet-cell toxicity.

AU Fischer L J; Rickert D E
SO CRC critical reviews in toxicology, (1975 Jan) Vol. 3, No. 2, pp. 231-63.
Ref: 170
Journal code: 1305020. ISSN: 0045-6446.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
General Review; (REVIEW)

LA English
FS Priority Journals
EM 197508
ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 20 Aug 1975

L4 ANSWER 220 OF 658 MEDLINE on STN
Full Text

AN 75158651 MEDLINE
DN PubMed ID: 4376601
TI Studies on the effect of oral hypoglycaemic agents on hepatic
glycogenolysis.

AU Saleh S; Abdel-Khalek A; Khayyal M T; Masri A M; Sharat A A
SO Pharmacological research communications, (1974 Dec) Vol. 6, No. 6, pp.
539-50.
Journal code: 0236354. ISSN: 0031-6989.

CY ENGLAND: United Kingdom
DT (IN VITRO)
Journal; Article; (JOURNAL ARTICLE)

LA English
FS Priority Journals
EM 197507
ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 28 Jul 1975

L4 ANSWER 221 OF 658 MEDLINE on STN

Full Text

AN 75157682 MEDLINE
DN PubMed ID: 1093131
TI [Glipizide: a 2d generation sulfonamide and new antidiabetic].
Le glipizide. Sulfamide de la deuxieme generation, antidiabetique nouveau.
AU Deuil R
SO La Nouvelle presse medicale, (1975 Feb 15) Vol. 4, No. 7, pp. 500-1.
Journal code: 0312552. ISSN: 0301-1518.
CY France
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 197507
ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 28 Jul 1975

L4 ANSWER 222 OF 658 MEDLINE on STN

Full Text

AN 75149306 MEDLINE
DN PubMed ID: 1092541
TI Diuretics: mechanism of action and clinical application.
AU Davies D L; Wilson G M
SO Drugs, (1975) Vol. 9, No. 3, pp. 178-226. Ref: 372
Journal code: 7600076. ISSN: 0012-6667.
CY Switzerland
DT (IN VITRO)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 197507
ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 28 Jul 1975

L4 ANSWER 223 OF 658 MEDLINE on STN

Full Text

AN 75141284 MEDLINE
DN PubMed ID: 4458085
TI [Effect of sulfaguanol (Enterocura) on carbohydrate metabolism in diabetic patients and people with normal metabolism].
Wirkung von Sulfaguanol (Enterocura) auf den Kohlenhydratstoffwechsel von Diabetikern und Stoffwechselgesunden.
AU Janka J U; Mehnert H
SO Therapie der Gegenwart, (1974 Dec) Vol. 113, No. 12, pp. 2163-4, 2166-8.
Journal code: 0413576. ISSN: 0040-5965.
CY GERMANY, WEST: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals
EM 197506
ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 27 Jun 1975

L4 ANSWER 224 OF 658 MEDLINE on STN

Full Text

AN 75017860 MEDLINE
DN PubMed ID: 4417092
TI Side effects of some non-antibacterial sulfonamide derivatives.
AU Kaldor A
SO International journal of clinical pharmacology, therapy and toxicology,

(1974 Jun) Vol. 9, No. 4, pp. 283-6.
 Journal code: 7505528. ISSN: 0300-9718.
 CY GERMANY, WEST: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 197501
 ED Entered STN: 10 Mar 1990
 Last Updated on STN: 10 Mar 1990
 Entered Medline: 6 Jan 1975

L4 ANSWER 225 OF 658 MEDLINE on STN

Full Text

AN 75005919 MEDLINE
 DN PubMed ID: 4606062
 TI [Variations of basal and post-stimulative insulin blood levels, during prolonged treatment with hypoglycemic sulfamides].
 Variations de l'insulinemie basale et post-stimulative au cours des traitements prolonges aux sulfamides hypoglycemiants.
 AU Pirart J; Lauvaux J P; Mandart G
 SO Journees annuelles de diabetologie de l'Hotel-Dieu, (1972) Vol. 13, pp. 67-79. Ref: 67
 Journal code: 0424745. ISSN: 0075-4439.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA French
 FS Priority Journals
 EM 197412
 ED Entered STN: 10 Mar 1990
 Last Updated on STN: 10 Mar 1990
 Entered Medline: 5 Dec 1974

L4 ANSWER 226 OF 658 MEDLINE on STN

Full Text

AN 75005905 MEDLINE
 DN PubMed ID: 4679623
 TI [Value of a new sulfonamide-biguanide association in the treatment of diabetes mellitus].
 Interet d'une nouvelle association sulfamide-biguanide dans le traitement du diabete sucre.
 AU Chon A
 SO Journees annuelles de diabetologie de l'Hotel-Dieu, (1972) Vol. 13, pp. 321-5.
 Journal code: 0424745. ISSN: 0075-4439.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 197412
 ED Entered STN: 10 Mar 1990
 Last Updated on STN: 10 Mar 1990
 Entered Medline: 5 Dec 1974

L4 ANSWER 227 OF 658 MEDLINE on STN

Full Text

AN 75001116 MEDLINE
 DN PubMed ID: 4802162
 TI [Comparative characteristics of the hypoglycemic effect of a new 3,5-dioxypyrazolidine derivative, DSB, and butamide].
 Sravnitel'naia kharakteristika gipoglikemiziruiushchego effekta novogo proizvodnogo 3,5-dioksopirazolidina DSB i butamida.
 AU Voronkova L A
 SO Farmakologiya i toksikologiya, (1973) Vol. 36, No. 5, pp. 706-7.
 Journal code: 16920420R. ISSN: 0014-8318.
 CY USSR
 DT (COMPARATIVE STUDY)
 (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 LA Russian
 FS Priority Journals
 EM 197412

ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 6 Dec 1974

L4 ANSWER 228 OF 658 MEDLINE on STN

Full Text

AN 74296493 MEDLINE
DN PubMed ID: 5164783
TI [The correct use of a good antidiabetic sulfonamide].
Du bon usage d'un bon sulfamide antidiabetique.
AU Anonymous
SO Journees annuelles de diabetologie de l'Hotel-Dieu, (1971 May 6) Vol. 12,
pp. 261-5.
Journal code: 0424745. ISSN: 0075-4439.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 197411
ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 14 Nov 1974

L4 ANSWER 229 OF 658 MEDLINE on STN

Full Text

AN 74294985 MEDLINE
DN PubMed ID: 4211557
TI [Pharmacologic study with glisoxepide and other blood sugar reducing
sulfonamide derivatives in metabolically healthy subjects and diabetics].
Pharmakologische Untersuchungen mit Glisocepid und anderen
blutzuckersenkenden Sulfonamidderivaten an Stoffwechselgesunden und
Diabetikern.
AU Haupt E; Beyer J; Schoffling K
SO Arzneimittel-Forschung, (1974 Mar) Vol. 24, pp. 418-25.
Journal code: 0372660. ISSN: 0004-4172.
CY GERMANY, WEST: Germany, Federal Republic of
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals
EM 197411
ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 8 Nov 1974

L4 ANSWER 230 OF 658 MEDLINE on STN

Full Text

AN 74291986 MEDLINE
DN PubMed ID: 4603399
TI [Clinical experience with the blood sugar reducing sulfonamide
derivative glisoxepide].
Klinische Erfahrungen mit dem blutzuckersenkenden Sulfonamidderivat
Glisoxepid.
AU Petzoldt R; Riedesel G; Ramrath M; Grabs V; Haupt E; Schwedes U; Ewald W;
Beyer J; Schoffling K
SO Arzneimittel-Forschung, (1974 Mar) Vol. 24, pp. 429-32.
Journal code: 0372660. ISSN: 0004-4172.
CY GERMANY, WEST: Germany, Federal Republic of
DT (CLINICAL TRIAL)
(ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals
EM 197411
ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 8 Nov 1974

L4 ANSWER 231 OF 658 MEDLINE on STN

Full Text

AN 74261355 MEDLINE
DN PubMed ID: 4836869

TI [Application of the method of continuous recording of glycemia to the study of the action of hypoglycemic agents in the diabetic].
Application de la methode des enregistrements continus de glycemie a l'etude de l'action des substances hypoglycemiantes chez le diabetique.

AU Drouin P; Mejean L; Guisard D; Debry G

SO Nutrition and metabolism, (1974) Vol. 16, No. 5, pp. 261-7.
Journal code: 0330472. ISSN: 0029-6678.

CY Switzerland

DT (ENGLISH ABSTRACT)

LA French

FS Priority Journals

EM 197408

ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 28 Aug 1974

L4 ANSWER 232 OF 658 MEDLINE on STN

Full Text

AN 74164893 MEDLINE

DN PubMed ID: 4208216

TI [Longtime effect of blood sugar decreasing **sulfonamides** on glucose tolerance and insulin secretion in adult diabetic patients].
Untersuchungen zur Frage des Langzeiteffektes von blutzuckersenkenden **Sulfonamiden** auf Glucosetoleranz und Insulinsekretion bei erwachsenen Diabetikern.

AU Haupt E; Cordes U; Petzoldt R; Beyer J; Schoffling K

SO Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, (1973) Vol. 79, pp. 1216-20.
Journal code: 7503702. ISSN: 0070-4067.

CY GERMANY, WEST: Germany, Federal Republic of

DT Journal; Article; (JOURNAL ARTICLE)

LA German

FS Priority Journals

EM 197407

ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 16 Jul 1974

L4 ANSWER 233 OF 658 MEDLINE on STN

Full Text

AN 74160494 MEDLINE

DN PubMed ID: 4857088

TI A study of the effect of metolazone on carbohydrate metabolism in diabetic subjects.

AU Walsh C H; O'Sullivan D J

SO Journal of the Irish Medical Association, (1974 Apr 27) Vol. 67, No. 8, pp. 223-6.
Journal code: 0430304. ISSN: 0021-129X.

CY Ireland

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 197407

ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 12 Jul 1974

L4 ANSWER 234 OF 658 MEDLINE on STN

Full Text

AN 74144504 MEDLINE

DN PubMed ID: 4822858

TI [Studies on the effect of sulfamethoxypyrazine (Longum) on carbohydrate metabolism in diabetic patients].
Untersuchungen uber den Einfluss von Sulfamethoxypyrazin (Longum) auf den Zuckerstoffwechsel des Diabetikers.

AU Stotter G; Riederle K

SO Fortschritte der Medizin, (1974 Apr 11) Vol. 92, No. 10, pp. 442-4.
Journal code: 2984763R. ISSN: 0015-8178.

CY GERMANY, WEST: Germany, Federal Republic of

DT Journal; Article; (JOURNAL ARTICLE)

LA German

FS Priority Journals
EM 197406
ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 14 Jun 1974

L4 ANSWER 235 OF 658 MEDLINE on STN

Full Text

AN 74142603 MEDLINE
DN PubMed ID: 4822160
TI [Management of **diabetes** mellitus].
Un **diabete** sucre.
AU Wechsler B
SO La Nouvelle presse medicale, (1974 Mar 2) Vol. 3, No. 9, pp. 531-4.
Journal code: 0312552. ISSN: 0301-1518.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals
EM 197406
ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 12 Jun 1974

L4 ANSWER 236 OF 658 MEDLINE on STN

Full Text

AN 74102013 MEDLINE
DN PubMed ID: 4591686
TI [Skin and **diabetes**].
Peau et **diabete**.
AU Delacretaz J
SO Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine
Praxis, (1973 Nov 13) Vol. 62, No. 46, pp. 1419-25. Ref: 39
Journal code: 8403202. ISSN: 1013-2058.
CY Switzerland
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA French
FS Priority Journals
EM 197404
ED Entered STN: 10 Mar 1990
Last Updated on STN: 3 Feb 1997
Entered Medline: 11 Apr 1974

L4 ANSWER 237 OF 658 MEDLINE on STN

Full Text

AN 74092737 MEDLINE
DN PubMed ID: 4775874
TI Studies on new antidiabetic compounds. II. N-(aminoacyl)-p-
toluenesulfonamides.
AU Muzalewski F; Przybylski J; Kupryszewski G; Hac E; Matuszek M
SO Polish journal of pharmacology and pharmacy, (1973 Mar-Apr) Vol. 25, No.
2, pp. 181-5.
Journal code: 0366561. ISSN: 0301-0244.
CY Poland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197404
ED Entered STN: 10 Mar 1990
Last Updated on STN: 10 Mar 1990
Entered Medline: 2 Apr 1974

L4 ANSWER 238 OF 658 MEDLINE on STN

Full Text

AN 73235140 MEDLINE
DN PubMed ID: 4198967
TI [Insulin liberation by blood sugar decreasing **sulfonamides** and by
glucose in adult diabetic patients].
Zur Insulinfreisetzung durch blutzuckersenkende **Sulfonamide** und Glucose
bei Erwachsenen-Diabetikern.
AU Haupt E; Koberich W; Rosak C; Beyer J; Schoffling K

SO Arzneimittel-Forschung, (1972 Dec) Vol. 22, pp. Suppl 12A:2198.
 Journal code: 0372660. ISSN: 0004-4172.
 CY GERMANY, WEST: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 197310
 ED Entered STN: 10 Mar 1990
 Last Updated on STN: 10 Mar 1990
 Entered Medline: 14 Oct 1973

L4 ANSWER 239 OF 658 MEDLINE on STN

Full Text

AN 73210745 MEDLINE
 DN PubMed ID: 4351885
 TI [Problems of long-term therapy of chronic pyelonephritis].
 Zur Problematik der Langzeittherapie der chronischen Pyelonephritis.
 AU Tauchnitz C; Schauer A; Dadaliaris D
 SO Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, (1973
 Apr 1) Vol. 28, No. 7, pp. 97-9.
 Journal code: 21730470R. ISSN: 0044-2542.
 CY GERMANY, EAST: German Democratic Republic
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS Priority Journals
 EM 197309
 ED Entered STN: 10 Mar 1990
 Last Updated on STN: 10 Mar 1990
 Entered Medline: 6 Sep 1973

L4 ANSWER 240 OF 658 MEDLINE on STN

Full Text

AN 73181907 MEDLINE
 DN PubMed ID: 4661228
 TI [Effect of administration of hypoglycemic sulfonamide on glycoregulation
 balance].
 Etude du mode d'administration d'un sulfamide hypoglycemiant sur
 l'equilibration de la glyco-regulation.
 AU Schrub J C; Courtois H; Birembau Y
 SO Therapie, (1972 Nov-Dec) Vol. 27, No. 6, pp. 983-7.
 Journal code: 0420544. ISSN: 0040-5957.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 197307
 ED Entered STN: 10 Mar 1990
 Last Updated on STN: 3 Feb 1997
 Entered Medline: 19 Jul 1973

=> d 14 170-200

L4 ANSWER 170 OF 658 MEDLINE on STN

Full Text

AN 95167596 MEDLINE
 DN PubMed ID: 7863436
 TI [The peroral therapy of non-insulin-dependent diabetes mellitus].
 Peroral'naia terapiia insulinnezavisimogo sakharnogo diabeta.
 AU Ametov A S; Granovskaia-Tsvetkova A M
 SO Terapevticheskii arkhiv, (1994) Vol. 66, No. 10, pp. 17-9.
 Journal code: 2984818R. ISSN: 0040-3660.
 CY RUSSIA: Russian Federation
 DT (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 LA Russian
 FS Priority Journals
 EM 199503
 ED Entered STN: 4 Apr 1995
 Last Updated on STN: 4 Apr 1995
 Entered Medline: 23 Mar 1995

L4 ANSWER 171 OF 658 MEDLINE on STN
Full Text
 AN 95104544 MEDLINE
 DN PubMed ID: 7805953
 TI New perspectives on the actions of sulphonylureas and hyperglycaemic sulphonamides on the pancreatic beta-cell.
 AU Flatt P R; Shibier O; Szechowka J; Berggren P O
 CS Department of Biological and Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, U.K.
 SO Diabete & metabolisme, (1994 Mar-Apr) Vol. 20, No. 2, pp. 157-62. Ref: 26
 Journal code: 7604157. ISSN: 0338-1684.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 199502
 ED Entered STN: 15 Feb 1995
 Last Updated on STN: 15 Feb 1995
 Entered Medline: 2 Feb 1995

L4 ANSWER 172 OF 658 MEDLINE on STN
Full Text
 AN 94367601 MEDLINE
 DN PubMed ID: 8085357
 TI [The computer support of hypoglycemic therapy in non-insulin-dependent diabetes mellitus].
 Komp'iuternoe obespechenie sakharosnizhaiushchei terapii pri insulinonezavisimom sakharnom diabete.
 AU Shcherbak A V; Efimov D A; Plaksin K V
 SO Likars'ka sprava / Ministerstvo okhorony zdorov'ia Ukrainy, (1993 Sep) No. 9, pp. 81-3.
 Journal code: 9601540. ISSN: 1019-5297.
 CY Ukraine
 DT (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 LA Russian
 FS Priority Journals
 EM 199410
 ED Entered STN: 21 Oct 1994
 Last Updated on STN: 3 Feb 1997
 Entered Medline: 13 Oct 1994

L4 ANSWER 173 OF 658 MEDLINE on STN
Full Text
 AN 94328447 MEDLINE
 DN PubMed ID: 8051810
 TI [Principles of the prospective study on diabetes at Royaume-Uni].
 Principes de l'etude prospective sur le diabete au Royaume-Uni.
 AU Turner R C
 CS Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, England.
 SO Journees annuelles de diabetologie de l'Hotel-Dieu, (1994) pp. 101-10.
 Ref: 26
 Journal code: 0424745. ISSN: 0075-4439.
 CY France
 DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)
 General Review; (REVIEW)
 LA French
 FS Priority Journals
 EM 199409
 ED Entered STN: 14 Sep 1994
 Last Updated on STN: 14 Sep 1994
 Entered Medline: 6 Sep 1994

L4 ANSWER 174 OF 658 MEDLINE on STN
Full Text
 AN 94254360 MEDLINE
 DN PubMed ID: 8196281
 TI Acute and chronic effects of thromboxane A2 inhibition on the renal

hemodynamics in streptozotocin-induced diabetic rats.
AU Uriu K; Kaizu K; Hashimoto O; Komine N; Etoh S
CS Kidney Center, University of Occupational and Environmental Health, School
of Medicine, Fukuoka, Japan.
SO Kidney international, (1994 Mar) Vol. 45, No. 3, pp. 794-802.
Journal code: 0323470. ISSN: 0085-2538.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199406
ED Entered STN: 7 Jul 1994
Last Updated on STN: 6 Feb 1998
Entered Medline: 27 Jun 1994

L4 ANSWER 175 OF 658 MEDLINE on STN

Full Text

AN 93323426 MEDLINE
DN PubMed ID: 8331877
TI [Delayed action of oral antidiabetic treatments. Place of combination of
insulin and hypoglycemic sulfamides].
Les echecs retards des traitements antidiabetiques oraux. Place de
l'association insuline-sulfamides hypoglycemiants.
AU Leutenegger M; Nakib Y; Grulet H; Gross A; Boirie Y
CS Clinique Medicale, Hopital Robert-Debre, Reims.
SO Journees annuelles de diabetologie de l'Hotel-Dieu, (1993) pp. 97-114.
Ref: 60
Journal code: 0424745. ISSN: 0075-4439.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA French
FS Priority Journals
EM 199308
ED Entered STN: 26 Aug 1993
Last Updated on STN: 26 Aug 1993
Entered Medline: 19 Aug 1993

L4 ANSWER 176 OF 658 MEDLINE on STN

Full Text

AN 93323402 MEDLINE
DN PubMed ID: 8331860
TI [The UKPDS study on glycemic control and arterial hypertension in type II
diabetes: objectives, structure and preliminary results].
L'etude ukpds sur le controle de la glycemie et de l'hypertension
arterielle dans le diabete de type II: objectifs, structure et resultats
preliminaires.
AU Levy J C; Cull C A; Stratton I M; Holman R R; Turner R C
CS Diabetes Research Laboratories, Radcliffe Infirmary, Oxford.
SO Journees annuelles de diabetologie de l'Hotel-Dieu, (1993) pp. 123-37.
Journal code: 0424745. ISSN: 0075-4439.
CY France
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
LA French
FS Priority Journals
EM 199308
ED Entered STN: 26 Aug 1993
Last Updated on STN: 26 Aug 1993
Entered Medline: 19 Aug 1993

L4 ANSWER 177 OF 658 MEDLINE on STN

Full Text

AN 93083824 MEDLINE
DN PubMed ID: 1451945
TI The fiftieth anniversary of hypoglycaemic sulphonamides. How did the
mother compound work?.
AU Henquin J C
CS Unite de Diabetologie et Nutrition, University of Louvain School of
Medicine, Brussels, Belgium.

SO Diabetologia, (1992 Oct) Vol. 35, No. 10, pp. 907-12.
Journal code: 0006777. ISSN: 0012-186X.
CY GERMANY: Germany, Federal Republic of
DT Historical
LA English
FS Priority Journals; History of Medicine
EM 199301
ED Entered STN: 29 Jan 1993
Last Updated on STN: 29 Jan 1993
Entered Medline: 6 Jan 1993

L4 ANSWER 178 OF 658 MEDLINE on STN

Full Text

AN 92193820 MEDLINE
DN PubMed ID: 1312572
TI Inhibition of protein kinase C restores Na⁺,K⁺-ATPase activity in
sciatic nerve of diabetic mice.
AU Hermenegildo C; Felipo V; Minana M D; Grisolia S
CS Instituto de Investigaciones Citologicas, Valencia, Spain.
SO Journal of neurochemistry, (1992 Apr) Vol. 58, No. 4, pp. 1246-9.
Journal code: 2985190R. ISSN: 0022-3042.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 199204
ED Entered STN: 9 May 1992
Last Updated on STN: 3 Feb 1997
Entered Medline: 17 Apr 1992

L4 ANSWER 179 OF 658 MEDLINE on STN

Full Text

AN 92187399 MEDLINE
DN PubMed ID: 1798653
TI [The dynamics of the Zn content in the pancreatic islets of rabbits after
the administration of the diabetogenic agent dithizone].
Dinamika sodержaniia Zn v pankreaticheskikh ostrovkakh krolikov posle
vvedeniia diabetogennogo agenta ditizona.
AU Gol'dberg E D; Eshchenko V A; Bovt V D
SO Patologicheskaiia fiziologiia i eksperimental'naia terapiia, (1991 Jul-Aug)
No. 4, pp. 43-5.
Journal code: 0376421. ISSN: 0031-2991.
CY USSR
DT (COMPARATIVE STUDY)
(ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA Russian
FS Priority Journals
EM 199204
ED Entered STN: 24 Apr 1992
Last Updated on STN: 3 Feb 1997
Entered Medline: 15 Apr 1992

L4 ANSWER 180 OF 658 MEDLINE on STN

Full Text

AN 91308631 MEDLINE
DN PubMed ID: 1854952
TI [The effect of diabetogenic substances on the zinc and calcium content in
the pancreatic islet cells of rabbits].
Vliianie diabetogennykh veshchestv na sodержanie tsinka i kal'tsiia v
kletkakh pankreaticheskikh ostrovkov u krolikov.
AU Gol'dberg E D; Eshchenko V A; Bovt V D
SO Biulleten' eksperimental'noi biologii i meditsiny, (1991 Feb) Vol. 111,
No. 2, pp. 135-7.
Journal code: 0370627. ISSN: 0365-9615.
CY USSR
DT (COMPARATIVE STUDY)
(ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA Russian

FS Priority Journals
 EM 199108
 ED Entered STN: 13 Sep 1991
 Last Updated on STN: 3 Feb 1997
 Entered Medline: 29 Aug 1991

L4 ANSWER 181 OF 658 MEDLINE on STN
Full Text
 AN 91029049 MEDLINE
 DN PubMed ID: 2224754
 TI Use of sulfonylurea agents in older diabetic patients.
 AU Peters A L; Davidson M B
 CS Cedars-Sinai Medical Center, Los Angeles, California.
 SO Clinics in geriatric medicine, (1990 Nov) Vol. 6, No. 4, pp. 903-21. Ref: 74
 Journal code: 8603766. ISSN: 0749-0690.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 199012
 ED Entered STN: 8 Feb 1991
 Last Updated on STN: 8 Feb 1991
 Entered Medline: 20 Dec 1990

L4 ANSWER 182 OF 658 MEDLINE on STN
Full Text
 AN 90353256 MEDLINE
 DN PubMed ID: 2387254
 TI Calcium-dependent protein kinase activity is decreased in diabetic rat sciatic nerve.
 AU Gabbay R A; Siconolfi-Baez L; Lebovitz H E
 CS Department of Medicine, State University of New York Health Science Center, Brooklyn 11203.
 SO Endocrinology, (1990 Sep) Vol. 127, No. 3, pp. 1194-8.
 Journal code: 0375040. ISSN: 0013-7227.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 199009
 ED Entered STN: 26 Oct 1990
 Last Updated on STN: 3 Feb 1997
 Entered Medline: 21 Sep 1990

L4 ANSWER 183 OF 658 MEDLINE on STN
Full Text
 AN 90195009 MEDLINE
 DN PubMed ID: 2316232
 TI Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.
 AU Johnson J F; Dobmeier M E
 CS Rochester General Hospital, NY 14621.
 SO DICP : the annals of pharmacotherapy, (1990 Mar) Vol. 24, No. 3, pp. 250-1.
 Journal code: 8904338. ISSN: 1042-9611.
 CY United States
 DT (CASE REPORTS)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199004
 ED Entered STN: 1 Jun 1990
 Last Updated on STN: 1 Jun 1990
 Entered Medline: 26 Apr 1990

L4 ANSWER 184 OF 658 MEDLINE on STN
Full Text
 AN 89284453 MEDLINE
 DN PubMed ID: 2734988
 TI [Change in the panorama of chronic diseases and their insurability by life

insurance].
Panoramawandel chronischer Erkrankungen und ihre Versicherbarkeit in der
Lebensversicherung.

AU Frohlich E M
SO Versicherungsmedizin / herausgegeben von Verband der Lebensversicherungs-
Unternehmen e.V. und Verband der Privaten Krankenversicherung e.V, (1989
May 1) Vol. 41, No. 3, pp. 97-102.
Journal code: 8803623. ISSN: 0933-4548.

CY GERMANY, WEST: Germany, Federal Republic of
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)

LA German
FS Priority Journals; AIDS
EM 198907
ED Entered STN: 9 Mar 1990
Last Updated on STN: 9 Mar 1990
Entered Medline: 25 Jul 1989

L4 ANSWER 185 OF 658 MEDLINE on STN
Full Text

AN 89226743 MEDLINE
DN PubMed ID: 3072890
TI [Hyponatremia induced by hypoglycemic sulfonamides: a study of 70
patients].
Hyponatremie induite par les sulfamides hypoglycemiants: etude chez 70
patients.

AU Gin H; Lars I; Morlat P; Beauvieux J M; Aubertin J
CS Clinique Medicale et des Maladies Infectieuses, Hopital Pellegrin,
Bordeaux.

SO Annales de medecine interne, (1988) Vol. 139, No. 7, pp. 455-9. Ref: 26
Journal code: 0171744. ISSN: 0003-410X.

CY France
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)

LA French
FS Priority Journals
EM 198906
ED Entered STN: 6 Mar 1990
Last Updated on STN: 6 Mar 1990
Entered Medline: 2 Jun 1989

L4 ANSWER 186 OF 658 MEDLINE on STN
Full Text

AN 89120178 MEDLINE
DN PubMed ID: 3219881
TI The effects of piretanide in patients with congestive heart failure and
diabetes mellitus: a double-blind comparison with furosemide.

AU Car N; Skrabalo Z; Verho M
CS Institute for Diabetes, Endocrinology and Metabolic Diseases Vuk Vrhovack,
Medical Faculty, University of Zagreb, Yugoslavia.

SO Current medical research and opinion, (1988) Vol. 11, No. 2, pp. 133-41.
Journal code: 0351014. ISSN: 0300-7995.

CY ENGLAND: United Kingdom
DT (CLINICAL TRIAL)
(COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)

LA English
FS Priority Journals
EM 198903
ED Entered STN: 8 Mar 1990
Last Updated on STN: 6 Feb 1995
Entered Medline: 23 Mar 1989

L4 ANSWER 187 OF 658 MEDLINE on STN
Full Text

AN 87238699 MEDLINE
DN PubMed ID: 3296753
TI Studies in neural tube defects. I. Epidemiologic and etiologic aspects.

AU Myrianthopoulos N C; Melnick M
SO American journal of medical genetics, (1987 Apr) Vol. 26, No. 4, pp.

783-96.
 Journal code: 7708900. ISSN: 0148-7299.

CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198706
 ED Entered STN: 5 Mar 1990
 Last Updated on STN: 5 Mar 1990
 Entered Medline: 26 Jun 1987

L4 ANSWER 188 OF 658 MEDLINE on STN
Full Text
 AN 86257956 MEDLINE
 DN PubMed ID: 3523302
 TI [Nonketotic hyperosmolar coma. Clinical aspects and treatment in 12 cases].
 Il coma iperosmolare non chetosico. Aspetti clinici e trattamento in 12 casi.
 AU Ghiazza G F; Grillo G; Cali M V; Lanero M; Mondavio M
 SO Minerva medica, (1986 May 19) Vol. 77, No. 21, pp. 953-7.
 Journal code: 0400732. ISSN: 0026-4806.

CY Italy
 DT (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 LA Italian
 FS Priority Journals
 EM 198608
 ED Entered STN: 21 Mar 1990
 Last Updated on STN: 21 Mar 1990
 Entered Medline: 11 Aug 1986

L4 ANSWER 189 OF 658 MEDLINE on STN
Full Text
 AN 85250512 MEDLINE
 DN PubMed ID: 4015136
 TI Nocardia asteroides infection with dissemination to skin and joints.
 AU Boudoulas O; Camisa C
 SO Archives of dermatology, (1985 Jul) Vol. 121, No. 7, pp. 898-900.
 Journal code: 0372433. ISSN: 0003-987X.

CY United States
 DT (CASE REPORTS)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 198508
 ED Entered STN: 20 Mar 1990
 Last Updated on STN: 3 Feb 1997
 Entered Medline: 7 Aug 1985

L4 ANSWER 190 OF 658 MEDLINE on STN
Full Text
 AN 85196154 MEDLINE
 DN PubMed ID: 2859803
 TI Chlorpropamide-induced cholestatic jaundice and pseudomembranous colitis.
 AU Gupta R; Sachar D B
 SO The American journal of gastroenterology, (1985 May) Vol. 80, No. 5, pp. 381-3.
 Journal code: 0421030. ISSN: 0002-9270.

CY United States
 DT (CASE REPORTS)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198506
 ED Entered STN: 20 Mar 1990
 Last Updated on STN: 6 Feb 1995
 Entered Medline: 18 Jun 1985

L4 ANSWER 191 OF 658 MEDLINE on STN
Full Text
 AN 84235378 MEDLINE

DN PubMed ID: 6376027
 TI Sulfonylureas: background and development of the field.
 AU Levine R
 SO Diabetes care, (1984 May-Jun) Vol. 7 Suppl 1, pp. 3-7.
 Journal code: 7805975. ISSN: 0149-5992.
 CY United States
 DT Historical
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; History of Medicine
 EM 198408
 ED Entered STN: 20 Mar 1990
 Last Updated on STN: 20 Mar 1990
 Entered Medline: 15 Aug 1984

L4 ANSWER 192 OF 658 MEDLINE on STN
Full Text
 AN 83113521 MEDLINE
 DN PubMed ID: 6185787
 TI Comparison of intravenous piretanide and furosemide in patients with congestive heart failure.
 AU Marsh J D; Nesto R; Glynn M A; Smith T W
 NC K08-HL00691 (NHLBI)
 RR00888 (NCRR)
 SO Journal of cardiovascular pharmacology, (1982 Nov-Dec) Vol. 4, No. 6, pp. 949-54.
 Journal code: 7902492. ISSN: 0160-2446.
 CY United States
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
 LA English
 FS Priority Journals
 EM 198303
 ED Entered STN: 18 Mar 1990
 Last Updated on STN: 3 Feb 1997
 Entered Medline: 11 Mar 1983

L4 ANSWER 193 OF 658 MEDLINE on STN
Full Text
 AN 82281941 MEDLINE
 DN PubMed ID: 6126138
 TI [Iatrogenic diabetes mellitus (side effects and interactions of drugs during clinical diabetes mellitus (author's transl))].
 Iatrogenes Diabetes mellitus (Medikamentöse Interaktion und klinischer Diabetesverlauf).
 AU Königstein R P
 SO Aktuelle Gerontologie, (1982 Jul) Vol. 12, No. 4, pp. 142-4.
 Journal code: 0421403. ISSN: 0300-5704.
 CY GERMANY, WEST: Germany, Federal Republic of
 DT (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA German
 FS Priority Journals
 EM 198210
 ED Entered STN: 17 Mar 1990
 Last Updated on STN: 6 Feb 1995
 Entered Medline: 29 Oct 1982

L4 ANSWER 194 OF 658 MEDLINE on STN
Full Text
 AN 81126040 MEDLINE
 DN PubMed ID: 7466265
 TI [Treatment of diabetes mellitus in the adult or so-called maturity-onset diabetes. The role of oral antidiabetics].
 Le traitement du diabète sucré de l'adulte dit diabète de la maturité.
 Place des antidiabétiques oraux.
 AU Mirouze J; Monnier L
 SO La Revue du praticien, (1981 Feb 11) Vol. 31, No. 9, pp. 615-6, 619-20, 623-4 passim.

Journal code: 0404334. ISSN: 0035-2640.
CY France
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA French
FS Foreign
EM 198104
ED Entered STN: 16 Mar 1990
Last Updated on STN: 16 Mar 1990
Entered Medline: 24 Apr 1981

L4 ANSWER 195 OF 658 MEDLINE on STN
Full Text

AN 80215905 MEDLINE
DN PubMed ID: 161940
TI [New aspects of therapy with oral antidiabetic agents].
Neuere Gesichtspunkte der Therapie mit oralen Antidiabetika.
AU Haslbeck M
SO Wiener medizinische Wochenschrift (1946), (1979 Dec 30) Vol. 199, No. 24,
pp. 689-95. Ref: 47
Journal code: 8708475. ISSN: 0043-5341.
CY Austria
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA German
FS Priority Journals
EM 198008
ED Entered STN: 15 Mar 1990
Last Updated on STN: 15 Mar 1990
Entered Medline: 25 Aug 1980

L4 ANSWER 196 OF 658 MEDLINE on STN
Full Text

AN 80179069 MEDLINE
DN PubMed ID: 6989626
TI [Peroral sugar-reducing sulfamides].
Peroral'ni tsukroznyzhuval'ni sul'famidy.
AU Chernykh V P
SO Farmatsevtichnyi zhurnal, (1980) No. 1, pp. 13-8. Ref: 100
Journal code: 0374603. ISSN: 0014-8342.
CY USSR
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA Ukrainian
FS Priority Journals
EM 198007
ED Entered STN: 15 Mar 1990
Last Updated on STN: 15 Mar 1990
Entered Medline: 12 Jul 1980

L4 ANSWER 197 OF 658 MEDLINE on STN
Full Text

AN 80016123 MEDLINE
DN PubMed ID: 158261
TI [Modern treatment of diabetes mellitus with sulfonylurea compounds].
Moderne Behandlung des Diabetes mellitus mit Sulfonylharnstoffderivaten.
AU Haller H; Hanefeld M; Leonhardt W
SO Zeitschrift fur arztliche Fortbildung, (1979 May 15) Vol. 73, No. 10, pp.
482-7.
Journal code: 0414004. ISSN: 0044-2178.
CY GERMANY, EAST: German Democratic Republic
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals
EM 197911
ED Entered STN: 15 Mar 1990
Last Updated on STN: 15 Mar 1990
Entered Medline: 28 Nov 1979

L4 ANSWER 198 OF 658 MEDLINE on STN
Full Text

AN 79117988 MEDLINE
 DN PubMed ID: 217095
 TI [Long term course of insulin secretion in treated noninsulin dependent
 diabetics (author's transl)].
 Evolution a long terme de l'insulino-secretion chez le diabetique non
 insulino-dependant traite.
 AU Moinade S; Gaillard G; Champeyroux J; Doly M; Glanddier Y; Dupuy-Cordez A
 SO La semaine des hopitaux : organe fonde par l'Association d'enseignement
 medical des hopitaux de Paris, (Nov 8-15 1978) Vol. 54, No. 37-40, pp.
 1151-4.
 Journal code: 9410059.
 CY France
 DT (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 197904
 ED Entered STN: 15 Mar 1990
 Last Updated on STN: 15 Mar 1990
 Entered Medline: 25 Apr 1979

L4 ANSWER 199 OF 658 MEDLINE on STN

Full Text

AN 79011534 MEDLINE
 DN PubMed ID: 358101
 TI [Long term course of insulin secretion in treated non-insulin dependent
 diabetics (author's transl)].
 Evolution a long terme de l'insulino-secretion chez le diabetique non
 insulino-dependant traite.
 AU Moinade S; Gaillard G; Champeyroux J; Doly M; Glanddier Y; Dupuy-Cordez A
 SO Pathologie-biologie, (1978 May-Jun) Vol. 26, No. 5, pp. 241-4.
 Journal code: 0265365. ISSN: 0369-8114.
 CY France
 DT (COMPARATIVE STUDY)
 (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 197812
 ED Entered STN: 14 Mar 1990
 Last Updated on STN: 14 Mar 1990
 Entered Medline: 2 Dec 1978

L4 ANSWER 200 OF 658 MEDLINE on STN

Full Text

AN 78226142 MEDLINE
 DN PubMed ID: 353789
 TI [State of the islands of Langerhans in various animal species after
 administration of 8-(arensulfonylamino)-quinolines].
 Sostoianie ostrovkov Langergansa u zhivotnykh raznykh vidov pri vvedenii
 8-(arensul'fonilamino)-khinolinov.
 AU Eshchenko V A
 SO Problemy e ndokrinologii, (1978 May-Jun) Vol. 24, No. 3, pp. 103-7.
 Journal code: 0140673. ISSN: 0375-9660.
 CY USSR
 DT (COMPARATIVE STUDY)
 (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 LA Russian
 FS Priority Journals
 EM 197809
 ED Entered STN: 14 Mar 1990
 Last Updated on STN: 3 Feb 1997
 Entered Medline: 29 Sep 1978

=> d 14 150-170

L4 ANSWER 150 OF 658 MEDLINE on STN

Full Text

AN 1999288571 MEDLINE
 DN PubMed ID: 10360291

TI Clinical estimation of corneal endothelial pump function.
 AU Bourne W M
 CS Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
 NC EY 02037 (NEI)
 SO Transactions of the American Ophthalmological Society, (1998) Vol. 96, pp. 229-39; discussion 239-42.
 Journal code: 7506106. ISSN: 0065-9533.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
 LA English
 FS Priority Journals
 EM 199907
 ED Entered STN: 6 Aug 1999
 Last Updated on STN: 6 Aug 1999
 Entered Medline: 27 Jul 1999

L4 ANSWER 151 OF 658 MEDLINE on STN

Full Text

AN 1999259321 MEDLINE
 DN PubMed ID: 10327345
 TI [Is corneal thickness measurement reliable and useful?].
 La mesure de l'epaisseur corneenne est-elle fiable et utile?.
 AU Bron A; Chapard J; Creuzot-Garcher C; Guertzider V; D'Athis P
 CS Service d'Ophtalmologie, CHU Dijon.
 SO Journal francais d'ophtalmologie, (1999 Mar) Vol. 22, No. 2, pp. 160-8.
 Journal code: 7804128. ISSN: 0181-5512.
 CY France
 DT (COMPARATIVE STUDY)
 (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS Priority Journals
 EM 199906
 ED Entered STN: 14 Jun 1999
 Last Updated on STN: 14 Jun 1999
 Entered Medline: 1 Jun 1999

L4 ANSWER 152 OF 658 MEDLINE on STN

Full Text

AN 1999254076 MEDLINE
 DN PubMed ID: 10318919
 TI The stimulatory action of tolbutamide on Ca²⁺-dependent exocytosis in pancreatic beta cells is mediated by a 65-kDa mdr-like P-glycoprotein.
 AU Barg S; Renstrom E; Berggren P O; Bertorello A; Bokvist K; Braun M; Eliasson L; Holmes W E; Kohler M; Rorsman P; Thevenod F
 CS Department of Physiological Sciences, Lund University, Solvegatan 19, S-223 62 Lund, Sweden.
 SO Proceedings of the National Academy of Sciences of the United States of America, (1999 May 11) Vol. 96, No. 10, pp. 5539-44.
 Journal code: 7505876. ISSN: 0027-8424.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 199906
 ED Entered STN: 28 Jun 1999
 Last Updated on STN: 10 Dec 2002
 Entered Medline: 17 Jun 1999

L4 ANSWER 153 OF 658 MEDLINE on STN

Full Text

AN 1999224174 MEDLINE
 DN PubMed ID: 10207767
 TI Fluid balance therapy of nocturia in women.
 AU Reynard J
 CS Christchurch Hospital, New Zealand.
 SO International urogynecology journal and pelvic floor dysfunction, (1999) Vol. 10, No. 1, pp. 43-8. Ref: 35
 Journal code: 9514583. ISSN: 0937-3462.

CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 199906
ED Entered STN: 28 Jun 1999
Last Updated on STN: 30 Oct 2002
Entered Medline: 15 Jun 1999

L4 ANSWER 154 OF 658 MEDLINE on STN

Full Text

AN 1999200502 MEDLINE
DN PubMed ID: 10102379
TI In vivo effect of 8-epi-PGF2alpha on retinal circulation in diabetic and non-diabetic rats.
AU Michoud E; Lecomte M; Lagarde M; Wiernsperger N
CS Diabetic Microangiopathy Research Unit, LIPHA-INSERM U352, INSA-Lyon, Villeurbanne, France.. michoud@insa-lyon.fr
SO Prostaglandins, leukotrienes, and essential fatty acids, (1998 Dec) Vol. 59, No. 6, pp. 349-55.
Journal code: 8802730. ISSN: 0952-3278.
CY SCOTLAND: United Kingdom
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199907
ED Entered STN: 27 Jul 1999
Last Updated on STN: 27 Jul 1999
Entered Medline: 12 Jul 1999

L4 ANSWER 155 OF 658 MEDLINE on STN

Full Text

AN 1999183628 MEDLINE
DN PubMed ID: 10083882
TI [New classification and diagnostic criteria of diabetes. Interview with Prof. B. Charbonnel].
A propos de la nouvelle classification et des nouveaux criteres diagnostiques du diabete. Un entretien avec le Pr B. Charbonnel.
AU Charbonnel B
SO Presse medicale (Paris, France : 1983), (1999 Feb 20) Vol. 28, No. 7, pp. 354-7.
Journal code: 8302490. ISSN: 0755-4982.
CY France
DT (INTERVIEW)
LA French
FS Priority Journals
EM 199903
ED Entered STN: 2 Apr 1999
Last Updated on STN: 2 Apr 1999
Entered Medline: 25 Mar 1999

L4 ANSWER 156 OF 658 MEDLINE on STN

Full Text

AN 1999076067 MEDLINE
DN PubMed ID: 9858970
TI [Interaction between converting enzyme inhibitors and hypoglycemic sulfonamides or insulin].
Interaction entre inhibiteurs de l'enzyme de conversion et sulfamides hypoglycemiants ou insuline.
AU Girardin E; Raccach D
CS Service de medecine D, Hopital Layne, Mont de Marsan.
SO Presse medicale (Paris, France : 1983), (1998 Nov 28) Vol. 27, No. 37, pp. 1914-23. Ref: 48
Journal code: 8302490. ISSN: 0755-4982.
CY France
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA French
FS Priority Journals

EM 199812
ED Entered STN: 15 Jan 1999
Last Updated on STN: 15 Jan 1999
Entered Medline: 30 Dec 1998

L4 ANSWER 157 OF 658 MEDLINE on STN
Full Text
AN 1999035881 MEDLINE
DN PubMed ID: 9818475
TI [Pharmacologic importance of glycation of plasma proteins].
Farmakologicky vyznam glykaci plazmatickych proteinu.
AU Beranek M; Palicka V
CS Ustav klinicke biochemie a diagnostiky Fakultni nemocnice, Hradec Kralove.
SO Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a
Slovenske farmaceuticke spolecnosti, (1998 Sep) Vol. 47, No. 5, pp. 211-4.
Journal code: 9433765. ISSN: 1210-7816.
CY Czech Republic
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA Czech
FS Priority Journals
EM 199812
ED Entered STN: 15 Jan 1999
Last Updated on STN: 15 Jan 1999
Entered Medline: 14 Dec 1998

L4 ANSWER 158 OF 658 MEDLINE on STN
Full Text
AN 1998403364 MEDLINE
DN PubMed ID: 9732827
TI Tamsulosin: real life clinical experience in 19,365 patients.
AU Michel M C; Bressel H U; Mehlburger L; Goepel M
CS Department of Medicine, University of Essen, Germany..
martin.michel@uni-essen.de
SO European urology, (1998) Vol. 34 Suppl 2, pp. 37-45.
Journal code: 7512719. ISSN: 0302-2838.
CY Switzerland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199811
ED Entered STN: 6 Jan 1999
Last Updated on STN: 6 Jan 1999
Entered Medline: 19 Nov 1998

L4 ANSWER 159 OF 658 MEDLINE on STN
Full Text
AN 1998385502 MEDLINE
DN PubMed ID: 9720548
TI Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms:
does co-morbidity alter tolerability?..
AU Michel M C; Mehlburger L; Bressel H U; Schumacher H; Schaefers R F; Goepel
M
CS Department of Medicine, University of Essen, Germany.
SO The Journal of urology, (1998 Sep) Vol. 160, No. 3 Pt 1, pp. 784-91.
Journal code: 0376374. ISSN: 0022-5347.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199809
ED Entered STN: 6 Oct 1998
Last Updated on STN: 3 Mar 2000
Entered Medline: 24 Sep 1998

L4 ANSWER 160 OF 658 MEDLINE on STN
Full Text
AN 1998155054 MEDLINE
DN PubMed ID: 9495666
TI Urinary tract infections with Aerococcus urinae in the south of The
Netherlands.
AU Schuur P M; Kasteren M E; Sabbe L; Vos M C; Janssens M M; Buiting A G

CS Department of Medical Microbiology, St. Elisabeth Hospital, Tilburg, The Netherlands.
 SO European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, (1997 Dec) Vol. 16, No. 12, pp. 871-5.
 Journal code: 8804297. ISSN: 0934-9723.
 CY GERMANY: Germany, Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199804
 ED Entered STN: 7 May 1998
 Last Updated on STN: 7 May 1998
 Entered Medline: 29 Apr 1998

L4 ANSWER 161 OF 658 MEDLINE on STN

Full Text

AN 1998083454 MEDLINE
 DN PubMed ID: 9463023
 TI [Pharmacokinetics of hypoglycemic sulfonamides: Ozidia, a new concept].
 Pharmacocinetique des sulfamides hypoglycemiants: OZIDIA un nouveau concept.
 AU Selam J L
 CS Service de Diabetologie, Hotel-Dieu, Paris.
 SO Diabetes & metabolism, (1997 Nov) Vol. 23 Suppl 4, pp. 39-43. Ref: 25
 Journal code: 9607599. ISSN: 1262-3636.
 CY France
 DT (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA French
 FS Priority Journals
 EM 199802
 ED Entered STN: 24 Feb 1998
 Last Updated on STN: 24 Feb 1998
 Entered Medline: 12 Feb 1998

L4 ANSWER 162 OF 658 MEDLINE on STN

Full Text

AN 97360921 MEDLINE
 DN PubMed ID: 9217884
 TI Diabetic-induced endothelial dysfunction in rat aorta: role of hydroxyl radicals.
 AU Pieper G M; Langenstroer P; Siebeneich W
 CS Department of Transplant Surgery, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, Milwaukee 53226, USA.
 NC HL47072 (NHLBI)
 SO Cardiovascular research, (1997 Apr) Vol. 34, No. 1, pp. 145-56.
 Journal code: 0077427. ISSN: 0008-6363.
 CY Netherlands
 DT (IN VITRO)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
 LA English
 FS Priority Journals
 EM 199708
 ED Entered STN: 25 Aug 1997
 Last Updated on STN: 25 Aug 1997
 Entered Medline: 11 Aug 1997

L4 ANSWER 163 OF 658 MEDLINE on STN

Full Text

AN 97356325 MEDLINE
 DN PubMed ID: 9212761
 TI A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome.
 AU Lindor N M; Arsenault T M; Solomon H; Seidman C E; McEvoy M T
 CS Department of Medical Genetics, Mayo Clinic Rochester, MN 55905, USA.
 SO Mayo Clinic proceedings. Mayo Clinic, (1997 Jul) Vol. 72, No. 7, pp. 611-5.
 Journal code: 0405543. ISSN: 0025-6196.
 CY United States

DT (CASE REPORTS)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 199707
 ED Entered STN: 12 Aug 1997
 Last Updated on STN: 25 Jan 2002
 Entered Medline: 29 Jul 1997.

L4 ANSWER 164 OF 658 MEDLINE on STN
Full Text
 AN 97242217 MEDLINE
 DN PubMed ID: 9125207
 TI Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells.
 AU Okuda Y; Kawashima K; Sawada T; Tsurumaru K; Asano M; Suzuki S; Soma M; Nakajima T; Yamashita K
 CS Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan.
 SO Biochemical and biophysical research communications, (1997 Mar 17) Vol. 232, No. 2, pp. 487-91.
 Journal code: 0372516. ISSN: 0006-291X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English
 FS Priority Journals
 EM 199704
 ED Entered STN: 6 May 1997
 Last Updated on STN: 6 May 1997
 Entered Medline: 22 Apr 1997

L4 ANSWER 165 OF 658 MEDLINE on STN
Full Text
 AN 97212972 MEDLINE
 DN PubMed ID: 9102191
 TI [Hypoglycemia in the diabetic patient. Recommendations of ALFEDIAM].
 L'hypoglycémie du patient diabétique. Recommendations of ALFEDIAM (French Language Association for the Study of **Diabetes** and Metabolic Diseases.
 AU Grimaldi A; Slama G; Tubiana-Rufi N; Heurtier A; Selam J L; Scheen A; Sachon C; Vialettes B; Robert J J; Perlemuter L
 CS Service de Diabetologie et métabolisme, Hopital Pitie-Salpetriere, Paris, France.
 SO Diabetes & metabolism, (1997 Feb) Vol. 23, No. 1, pp. 100-8.
 Journal code: 9607599. ISSN: 1262-3636.
 CY France
 DT (GUIDELINE)
 Journal; Article; (JOURNAL ARTICLE)
 (PRACTICE GUIDELINE)

LA French
 FS Priority Journals
 EM 199704
 ED Entered STN: 24 Apr 1997
 Last Updated on STN: 24 Apr 1997
 Entered Medline: 17 Apr 1997

L4 ANSWER 166 OF 658 MEDLINE on STN
Full Text
 AN 96392851 MEDLINE
 DN PubMed ID: 8799639
 TI Decreased HbA1c levels due to sulfonamide-induced hemolysis in two IDDM patients.
 AU Tack C J; Wetzels J F
 CS Department of Medicine, University Hospital Nijmegen, The Netherlands..
c.tack@aig.azn.nl
 SO Diabetes care, (1996 Jul) Vol. 19, No. 7, pp. 775-6.
 Journal code: 7805975. ISSN: 0149-5992.
 CY United States
 DT (CASE REPORTS)
 Journal; Article; (JOURNAL ARTICLE)

LA English
 FS Priority Journals

EM 199703
ED Entered STN: 27 Mar 1997
Last Updated on STN: 27 Mar 1997
Entered Medline: 18 Mar 1997

L4 ANSWER 167 OF 658 MEDLINE on STN

Full Text

AN 96308105 MEDLINE
DN PubMed ID: 8701146
TI [Hypoglycemic sulfamides, 50 years after Loubatiere].
Les sulfamides hypoglycemiants, 50 ans apres Loubatieres.
AU Scheen A J
CS Departement de Medecine, Universite de Liege.
SO Revue medicale de Liege, (1996 Jan) Vol. 51, No. 1, pp. 90-3.
Journal code: 0404317. ISSN: 0370-629X.
CY Belgium
DT Biography
Historical
Journal; Article; (JOURNAL ARTICLE)
LA French
FS Priority Journals; History of Medicine
EM 199609
ED Entered STN: 12 Sep 1996
Last Updated on STN: 12 Sep 1996
Entered Medline: 4 Sep 1996

L4 ANSWER 168 OF 658 MEDLINE on STN

Full Text

AN 96100972 MEDLINE
DN PubMed ID: 8526441
TI [Antibiotic prophylaxis in biliary surgery].
L'antibioprophylaxie en chirurgie biliaire.
AU Gondret R; Viallard M L; Huguier M
CS Service d'Anesthesie-Reanimation, Hopital Tenon, Paris.
SO Annales de chirurgie, (1995) Vol. 49, No. 6, pp. 493-9. Ref: 52
Journal code: 0140722. ISSN: 0003-3944.
CY France
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA French
FS Priority Journals
EM 199601
ED Entered STN: 19 Feb 1996
Last Updated on STN: 19 Feb 1996
Entered Medline: 19 Jan 1996

L4 ANSWER 169 OF 658 MEDLINE on STN

Full Text

AN 95400611 MEDLINE
DN PubMed ID: 7670740
TI Effects of endothelin receptor antagonism with bosentan on peripheral
nerve function in experimental diabetes.
AU Stevens E J; Tomlinson D R
CS William Harvey Research Institute, Department of Pharmacology, Queen Mary
and Westfield College, London.
SO British journal of pharmacology, (1995 May) Vol. 115, No. 2, pp. 373-9.
Journal code: 7502536. ISSN: 0007-1188.
CY ENGLAND: United Kingdom
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 199510
ED Entered STN: 26 Oct 1995
Last Updated on STN: 26 Oct 1995
Entered Medline: 18 Oct 1995

L4 ANSWER 170 OF 658 MEDLINE on STN

Full Text

AN 95167596 MEDLINE

DN PubMed ID: 7863436
 TI [The peroral therapy of non-insulin-dependent **diabetes** mellitus].
 Peroral'naia terapiia insulinnezavisimogo sakharnogo diabeta.
 AU Ametov A S; Granovskaia-Tsvetkova A M
 SO Terapevticheskii arkhiv, (1994) Vol. 66, No. 10, pp. 17-9.
 Journal code: 2984818R. ISSN: 0040-3660.
 CY RUSSIA: Russian Federation
 DT (ENGLISH ABSTRACT)
 Journal; Article; (JOURNAL ARTICLE)
 LA Russian
 FS Priority Journals
 EM 199503
 ED Entered STN: 4 Apr 1995
 Last Updated on STN: 4 Apr 1995
 Entered Medline: 23 Mar 1995

=> d 14 100-140

L4 ANSWER 100 OF 658 MEDLINE on STN
Full Text
 AN 2002697349 MEDLINE
 DN PubMed ID: 12458661
 TI Endothelin-1-mediated alteration of metallothionein and trace metals in
 the liver and kidneys of chronically diabetic rats.
 AU Cai Lu; Chen Shali; Evans Terry; Cherian M George; Chakrabarti Subrata
 CS Department of Pathology, The University of Western Ontario, London,
 Ontario, Canada.
 SO International journal of experimental diabetes research, (2002 Jul-Sep)
 Vol. 3, No. 3, pp. 193-8.
 Journal code: 100962067. ISSN: 1560-4284.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 200304
 ED Entered STN: 17 Dec 2002
 Last Updated on STN: 26 Apr 2003
 Entered Medline: 25 Apr 2003

L4 ANSWER 101 OF 658 MEDLINE on STN
Full Text
 AN 2002686071 MEDLINE
 DN PubMed ID: 12450064
 TI Exaggerated coronary reactivity to endothelin-1 in **diabetes**: reversal
 with bosentan.
 AU Verma Subodh; Arikawa Emi; Lee Sammy; Dumont Aaron S; Yao Linfu; McNeill
 John H
 CS Division of Pharmacology and Toxicology, Faculty of Pharmaceutical
 Sciences, The University of British Columbia, 2146 East Mall, Vancouver,
 BC V6T 1Z3, Canada.
 SO Canadian journal of physiology and pharmacology, (2002 Oct) Vol. 80, No.
 10, pp. 980-6.
 Journal code: 0372712. ISSN: 0008-4212.
 CY Canada
 DT (IN VITRO)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 200305
 ED Entered STN: 14 Dec 2002
 Last Updated on STN: 6 May 2003
 Entered Medline: 5 May 2003

L4 ANSWER 102 OF 658 MEDLINE on STN
Full Text
 AN 2002675078 MEDLINE
 DN PubMed ID: 12436336
 TI Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1
 decreases blood glucose concentrations in hyperglycaemic mice.

AU Alberts P; Engblom L; Edling N; Forsgren M; Klingstrom G; Larsson C;
 Ronquist-Nii Y; Ohman B; Abrahmsen L
 CS Pharmacology 2, Department of Biology, Research, Biovitrum, Stockholm,
 Sweden.. peteris.alberts@biovitrum.com
 SO Diabetologia, (2002 Nov) Vol. 45, No. 11, pp. 1528-32.. Electronic
 Publication: 2002-09-18.
 Journal code: 0006777. ISSN: 0012-186X.
 CY Germany; Federal Republic of
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200306
 ED Entered STN: 19 Nov 2002
 Last Updated on STN: 17 Jun 2003
 Entered Medline: 16 Jun 2003

L4 ANSWER 103 OF 658 MEDLINE on STN
Full Text
 AN 2002646670 MEDLINE
 DN PubMed ID: 12407655
 TI Nephrotic syndrome and interstitial nephritis associated with celecoxib.
 AU Alper Arnold B Jr; Meleg-Smith Suzanne; Krane N Kevin
 CS Department of Medicine, Section of Nephrology, Tulane University School of
 Medicine, New Orleans, LA 70112, USA.
 SO American journal of kidney diseases : the official journal of the National
 Kidney Foundation, (2002 Nov) Vol. 40, No. 5, pp. 1086-90.
 Journal code: 8110075. E-ISSN: 1523-6838.
 CY United States
 DT (CASE REPORTS)
 Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200212
 ED Entered STN: 31 Oct 2002
 Last Updated on STN: 17 Dec 2002
 Entered Medline: 4 Dec 2002

L4 ANSWER 104 OF 658 MEDLINE on STN
Full Text
 AN 2002637592 MEDLINE
 DN PubMed ID: 12397581
 TI Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the
 diabetic myocardium.
 AU Hileeto Denise; Cukiernik Mark; Mukherjee Suranjana; Evans Terry; Barbin
 Yousef; Downey Donal; Karmazyn Morris; Chakrabarti Subrata
 CS Department of Pathology, The University of Western Ontario, London,
 Ontario, Canada.
 SO Diabetes/metabolism research and reviews, (2002 Sep-Oct) Vol. 18, No. 5,
 pp. 386-94.
 Journal code: 100883450. ISSN: 1520-7552.
 CY England: United Kingdom
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 200304
 ED Entered STN: 26 Oct 2002
 Last Updated on STN: 18 Apr 2003
 Entered Medline: 17 Apr 2003

L4 ANSWER 105 OF 658 MEDLINE on STN
Full Text
 AN 2002637545 MEDLINE
 DN PubMed ID: 12397372
 TI Cellular distribution and contribution of cyclooxygenase COX-2 to
 diabetogenesis in NOD mouse.
 AU Luo Cheng; Kallajoki Markku; Gross Rene; Mulari Mika; Teros Tamara; Ylinen
 Laura; Makinen Marjaana; Laine Jukka; Simell Olli
 CS Juvenile Diabetes Research Foundation (FDRF) Center for Prevention of Type
 1 Diabetes in Finland, University of Turku, Turku, Finland..
cheng.luo@utu.fi

SO Cell and tissue research, (2002 Nov) Vol. 310, No. 2, pp. 169-75.
Electronic Publication: 2002-08-27.
Journal code: 0417625. ISSN: 0302-766X.

CY Germany: Germany, Federal Republic of
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English
FS Priority Journals
EM 200307
ED Entered STN: 26 Oct 2002
Last Updated on STN: 13 Jul 2003
Entered Medline: 11 Jul 2003

L4 ANSWER 106 OF 658 MEDLINE on STN
Full Text
AN 2002483572 MEDLINE
DN PubMed ID: 12269519
TI Cardioversion of atrial fibrillation with ibutilide: when is it most effective?.

AU Das Mithilesh Kumar; Cheriparambil Kuruvilla; Bedi Ashwini; Kassotis John; Reddy Chatla V R; Saul Barry; Makan Majesh
CS Division of Cardiology (Starr4), New York Presbyterian Hospital-Cornell University Medical College, New York 10021, USA.. mithileshdas@hotmail.com
SO Clinical cardiology, (2002 Sep) Vol. 25, No. 9, pp. 411-5.
Journal code: 7903272. ISSN: 0160-9289.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200302
ED Entered STN: 25 Sep 2002
Last Updated on STN: 25 Feb 2003
Entered Medline: 24 Feb 2003

L4 ANSWER 107 OF 658 MEDLINE on STN
Full Text
AN 2002472421 MEDLINE
DN PubMed ID: 12234117
TI Streptozotocin induces lipolysis in rat adipocytes in vitro.

AU Szkudelski T; Szkudelska Ktszkudel@iav.au.poznan.pl
SO Physiological research / Academia Scientiarum Bohemoslovaca, (2002) Vol. 51, No. 3, pp. 255-9.
Journal code: 9112413. ISSN: 0862-8408.

CY Czech Republic
DT (IN VITRO)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200303
ED Entered STN: 18 Sep 2002
Last Updated on STN: 25 Mar 2003
Entered Medline: 24 Mar 2003

L4 ANSWER 108 OF 658 MEDLINE on STN
Full Text
AN 2002471893 MEDLINE
DN PubMed ID: 12234768
TI Depressed PKA activity contributes to impaired SERCA function and is linked to the pathogenesis of glucose-induced cardiomyopathy.

AU Dutta Kaushik; Carmody Marybeth W; Cala Steven E; Davidoff Amy J
CS College of Osteopathic Medicine, University of New England, 11 Hills Beach Road, Biddeford, ME 04005, USA.
NC HL 60303 (NHLBI)
HL 66895 (NHLBI)
SO Journal of molecular and cellular cardiology, (2002 Aug) Vol. 34, No. 8, pp. 985-96.
Journal code: 0262322. ISSN: 0022-2828.

CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English

FS Priority Journals
EM 200303
ED Entered STN: 18 Sep 2002
Last Updated on STN: 6 Mar 2003
Entered Medline: 5 Mar 2003

L4 ANSWER 109 OF 658 MEDLINE on STN
Full Text
AN 2002467396 MEDLINE
DN PubMed ID: 12208707
TI The European glaucoma prevention study design and baseline description of the participants.
AU Miglioni Stefano; Zeyen Thierry; Pfeiffer Norbert; Cunha-Vaz Jose; Torri Valter; Adamsons Ingrid
CS European Glaucoma Prevention Study Group.
SO Ophthalmology, (2002 Sep) Vol. 109, No. 9, pp. 1612-21.
Journal code: 7802443. ISSN: 0161-6420.
CY United States
DT (CLINICAL TRIAL)
(COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200209
ED Entered STN: 14 Sep 2002
Last Updated on STN: 20 Sep 2002
Entered Medline: 19 Sep 2002

L4 ANSWER 110 OF 658 MEDLINE on STN
Full Text
AN 2002450906 MEDLINE
DN PubMed ID: 12190302
TI Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.
AU Barf Tjeerd; Vallgarda Jerk; Emond Rikard; Haggstrom Charlotta; Kurz Guido; Nygren Alf; Larwood Vivienne; Mosialou Erifili; Axelsson Kent; Olsson Rolf; Engblom Lars; Edling Naimie; Ronquist-Nii Yuko; Ohman Birgitta; Alberts Peteris; Abrahmsen Lars
CS Department of Medicinal Chemistry, Biovitrum, Box 6443, SE-751 37, Uppsala, Sweden.. tjeerd.barf@biovitrum.com
SO Journal of medicinal chemistry, (2002 Aug 29) Vol. 45, No. 18, pp. 3813-5.
Journal code: 9716531. ISSN: 0022-2623.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200209
ED Entered STN: 6 Sep 2002
Last Updated on STN: 24 Sep 2002
Entered Medline: 23 Sep 2002

L4 ANSWER 111 OF 658 MEDLINE on STN
Full Text
AN 2002448994 MEDLINE
DN PubMed ID: 12206857
TI Renal protective effect of YM598, a selective endothelin ET(A) receptor antagonist, against diabetic nephropathy in OLETF rats.
AU Sugimoto Koh-ichi; Tsuruoka Shuichi; Fujimura Akio
CS Department of Clinical Pharmacology, Jichi Medical School, 3311-1 Minamikawachi, Tochigi 329-0498, Japan.. ksugi@jichi.ac.jp
SO European journal of pharmacology, (2002 Aug 23) Vol. 450, No. 2, pp. 183-9.
Journal code: 1254354. ISSN: 0014-2999.
CY Netherlands
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English

FS Priority Journals
EM 200303
ED Entered STN: 4 Sep 2002
Last Updated on STN: 25 Mar 2003
Entered Medline: 24 Mar 2003

L4 ANSWER 112 OF 658 MEDLINE on STN
Full Text
AN 2002411175 MEDLINE
DN PubMed ID: 12164875
TI Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension.
AU Cheng Hui-Fang; Wang Connie J; Moeckel Gilbert W; Zhang Ming-Zhi; McKanna James A; Harris Raymond C
CS George M. O'Brien Kidney Disease Center and Division of Nephrology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232-2372, USA.
NC DK 39261 (NIDDK)
SO Kidney international, (2002 Sep) Vol. 62, No. 3, pp. 929-39.
Journal code: 0323470. ISSN: 0085-2538.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 200302
ED Entered STN: 8 Aug 2002
Last Updated on STN: 12 Feb 2003
Entered Medline: 11 Feb 2003

L4 ANSWER 113 OF 658 MEDLINE on STN
Full Text
AN 2002401752 MEDLINE
DN PubMed ID: 12150723
TI Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes.
AU Chen Jing; Gu Yong; Lin Fan; Yang Haichun; Zhu Weiyu; Ma Ji; Lin Shanyan
CS Division of Nephrology, Huashan Hospital, Fudan University, Shanghai 200040, China.
SO Chinese medical journal, (2002 Jul) Vol. 115, No. 7, pp. 972-8.
Journal code: 7513795. ISSN: 0366-6999.
CY China
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200209
ED Entered STN: 2 Aug 2002
Last Updated on STN: 11 Sep 2002
Entered Medline: 10 Sep 2002

L4 ANSWER 114 OF 658 MEDLINE on STN
Full Text
AN 2002320331 MEDLINE
DN PubMed ID: 12063458
TI Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocyte injury: reversal with endothelin antagonism.
AU Verma Subodh; Maitland Andrew; Weisel Richard D; Li Shu-Hong; Fedak Paul W M; Pomroy Neil C; Mickle Donald A G; Li Ren-Ke; Ko Lawrence; Rao Vivek
CS Division of Cardiac Surgery, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
SO The Journal of thoracic and cardiovascular surgery, (2002 Jun) Vol. 123, No. 6, pp. 1120-4.
Journal code: 0376343. ISSN: 0022-5223.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200207

ED Entered STN: 14 Jun 2002
Last Updated on STN: 13 Jul 2002
Entered Medline: 12 Jul 2002

L4 ANSWER 115 OF 658 MEDLINE on STN

Full Text

AN 2002303273 MEDLINE
DN PubMed ID: 12046048
TI Celecoxib-induced acute interstitial nephritis.
AU Henao Justine; Hisamuddin Irfan; Nzerue Chike M; Vasandani Geetanjali;
Hewan-Lowe Karlene
CS Department of Medicine, Morehouse School of Medicine, Emory University
School of Medicine, Atlanta, GA, USA.
SO American journal of kidney diseases : the official journal of the National
Kidney Foundation, (2002 Jun) Vol. 39, No. 6, pp. 1313-7.
Journal code: 8110075. E-ISSN: 1523-6838.
CY United States
DT (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200206
ED Entered STN: 5 Jun 2002
Last Updated on STN: 16 Mar 2003
Entered Medline: 14 Jun 2002

L4 ANSWER 116 OF 658 MEDLINE on STN

Full Text

AN 2002215445 MEDLINE
DN PubMed ID: 11953118
TI The effects of endothelin blockade on renal expression of angiotensin II
type 1 receptor in diabetic hypertensive rats.
AU Gu Yong; Chen Jing; Yang Haichun; Zhu Weiyu; Lin Fan; Zhu Chunxiao; Lin
Shantan
CS Department of Nephrology, Huashan Hospital, Fudan University, Shanghai
200040, China.
SO Zhonghua yi xue za zhi, (2002 Jan 10) Vol. 82, No. 1, pp. 10-3.
Journal code: 7511141. ISSN: 0376-2491.
CY China
DT (ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA Chinese
FS Priority Journals
EM 200205
ED Entered STN: 16 Apr 2002
Last Updated on STN: 15 May 2002
Entered Medline: 14 May 2002

L4 ANSWER 117 OF 658 MEDLINE on STN

Full Text

AN 2002214275 MEDLINE
DN PubMed ID: 11950378
TI Tamsulosin: a review of its pharmacology and therapeutic efficacy in the
management of lower urinary tract symptoms.
AU Dunn Christopher J; Matheson Anna; Faulds Diana M
CS Adis International Limited, Auckland, New Zealand.
SO Drugs & aging, (2002) Vol. 19, No. 2, pp. 135-61. Ref: 123
Journal code: 9102074. ISSN: 1170-229X.
CY New Zealand
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200206
ED Entered STN: 13 Apr 2002
Last Updated on STN: 14 Jun 2002
Entered Medline: 13 Jun 2002

L4 ANSWER 118 OF 658 MEDLINE on STN

Full Text

AN 2002177274 MEDLINE
DN PubMed ID: 11910307

TI Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental **diabetes**.
 AU Tikkanen Ilkka; Tikkanen Tuula; Cao Zemin; Allen Terri J; Davis Belinda J; Lassila Markus; Casley David; Johnston Colin I; Burrell Louise M; Cooper Mark E
 CS Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia.
 SO Journal of hypertension, (2002 Apr) Vol. 20, No. 4, pp. 707-14.
 Journal code: 8306882. ISSN: 0263-6352.
 CY England: United Kingdom
 DT (COMPARATIVE STUDY)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 200210
 ED Entered STN: 24 Mar 2002
 Last Updated on STN: 10 Oct 2002
 Entered Medline: 9 Oct 2002

L4 ANSWER 119 OF 658 MEDLINE on STN

Full Text

AN 2002168862 MEDLINE
 DN PubMed ID: 11900720
 TI Managing dyslipidemia in the high-risk patient.
 AU Stein Evan A
 CS Medical Research Laboratories International, Highland Heights, Kentucky 41076, USA.. ESTeinMRL@aol.com
 SO The American journal of cardiology, (2002 Mar 7) Vol. 89, No. 5A, pp. 50C-57C. Ref: 40
 Journal code: 0207277. ISSN: 0002-9149.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200204
 ED Entered STN: 20 Mar 2002
 Last Updated on STN: 18 Apr 2002
 Entered Medline: 17 Apr 2002

L4 ANSWER 120 OF 658 MEDLINE on STN

Full Text

AN 2002146219 MEDLINE
 DN PubMed ID: 11879191
 TI Decorin suppresses transforming growth factor-beta-induced expression of plasminogen activator inhibitor-1 in human mesangial cells through a mechanism that involves Ca2+-dependent phosphorylation of Smad2 at serine-240.
 AU Abdel-Wahab Nadia; Wicks Stephen J; Mason Roger M; Chantry Andrew
 CS Cell and Molecular Biology, Biomedical Sciences Division, Imperial College School of Medicine, South Kensington, London SW7 2AZ, U.K.
 SO The Biochemical journal, (2002 Mar 15) Vol. 362, No. Pt 3, pp. 643-9.
 Journal code: 2984726R. ISSN: 0264-6021.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 200204
 ED Entered STN: 7 Mar 2002
 Last Updated on STN: 26 Oct 2002
 Entered Medline: 19 Apr 2002

L4 ANSWER 121 OF 658 MEDLINE on STN

Full Text

AN 2002064914 MEDLINE
 DN PubMed ID: 11790159
 TI Tamsulosin: an update of its role in the management of lower urinary tract symptoms.
 AU Lyseng-Williamson Katherine A; Jarvis Blair; Wagstaff Antona J
 CS Adis International Limited, Auckland, New Zealand.. demail@adis.co.nz

SO Drugs, (2002) Vol. 62, No. 1, pp. 135-67. Ref: 140
 Journal code: 7600076. ISSN: 0012-6667.
 CY New Zealand
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200203
 ED Entered STN: 25 Jan 2002
 Last Updated on STN: 24 Mar 2002
 Entered Medline: 22 Mar 2002

L4 ANSWER 122 OF 658 MEDLINE on STN
Full Text
 AN 2002021906 MEDLINE
 DN PubMed ID: 11465653
 TI Long-term endothelin receptor blockade improves cardiovascular function in
 diabetes.
 AU Verma S; Arikawa E; McNeill J H
 CS Division of Pharmacology and Toxicology, Faculty of Pharmaceutical
 Sciences, The University of British Columbia, Vancouver, Canada.
 SO American journal of hypertension : journal of the American Society of
 Hypertension, (2001 Jul) Vol. 14, No. 7 Pt 1, pp. 679-87.
 Journal code: 8803676. ISSN: 0895-7061.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 200112
 ED Entered STN: 21 Jan 2002
 Last Updated on STN: 21 Jan 2002
 Entered Medline: 7 Dec 2001

L4 ANSWER 123 OF 658 MEDLINE on STN
Full Text
 AN 2001698617 MEDLINE
 DN PubMed ID: 11744810
 TI Hyperhexosemia induced functional and structural changes in the kidneys:
 role of endothelins.
 AU Chen S; Evans T; Deng D; Cukiernik M; Chakrabarti S
 CS Department of Pathology, University of Western Ontario, London, Ontario,
 Canada.
 SO Nephron, (2002 Jan) Vol. 90, No. 1, pp. 86-94.
 Journal code: 0331777. ISSN: 0028-2766.
 CY Switzerland
 DT Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 200207
 ED Entered STN: 18 Dec 2001
 Last Updated on STN: 17 Jul 2002
 Entered Medline: 16 Jul 2002

L4 ANSWER 124 OF 658 MEDLINE on STN
Full Text
 AN 2001594238 MEDLINE
 DN PubMed ID: 11629467
 TI [Not Available].
 La curieuse histoire de la decouverte des sulfamides hypoglycemiants
 (premiers antidiabetiques actifs par voie buccale).
 AU Decourt P
 SO Histoire des sciences medicales, (1985) Vol. 19, No. 1, pp. 55-61.
 Journal code: 0225346. ISSN: 0440-8888.
 CY France
 DT Historical
 Journal; Article; (JOURNAL ARTICLE)
 LA French
 FS History of Medicine
 EM 198509
 ED Entered STN: 2 Nov 2001

Last Updated on STN: 2 Nov 2001
Entered Medline: 13 Sep 1985

L4 ANSWER 125 OF 658 MEDLINE on STN

Full Text

AN 2001533235 MEDLINE
DN PubMed ID: 11579529
TI Pneumonia caused by Nocardia nova.
AU Ikeue T; Ueshima K; Watanabe S; Sugita T; Horikawa S; Suzuki Y; Nishiyama H; Maekawa N
CS Department of Respiratory Disease, Japan Red Cross Society, Wakayama Medical Center, Wakayama, Japan.
SO Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, (2001 Jul) Vol. 39, No. 7, pp. 492-7.
Journal code: 9808802. ISSN: 1343-3490.
CY Japan
DT (CASE REPORTS)
(ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA Japanese
FS Priority Journals
EM 200112
ED Entered STN: 3 Oct 2001
Last Updated on STN: 22 Jan 2002
Entered Medline: 4 Dec 2001

L4 ANSWER 126 OF 658 MEDLINE on STN

Full Text

AN 2001512306 MEDLINE
DN PubMed ID: 11560011
TI [Different clinical patterns of secondary drug failure in diabetes mellitus type II patients and their significance for diagnosis of secondary sulfonamide resistance].
Prakticheskoe znachenie klinicheskoi kharakteristiki bol'nykh sakharnym diabetom II tipa s neeffektivnoi terapiiei dlia diagnostiki vtorichnoi sul'fanilamidnoi rezistentnosti.
AU Gendeleka G F
SO Likars'ka sprava / Ministerstvo okhorony zdorov'ia Ukrainy, (2001 May-Jun) No. 3, pp. 158-9.
Journal code: 9601540. ISSN: 1019-5297.
CY Ukraine
DT (COMPARATIVE STUDY)
(ENGLISH ABSTRACT)
Journal; Article; (JOURNAL ARTICLE)
LA Russian
FS Priority Journals
EM 200208
ED Entered STN: 19 Sep 2001
Last Updated on STN: 8 Aug 2002
Entered Medline: 7 Aug 2002

L4 ANSWER 127 OF 658 MEDLINE on STN

Full Text

AN 2001461951 MEDLINE
DN PubMed ID: 11503861
TI Repaglinide and diabetes: new preparation. No better than glucose-lowering sulphonamides.
AU Anonymous
SO Prescrire international, (2001 Feb) Vol. 10, No. 51, pp. 9-11.
Journal code: 9439295. ISSN: 1167-7422.
CY France
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Health Technology
EM 200103
ED Entered STN: 20 Aug 2001
Last Updated on STN: 20 Aug 2001
Entered Medline: 29 Mar 2001

L4 ANSWER 128 OF 658 MEDLINE on STN

Full Text

AN 2001460038 MEDLINE
 DN PubMed ID: 11330884
 TI Chronic bosentan treatment improves renal artery vascular function in diabetes.
 AU Arikawa E; Verma S; Dumont A S; McNeill J H
 CS Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada.
 SO Journal of hypertension, (2001 Apr) Vol. 19, No. 4, pp. 803-12.
 Journal code: 8306882. ISSN: 0263-6352.
 CY England: United Kingdom
 DT (IN VITRO)
 Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA English
 FS Priority Journals
 EM 200108
 ED Entered STN: 20 Aug 2001
 Last Updated on STN: 20 Aug 2001
 Entered Medline: 16 Aug 2001

L4 ANSWER 129 OF 658 MEDLINE on STN
Full Text
 AN 2001450298 MEDLINE
 DN PubMed ID: 11495581
 TI Sorbitol dehydrogenase inhibitors (SDIs): a new potent, enantiomeric SDI, 4-[2-1R-hydroxy-ethyl)-pyrimidin-4-yl]piperazine-1-sulfonic acid dimethylamide.
 AU Mylari B L; Oates P J; Beebe D A; Brackett N S; Coutcher J B; Dina M S; Zembrowski W J
 CS Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research & Development, Pfizer Inc., Groton, Connecticut 06340, USA..
lmylari@home.com
 SO Journal of medicinal chemistry, (2001 Aug 16) Vol. 44, No. 17, pp. 2695-700.
 Journal code: 9716531. ISSN: 0022-2623.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200109
 ED Entered STN: 13 Aug 2001
 Last Updated on STN: 10 Sep 2001
 Entered Medline: 6 Sep 2001

L4 ANSWER 130 OF 658 MEDLINE on STN
Full Text
 AN 2001416463 MEDLINE
 DN PubMed ID: 11465074
 TI Normal and pathological erectile function: the potential clinical role of endothelin-1 antagonists.
 AU Khan M A; Calvert R C; Sullivan M E; Thompson C S; Mumtaz F H; Morgan R J; Mikhailidis D P
 CS Department of Urology, Royal Free and University College Medical School, University College London, UK.
 SO Current drug targets, (2000 Nov) Vol. 1, No. 3, pp. 247-60. Ref: 210
 Journal code: 100960531. ISSN: 1389-4501.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200108
 ED Entered STN: 3 Sep 2001
 Last Updated on STN: 3 Sep 2001
 Entered Medline: 30 Aug 2001

L4 ANSWER 131 OF 658 MEDLINE on STN
Full Text
 AN 2001344272 MEDLINE
 DN PubMed ID: 11407110
 TI Update in pharmacologic treatment of hypertension.
 AU Ferdinand K C

CS Department of Clinical Pharmacology, Xavier University College of
Pharmacy, New Orleans, Louisiana, USA.. kcferdmd@aol.com
SO Cardiology clinics, (2001 May) Vol. 19, No. 2, pp. 279-94, v. Ref: 77
Journal code: 8300331. ISSN: 0733-8651.
CY United States
DT Journal; Article; (JOURNAL ARTICLE).
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200110
ED Entered STN: 29 Oct 2001
Last Updated on STN: 13 Mar 2003
Entered Medline: 25 Oct 2001

L4 ANSWER 132 OF 658 MEDLINE on STN
Full Text
AN 2001287940 MEDLINE
DN PubMed ID: 11311069
TI (4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3)
agonists.
AU Hu B; Ellingboe J; Han S; Largis E; Mulvey R; Oliphant A; Sum F W; Tillett
J
CS Chemical Sciences and Cardiovascular/Metabolic Diseases Research,
Wyeth-Ayerst Research, Pearl River, New York 10965, USA..
hub@war.wyeth.com
SO Journal of medicinal chemistry, (2001 Apr 26) Vol. 44, No. 9, pp. 1456-66.
Journal code: 9716531. ISSN: 0022-2623.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200105
ED Entered STN: 29 May 2001
Last Updated on STN: 29 May 2001
Entered Medline: 24 May 2001

L4 ANSWER 133 OF 658 MEDLINE on STN
Full Text
AN 2001152059 MEDLINE
DN PubMed ID: 11229702
TI Adverse drug reactions.
AU Shenfield G M; Jacka J
SO Lancet, (2001 Feb 17) Vol. 357, No. 9255, pp. 561.
Journal code: 2985213R. ISSN: 0140-6736.
CY England: United Kingdom
DT Commentary
Letter
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200103
ED Entered STN: 4 Apr 2001
Last Updated on STN: 19 Feb 2002
Entered Medline: 15 Mar 2001

L4 ANSWER 134 OF 658 MEDLINE on STN
Full Text
AN 2001111342 MEDLINE
DN PubMed ID: 11123367
TI Hepatic uptake of synthetic chlorogenic acid derivatives by the organic
anion transport proteins.
AU Schwab D; Herling A W; Hemmerle H; Schubert G; Hagenbuch B; Burger H J
CS Aventis Pharma Deutschland GmbH, Frankfurt am Main, Germany.
SO The Journal of pharmacology and experimental therapeutics, (2001 Jan) Vol.
296, No. 1, pp. 91-8.
Journal code: 0376362. ISSN: 0022-3565.
CY United States
DT (IN VITRO)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200102
ED Entered STN: 22 Mar 2001

Last Updated on STN: 22 Mar 2001
Entered Medline: 2 Feb 2001

L4 ANSWER 135 OF 658 MEDLINE on STN

Full Text

AN 2001096121 MEDLINE
DN PubMed ID: 11127715
TI Apoptotic germ-cell death and testicular damage in experimental diabetes: prevention by endothelin antagonism.
AU Cai L; Chen S; Evans T; Deng D X; Mukherjee K; Chakrabarti S
CS Department of Pathology, The University of Western Ontario, London, Ontario, Canada.
SO Urological research, (2000 Oct) Vol. 28, No. 5, pp. 342-7.
Journal code: 0364311. ISSN: 0300-5623.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200102
ED Entered STN: 22 Mar 2001
Last Updated on STN: 22 Mar 2001
Entered Medline: 1 Feb 2001

L4 ANSWER 136 OF 658 MEDLINE on STN

Full Text

AN 2000495727 MEDLINE
DN PubMed ID: 10940126
TI Bullous pemphigoid possibly triggered and exacerbated by ophthalmic preparations.
AU Spivak D; Orion E; Brenner S
SO International journal of dermatology, (2000 Jul) Vol. 39, No. 7, pp. 554-5.
Journal code: 0243704. ISSN: 0011-9059.
CY United States
DT (CASE REPORTS)
Letter
LA English
FS Priority Journals
EM 200010
ED Entered STN: 27 Oct 2000
Last Updated on STN: 27 Oct 2000
Entered Medline: 18 Oct 2000

L4 ANSWER 137 OF 658 MEDLINE on STN

Full Text

AN 2000481588 MEDLINE
DN PubMed ID: 10868554
TI Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.
AU Fung H B; Kirschenbaum H L; Hameed R
CS Pharmacy Service, Veterans Affairs Medical Center, Bronx, New York 10468, USA.
SO Clinical therapeutics, (2000 May) Vol. 22, No. 5, pp. 549-72. Ref: 68
Journal code: 7706726. ISSN: 0149-2918.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals; AIDS
EM 200010
ED Entered STN: 19 Oct 2000
Last Updated on STN: 19 Oct 2000
Entered Medline: 12 Oct 2000

L4 ANSWER 138 OF 658 MEDLINE on STN

Full Text

AN 2000436103 MEDLINE
DN PubMed ID: 10965886
TI Stimulation of insulin-like growth factor binding protein-1 synthesis by interleukin-1beta: requirement of the mitogen-activated protein kinase pathway.
AU Frost R A; Nystrom G J; Lang C H

CS Department of Cellular and Molecular Physiology, The Pennsylvania State
University College of Medicine, Hershey 17033, USA.. rfrost@psu.edu
NC AA-11290 (NIAAA)
GM-38032 (NIGMS)
SO Endocrinology, (2000 Sep) Vol. 141, No. 9, pp. 3156-64.
Journal code: 0375040. ISSN: 0013-7227.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200009
ED Entered STN: 28 Sep 2000
Last Updated on STN: 28 Sep 2000
Entered Medline: 21 Sep 2000

L4 ANSWER 139 OF 658 MEDLINE on STN

Full Text

AN 2000400489 MEDLINE
DN PubMed ID: 10873667
TI COX-2 inhibition prevents insulin-dependent diabetes in low-dose
streptozotocin-treated mice.
AU Tabatabaie T; Waldon A M; Jacob J M; Floyd R A; Kotake Y
CS Free Radical Biology and Aging Research Program, Oklahoma Medical Research
Foundation, 825 N. E. 13th Street, Oklahoma City, Oklahoma 73104, USA..
Tahereh-Tabatabaie@omrf.ouhsc.edu
SO Biochemical and biophysical research communications, (2000 Jul 5) Vol.
273, No. 2, pp. 699-704.
Journal code: 0372516. ISSN: 0006-291X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200008
ED Entered STN: 24 Aug 2000
Last Updated on STN: 19 Dec 2002
Entered Medline: 17 Aug 2000

L4 ANSWER 140 OF 658 MEDLINE on STN

Full Text

AN 2000327021 MEDLINE
DN PubMed ID: 10871206
TI Endothelin receptor blockade prevents augmented extracellular matrix
component mRNA expression and capillary basement membrane thickening in
the retina of diabetic and galactose-fed rats.
AU Evans T; Deng D X; Chen S; Chakrabarti S
CS Department of Pathology, University of Western Ontario, London, Canada.
SO Diabetes, (2000 Apr) Vol. 49, No. 4, pp. 662-6.
Journal code: 0372763. ISSN: 0012-1797.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200007
ED Entered STN: 14 Jul 2000
Last Updated on STN: 14 Jul 2000
Entered Medline: 6 Jul 2000

=> d 14 an ti so ab kwic 161 283 298

L4 ANSWER 161 OF 658 MEDLINE on STN

Full Text

AN 1998083454 MEDLINE
TI [Pharmacokinetics of hypoglycemic sulfonamides: Ozidia, a new concept].
Pharmacocinétique des sulfamides hypoglycémisants: OZIDIA un nouveau
concept.
SO Diabetes & metabolism, (1997 Nov) Vol. 23 Suppl 4, pp. 39-43. Ref: 25
Journal code: 9607599. ISSN: 1262-3636.
AB Hypoglycaemic sulfonamides differ in their properties, which vary in

clinical importance. The potency of **sulfonamide** has increased with the generations. However, this potency is compensated in practice by the dose prescribed, which is much smaller for recent generations. The half-life is a far more important property. The effective action period is correlated with half-life but is much longer. The action period for "short-term" **sulfonamides** is $< \text{ or } = 24 \text{ h}$ (tolbutamide, glipizide) and can exceed 24 h for "long-term" **sulfonamides** (e.g. glibenclamide). Metabolism and elimination reduce the risk of accumulation. All **sulfonamides** are metabolised more than 95% by the liver. The metabolites are inactive except for one from glibenclamide. As a function of their action period and possibly of intrinsic properties, some **sulfonamides** more than others (e.g. glibenclamide) affect fasting hepatic glucose production, which is particularly increased early in the day in non-insulin-dependent diabetic patients because of a circadian drop in insulin sensitivity (dawn phenomenon). Finally, in chronic administration, all **sulfonamides** cause a progressive desensitisation of the beta cell, which responds by an insulin secretion peak only during food intake. This condition indicates the uselessness of **sulfonamide** fractionation and, contrary to the classic notion, the low risk of hypoglycaemia after a meal is skipped. The ideal product would be a **sulfonamide** with high potency and an ultra-short half-life, but capable of maintaining plasma concentrations for 24 h (which might seem incompatible except in continuous administration). Moreover, it would exert its action at relatively low levels of insulinaemia and be completely metabolisable. Glipizide in its osmotic oral form (Ozidia) satisfies all these conditions since it is a very potent **sulfonamide** with a quite short half-life but with intestinal delivery up to 16 h after administration because of its osmotic principle. It controls fasting glycaemia better than ordinary glipizide and at least as well as glibenclamide by acting on hepatic glucose production. Compared to glibenclamide, it has the advantage of generation this effect at lower levels of insulinaemia. In comparison with normal glipizide, it allows identical control for lower postprandial insulinaemias, which is proof of its powerful inductive effect on insulin sensitivity.

TI [Pharmacokinetics of hypoglycemic **sulfonamides**: Ozidia, a new concept].
Pharmacocinetique des sulfamides hypoglycemiantes: OZIDIA un nouveau concept.

AB Hypoglycaemic **sulfonamides** differ in their properties, which vary in clinical importance. The potency of **sulfonamide** has increased with the generations. However, this potency is compensated in practice by the dose prescribed, which is much smaller. . . . more important property. The effective action period is correlated with half-life but is much longer. The action period for "short-term" **sulfonamides** is $< \text{ or } = 24 \text{ h}$ (tolbutamide, glipizide) and can exceed 24 h for "long-term" **sulfonamides** (e.g. glibenclamide). Metabolism and elimination reduce the risk of accumulation. All **sulfonamides** are metabolised more than 95% by the liver. The metabolites are inactive except for one from glibenclamide. As a function of their action period and possibly of intrinsic properties, some **sulfonamides** more than others (e.g. glibenclamide) affect fasting hepatic glucose production, which is particularly increased early in the day in non-insulin-dependent diabetic patients because of a circadian drop in insulin sensitivity (dawn phenomenon). Finally, in chronic administration, all **sulfonamides** cause a progressive desensitisation of the beta cell, which responds by an insulin secretion peak only during food intake. This condition indicates the uselessness of **sulfonamide** fractionation and, contrary to the classic notion, the low risk of hypoglycaemia after a meal is skipped. The ideal product would be a **sulfonamide** with high potency and an ultra-short half-life, but capable of maintaining plasma concentrations for 24 h (which might seem incompatible. . . . be completely metabolisable. Glipizide in its osmotic oral form (Ozidia) satisfies all these conditions since it is a very potent **sulfonamide** with a quite short half-life but with intestinal delivery up to 16 h after administration because of its osmotic principle.. . .

CT Administration, Oral
Circadian Rhythm

Diabetes Mellitus, Type 2: DT, drug therapy

*Diabetes Mellitus, Type 2: PP, physiopathology

Glipizide: AD, administration & dosage

*Glipizide: PK, pharmacokinetics

Glipizide: TU, therapeutic use

Humans

*Hypoglycemic Agents: . . .

L4 ANSWER 283 OF 658 MEDLINE on STN

Full Text

AN 69298447 MEDLINE

TI HB419 (glibenclamide) in the treatment of **diabetes mellitus**.

SO South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, (1969 Aug 9) Vol. 43, No. 32, pp. 981-3.

Journal code: 0404520. ISSN: 0256-9574.

TI HB419 (glibenclamide) in the treatment of **diabetes mellitus**.

CT

Adult

Age Factors

Aged

*Biguanides: AD, administration & dosage

Biguanides: AE, adverse effects

Chlorpropamide: AD, administration & dosage

Clinical Trials

Diabetes Complications

***Diabetes Mellitus: DT, drug therapy**

Gallbladder Diseases: CO, complications

Gastrointestinal Diseases: CO, complications

Humans

*Hypoglycemic Agents: AD, administration & dosage

Hypoglycemic. . . . Kidney Diseases: CO, complications

Liver Diseases: CO, complications

Metformin: AD, administration & dosage

Middle Aged

Phenformin: AD, administration & dosage

Sulfonamides: AD, administration & dosage

Tolbutamide: AD, administration & dosage

*Urea: AD, administration & dosage

Urea: AE, adverse effects

Vascular. . . .

CN 0 (Biguanides); 0 (Hypoglycemic Agents); 0 (Sulfonamides)

L4 ANSWER 298 OF 658 MEDLINE on STN

Full Text

AN 69163162 MEDLINE

TI [Clinical study of a hypoglycemic **sulfonamide**: 1324 AN (gludiasse) in treatment of **diabetes**].

Etude clinique d'un sulfamide hypoglycemiant: le 1324 AN dans le traitement du **diabete**.

SO Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille, (1968 Dec) Vol. 13, No. 10, pp. Suppl 7:1065+.

Journal code: 8203780. ISSN: 0024-3507.

TI [Clinical study of a hypoglycemic **sulfonamide**: 1324 AN (gludiasse) in treatment of **diabetes**].

Etude clinique d'un sulfamide hypoglycemiant: le 1324 AN dans le traitement du **diabete**.

CT Check Tags: Female; Male

Aged

***Diabetes Mellitus: DT, drug therapy**

Humans

*Hypoglycemic Agents: TU, therapeutic use

Middle Aged

***Sulfonamides: TU, therapeutic use**

CN 0 (Hypoglycemic Agents); 0 (Sulfonamides)

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

46.33

46.54

FILE 'REGISTRY' ENTERED AT 00:38:31 ON 06 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 AUG 2007 HIGHEST RN 944028-34-6
DICTIONARY FILE UPDATES: 3 AUG 2007 HIGHEST RN 944028-34-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e glymidine/cn

E1	1	GLYME-ZINC HEXACYANOCOBALTATE COMPLEX/CN
E2	1	GLYMESASON/CN
E3	2 -->	GLYIMIDINE/CN
E4	1	GLYIMIDINE SODIUM/CN
E5	1	GLYIMIDINE SODIUM SALT/CN
E6	1	GLYMIN 1000/CN
E7	1	GLYMIN 500/CN
E8	1	GLYMINOX/CN
E9	1	GLYMO/CN
E10	1	GLYMO HOMOPOLYMER/CN
E11	1	GLYMO-SILANE/CN
E12	1	GLYMO-TETRAETHOXYSILANE COPOLYMER/CN

=> s e3

L6 2 GLYIMIDINE/CN

=> d 1-2

L6 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN

RN 3459-20-9 REGISTRY

ED Entered STN: 16 Nov 1984

CN Benzenesulfonamide, N-[5-(2-methoxyethoxy)-2-pyrimidinyl]-, sodium salt
(8CI, 9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Sodium, [N-[5-(2-methoxyethoxy)-2-pyrimidinyl]benzenesulfonamido]- (7CI)

OTHER NAMES:

CN BS 717

CN Glycanol

CN Glycodiazin

CN Glycodiazine

CN Glycodiazine sodium

CN Glyconormal

CN **Glymidine**

CN Glymidine sodium

CN Glymidine sodium salt

CN Gondafon

CN Lycanol

CN N-[5-(2-Methoxyethoxy)-2-pyrimidinyl]benzenesulfonamide sodium

CN Redul

CN Redul IF

CN Redul sodium

CN SH 717

CN Sodium 2-benzenesulphonylamino-5-(2-methoxyethoxy)pyrimidine

CN Sodium benzenesulfonamide, N-[5-(2-methoxyethoxy)-2-pyrimidinyl]-

CN Sodium glycodiazine

CN Sodium glymidine

DR 14349-73-6, 93427-85-1


MF C13 H15 N3 O4 S . Na

LC STN Files: BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMLIST, EMBASE,
IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, PS, RTECS*, TOXCENTER, USAN,
USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (339-44-6)




Na

****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

94 REFERENCES IN FILE CA (1907 TO DATE)
94 REFERENCES IN FILE CAPLUS (1907 TO DATE)
17 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L6 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN
RN 339-44-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzenesulfonamide, N-[5-(2-methoxyethoxy)-2-pyrimidinyl]- (CA INDEX NAME)
OTHER NAMES:
CN 2-Benzenesulfonamido-5-(2-methoxyethoxy)pyrimidine
CN Glidiazine
CN Glymidine
CN N-[5-(2-Methoxyethoxy)-2-pyrimidinyl]benzenesulfonamide
MF C13 H15 N3 O4 S
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMLIST, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

92 REFERENCES IN FILE CA (1907 TO DATE)
92 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> e glibenclamide/cn

E1	1	GLIBEN/CN
E2	1	GLIBEN-PUREN N/CN
E3	1	--> GLIBENCLAMIDE/CN
E4	1	GLIBENCLAMIDE SODIUM/CN
E5	1	GLIBENCLAMIDE-.BETA.-CYCLODEXTRIN COMPLEX (1:2)/CN
E6	1	GLIBENCLAMIDE-GLUCOSE MIXTURE/CN
E7	1	GLIBENCLAMIDE-METFORMIN MIXT./CN
E8	1	GLIBENCLAMIDE-PHENFORMIN HYDROCHLORIDE MIXT./CN
E9	1	GLIBENCLAMIDE-PHENFORMIN MIXT./CN
E10	1	GLIBENESE/CN
E11	1	GLIBENIL/CN
E12	1	GLIBENS/CN

```

=> s e3
L7      1 GLIBENCLAMIDE/CN


=> d

L7  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN  10238-21-8  REGISTRY
ED  Entered STN:  16 Nov 1984
CN  Benzamide, 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (CA INDEX NAME)

OTHER NAMES:
CN  1-[4-[2-(5-Chloro-2-methoxybenzamido)ethyl]phenylsulfonyl]-3-cyclohexylurea
CN  1-[p-2-(5-Chloro-o-anisamido)ethylphenylsulfonyl]-3-cyclohexylurea
CN  1-[[p-2-(5-Chloro-o-anisamido)ethyl]phenyl]sulfonyl]-3-cyclohexylurea
CN  Abbenclamide
CN  Adiab
CN  Antibet
CN  Apo-Glibenclamide
CN  Azuglucon
CN  Bastiverit
CN  Benclamin
CN  Betanase
CN  Betanaz
CN  Betanese 5
CN  Calabren
CN  Cytagon
CN  Daonil
CN  Daonil N
CN  Debtan
CN  Dia-basan
CN  Diaben
CN  Diabeta
CN  Diabiphage
CN  Dibelet
CN  Duraglucon
CN  Euglucon
CN  Euglucon
CN  Euglucon 5
CN  Euglykon
CN  GBN 5
CN  Gilemal
CN  Gl
CN  Glamide
CN  Gliban
CN  Gliben
CN  Gliben-Puren N
CN  Glibenclamide
CN  Glibenil
CN  Glibens
CN  Glibesyn
CN  Glibet
CN  Glibetic
CN  Glibil
CN  Gliboral
CN  Glicem
CN  Glidiabet
CN  Glimel
CN  Glimide
CN  Glimidstada
CN  Glisulin
CN  Glitisol
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY
MF  C23 H28 Cl N3 O5 S
CI  COM
LC  STN Files:  ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO,
      CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, CSNB,
      DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSPATENTS,
      IPA, MEDLINE, MRCK*, PIRA, PROMT, .PS, RTECS*, SCISEARCH, SPECINFO,
      TOXCENTER, USAN, USPAT2, USPATFULL

```

(*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3555 REFERENCES IN FILE CA (1907 TO DATE)
 34 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 3572 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file merck
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
18.00	64.54

FILE 'MRCK' ENTERED AT 00:41:24 ON 06 AUG 2007
 COPYRIGHT (C) 2007 Merck & Co., Inc., Whitehouse Station, New Jersey, USA. All Rights Reserve

FILE COVERS FROM LATE 19TH CENTURY TO PRESENT. LAST UPDATE: OCTOBER 2005

THE MERCK INDEX ONLINE is a service mark of Merck & Co., Inc., Whitehouse Station, NJ, USA and is registered in the United States Patent and Trademark Office.

=> d his

(FILE 'HOME' ENTERED AT 00:27:02 ON 06 AUG 2007)

FILE 'MEDLINE' ENTERED AT 00:27:15 ON 06 AUG 2007

L1 27268 S SULFONAMIDE?
 L2 252380 S (DIABETE?)
 L3 136295 S (OBESITY OR OBESE OR WEIGHT REDUCT? OR WEIGHT GAIN)
 L4 658 S L1 AND L2
 L5 121 S L1 AND L3

FILE 'REGISTRY' ENTERED AT 00:38:31 ON 06 AUG 2007

E GLYIMIDINE/CN
 L6 2 S E3
 E GLIBENCLAMIDE/CN
 L7 1 S E3

FILE 'MRCK' ENTERED AT 00:41:24 ON 06 AUG 2007


=> s 16

L8 1 L6

=> d all

L8 ANSWER 1 OF 1 MRCK COPYRIGHT (C) 2007 Merck and Co., Inc., Whitehouse Station, New Jersey, USA. All rights reserved. on STN
 MERCK Number (MNO): 4520
 CAS Registry No. (RN): 339-44-6
 MERCK Index Name (MIN): Glymidine
 CA Index Name (CN): N-[5-(2-Methoxyethoxy)-2-pyrimidinyl]benzenesulfonamide
 Synonym(s) (CN): 2-benzenesulfonamido-5-(β-methoxyethoxy)pyrimidine; Glycodiazine
 Molecular Form. (MF): C13 H15 N3 O4 S
 Wgt Composition (COMP): C 50.47%, H 4.89%, N 13.58%, O 20.69%, S 10.37%.
 Molecular Weight (MW): 309.34
 References (RE): Prepn: BE 609270; H. Priewe et al., US 3275635 (1962,

1966 both to Schering, AG); Gutsche et al., *Arzneim.-Forsch.* 14, 373 (1964). Series of articles on pharmacology: *ibid.* 377-412. Activity: Losert et al., *ibid.* 23, 1251 (1973). Metabolism: Soyfer et al., *Chim. Ther.* 5, 441 (1970). Toxicity data: Kramer et al., *Arzneim.-Forsch.* 14, 377 (1964).



Melting Point (MP):

Value
MP
deg C
=====

152 - 154

Other Properties (OCPP):

Crystals, mp 152-154° . Soly in ethanol: 0.91%; in toluene: 0.67%.

== DERIVATIVE == (1): Sodium salt

CAS Registry No. (RN.DRV): 3459-20-9


Drug Code(s) (CN.DRV): SH-717

Trade Name(s) (CN.DRV): Glyconormal; Gondafon (Schering); Lycanol; Redul (Schering)

Molecular Form. (MF.DRV): C13 H14 N3 Na O4 S

Wgt Composition (COMP.DRV): C 47.13%, H 4.26%, N 12.68%, Na 6.94%, O 19.32%, S 9.68%.

Molecular Weight (MW.DRV): 331.32



Na

Melting Point (MP.DRV):

Deriv. Number	Derivative Type	Value MP.DRV deg C
1	Sodium salt	221 - 226

Toxicity (TOX.DRV):

LD50 in mice, rats (g/kg): 1.48, 2.00 i.v.; 5.30, 2.85 orally (Kramer).

Other Properties (OCPP.DRV):

Crystals, mp 221-226° . Sparingly sol in alc. Soly in water at 37°: 70.5%. LD50 in mice, rats (g/kg): 1.48 , 2.00 i.v. ; 5.30 , 2.85 orally (Kramer) .

Therapeutic Codes (THER):

Antidiabetic.

Referenced Patent (RPN):

BE609270; US3275635

=> s 17

=> d all

L9. ANSWER 1 OF 1 MRCK COPYRIGHT (C) 2007 Merck and Co., Inc.,
 Whitehouse Station, New Jersey, USA. All rights reserved. on STN

MERCK Number (MNO): 4491
 CAS Registry No. (RN): 10238-21-8
 MERCK Index Name (MIN): Glyburide
 CA Index Name (CN): 5-Chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxybenzamide


Synonym(s) (CN): 1-[[p-[2-(5-chloro-o-anisamido)ethyl]phenyl]sulfonyl]-3-cyclohexylurea; N-[4-(β-(2-methoxy-5-chlorobenzamido)ethyl)benzenesulfonyl]-N'-cyclohexylurea; N1-[4-[β-(2-methoxy-5-chlorobenzoylamino)ethyl]benzenesulfonyl]-N2-cyclohexylurea; Glybenzcyclamide; Glibenclamide

Drug Code(s) (CN): HB-419; U-26452
 Trade Name(s) (CN): Azuglucon (Azupharma); Bastiverit (Bastian-Werk); Diabasan (Biofarma); Diabeta (Sanofi-Aventis); Daonil (Sanofi-Aventis); Duraglucon (Dura); Euglucon (Sanofi-Aventis); Gilemal (Chinoin); Glimidstada (Stada); Glycolande (Sanofi-Synthelabo); Libanil (Approved Prescrip.); Maninil (Berlin-Chemie); Micronase (Pharmacia & Upjohn); Praeciglucon (Pfleger)

Molecular Form. (MF): C23 H28 Cl N3 O5 S
 Wgt Composition (COMP): C 55.92%, H 5.71%, Cl 7.18%, N 8.51%, O 16.19%, S 6.49%.

Molecular Weight (MW): 494.00

References (RE): Second generation sulfonylurea with hypoglycemic activity. Prepn: Aumuller et al., *Arzneim.-Forsch.* 16, 1640 (1966); NL 6603398 (1966 to Boehringer, Mann.), C.A. 66, 65289h (1967); NL 6610580; H. Weber et al., US 3454635 (1967, 1969 both to Hoechst). Pharmacology: Loubatieres, Mariani, C.R. *Seances Acad. Sci. Ser. D* 265, 643 (1967). Toxicity: Mizukami et al., *Arzneim.-Forsch.* 19, 1413 (1969). Series of articles on synthesis, pharmacology, toxicology and clinical studies: *ibid.* 1323-1494. Effect on release of insulin, glucagon and somatostatin: S. Efendic et al., *Proc. Natl. Acad. Sci. USA* 76, 5901 (1979). Symposium on pharmacology, mechanism of action and clinical trials: *Ann. Clin. Res.* 15, Suppl. 37, 1-35 (1983). Comprehensive description: P. G. Takla, *Anal. Profiles Drug Subs.* 10, 337-355 (1981). Review of pharmacology and clinical efficacy: J. M. Feldman, *Pharmacotherapy* 5, 43-62 (1985).



Melting Point (MP):

Value MP deg C	Note
169 - 170	(Weber)
172 - 174	(Aumuller)

Toxicity (TOX):

LD50 in rats and mice (g/kg): >20 orally; >12.5 i.p.; >20 s.c. (Mizukami).

Other Properties (OCPP):

Crystals from methanol, mp 169-170° (Weber); also reported as mp 172-174° (Aumuller). pKa 5.3. Sparingly sol in water, sol in the usual organic solvents. LD50 in rats and mice (g/kg): > 20 orally; > 12.5 i.p.; > 20 s.c. (Mizukami).

Therapeutic Codes (THER):
Antidiabetic.
Other Sources (OS):
CA 66:65289
Referenced Patent (RPN):
NL6603398; NL6610580; US3454635

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.96	72.50

FILE 'USPATFULL' ENTERED AT 00:47:21 ON 06 AUG 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 00:47:21 ON 06 AUG 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d his

(FILE 'HOME' ENTERED AT 00:27:02 ON 06 AUG 2007)

FILE 'MEDLINE' ENTERED AT 00:27:15 ON 06 AUG 2007

L1 27268 S SULFONAMIDE?
L2 252380 S (DIABETE?)
L3 136295 S (OBESITY OR OBESE OR WEIGHT REDUCT? OR WEIGHT GAIN)
L4 658 S L1 AND L2
L5 121 S L1 AND L3

FILE 'REGISTRY' ENTERED AT 00:38:31 ON 06 AUG 2007

E GLYIMIDINE/CN
L6 2 S E3
E GLIBENCLAMIDE/CN
L7 1 S E3

FILE 'MRCK' ENTERED AT 00:41:24 ON 06 AUG 2007

L8 1 S L6
L9 1 S L7

FILE 'USPATFULL, USPAT2' ENTERED AT 00:47:21 ON 06 AUG 2007

=> s sulfonamide?
L10 38762 SULFONAMIDE?

=> s sulfonamide?/clm
L11 5385 SULFONAMIDE?/CLM

=> s diabete?
L12 67405 DIABETE?

=> s diabete?/clm
L13 12729 DIABETE?/CLM

=> s (obesity or obese or weight reduct? or weight gain)
L14 61802 (OBESITY OR OBESE OR WEIGHT REDUCT? OR WEIGHT GAIN)

=> s (obesity or obese or weight reduct? or weight gain)/clm
L15 7684 (OBESITY OR OBESE OR WEIGHT REDUCT? OR WEIGHT GAIN)/CLM

=> s l10 and l12
L16 7455 L10 AND L12

=> s l11 and l12
L17 705 L11 AND L12

=> s l11 and l13
L18 257 L11 AND L13

=> s l10 and l14
L19 4587 L10 AND L14

=> s 111 and 115
L20 155 L11 AND L15

=> d 100-140

L20 ANSWER 100 OF 155 USPATFULL on STN

Full Text

AN 2003:289142 USPATFULL
TI Methods of modulating tyrosine protein kinase function with indolinone compounds
IN Tang, Peng Cho, Moraga, CA, UNITED STATES
Sun, Li, Foster City, CA, UNITED STATES
PA SUGEN, INC. (U.S. corporation)
PI US 2003203901 A1 20031030
AI US 2002-302932 A1 20021125 (10)
RLI Division of Ser. No. US 1999-283657, filed on 1 Apr 1999, GRANTED, Pat. No. US 6514981
PRAI US 1998-80422P 19980402 (60)
DT Utility
FS APPLICATION
LN.CNT 4288
INCL INCLM: 514/228.200
INCLS: 514/234.500; 514/243.000; 514/250.000; 514/267.000; 514/248.000; 514/291.000; 544/060.000; 544/184.000; 544/251.000; 544/234.000; 544/345.000; 546/082.000
NCL NCLM: 514/228.200
NCLS: 514/234.500; 514/243.000; 514/248.000; 514/250.000; 514/267.000; 514/291.000; 544/060.000; 544/184.000; 544/234.000; 544/251.000; 544/345.000; 546/082.000
IC [7]
ICM A61K031-541
ICS A61K031-5377; A61K031-519; A61K031-53; A61K031-498; A61K031-502; A61K031-4745; C07D487-02
IPCI A61K0031-541 [ICM,7]; A61K0031-5377 [ICS,7]; A61K0031-5375 [ICS,7,C*]; A61K0031-519 [ICS,7]; A61K0031-53 [ICS,7]; A61K0031-498 [ICS,7]; A61K0031-502 [ICS,7]; A61K0031-4745 [ICS,7]; A61K0031-4738 [ICS,7,C*]; C07D0487-02 [ICS,7]; C07D0487-00 [ICS,7,C*]
IPCR C07D0209-00 [I,C*]; C07D0209-34 [I,A]; C07D0209-86 [I,A]; C07D0403-00 [I,C*]; C07D0403-06 [I,A]; C07D0409-00 [I,C*]; C07D0409-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 101 OF 155 USPATFULL on STN

Full Text

AN 2003:283157 USPATFULL
TI Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IN Nilsson, Marianne, Rimbo, SWEDEN
Vallgarda, Jerk, Uppsala, SWEDEN
Barf, Tjeerd, Uppsala, SWEDEN
PI US 2003199501 A1 20031023
US 7030135 B2 20060418
AI US 2003-296132 A1 20030318 (10)
WO 2001-SE1157 20010522
PRAI SE 2000-1899 20000522
DT Utility
FS APPLICATION
LN.CNT 987
INCL INCLM: 514/234.200
INCLS: 514/301.000; 514/367.000; 544/127.000; 544/135.000; 546/114.000; 548/161.000
NCL NCLM: 514/301.000; 514/234.200
NCLS: 514/367.000; 546/114.000; 548/161.000; 544/127.000; 544/135.000
IC [7]
ICM C07D498-02
ICS C07D417-02; A61K031-5377; A61K031-4745; A61K031-428
IPCI C07D0498-02 [ICM,7]; C07D0498-00 [ICM,7,C*]; C07D0417-02 [ICS,7]; C07D0417-00 [ICS,7,C*]; A61K0031-5377 [ICS,7]; A61K0031-5375 [ICS,7,C*]; A61K0031-4745 [ICS,7]; A61K0031-4738 [ICS,7,C*]; A61K0031-428 [ICS,7]
IPCI-2 A61K0031-428 [I,A]; C07D0277-82 [I,A]; C07D0277-00 [I,C*]
IPCR C07D0277-20 [I,A]; A61K0031-426 [I,C*]; A61K0031-426 [I,A];

A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-428 [I,C*];
A61K0031-428 [I,A]; A61K0031-429 [I,C*]; A61K0031-429 [I,A];
A61K0031-4353 [I,C*]; A61K0031-437 [I,A]; A61K0031-4427 [I,C*];
A61K0031-4439 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A];
A61K0031-472 [I,C*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*];
A61K0031-496 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61K0031-541 [I,C*];
A61K0031-541 [I,A]; A61K0031-553 [I,C*]; A61K0031-553 [I,A];
A61P0003-00 [I,C*]; A61P0003-00 [I,A]; A61P0003-04 [I,A];
A61P0003-06 [I,A]; A61P0003-08 [I,A]; A61P0003-10 [I,A];
A61P0005-00 [I,C*]; A61P0005-48 [I,A]; A61P0009-00 [I,C*];
A61P0009-04 [I,A]; A61P0019-00 [I,C*]; A61P0019-10 [I,A];
A61P0025-00 [I,C*]; A61P0025-24 [I,A]; A61P0025-28 [I,A];
A61P0027-00 [I,C*]; A61P0027-06 [I,A]; A61P0029-00 [I,C*];
A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-06 [I,A];
A61P0031-12 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A];
C07D0277-00 [I,C*]; C07D0277-28 [I,A]; C07D0277-38 [I,A];
C07D0277-48 [I,A]; C07D0277-52 [I,A]; C07D0277-56 [I,A];
C07D0277-58 [I,A]; C07D0277-60 [I,A]; C07D0277-82 [I,A];
C07D0277-84 [I,A]; C07D0417-00 [I,C*]; C07D0417-04 [I,A];
C07D0417-06 [I,A]; C07D0417-12 [I,A]; C07D0417-14 [I,A];
C07D0491-00 [I,C*]; C07D0491-08 [I,A]; C07D0513-00 [I,C*];
C07D0513-04 [I,A]; C07D0521-00 [I,C*]; C07D0521-00 [I,A];
A61K0031-428 [I,A]; A61K0031-428 [I,C]; C07D0277-00 [I,C];
C07D0277-82 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 102 OF 155 USPATFULL on STN

Full Text

AN 2003:265992 USPATFULL
TI 8-carboxamido-2,6-methano-3-benzazocines
IN Wentland, Mark P., Menands, NY, UNITED STATES
PI US 2003187009 A1 20031002
US 6784187 B2 20040831
AI US 2002-305287 A1 20021126 (10)
RLI Continuation-in-part of Ser. No. WO 2001-US45581, filed on 31 Oct 2001,
PENDING
PRAI US 2000-244438P 20001031 (60)
DT Utility
FS APPLICATION
LN.CNT 1228
INCL INCLM: 514/278.000
INCLS: 514/279.000; 514/282.000; 546/018.000; 546/030.000; 546/044.000
NCL NCLM: 514/282.000; 514/278.000
NCLS: 546/042.000; 546/044.000; 546/047.000; 514/279.000; 546/018.000;
546/030.000
IC [7]
ICM A61K031-485
ICS C07D489-02
IPCI A61K0031-485 [ICM,7]; C07D0489-02 [ICS,7]; C07D0489-00 [ICS,7,C*]
IPCI-2 A61K0031-4355 [ICM,7]; A61K0031-4353 [ICM,7,C*]; C07D0221-26
[ICS,7]; C07D0221-00 [ICS,7,C*]
IPCR A61K0031-485 [I,C*]; A61K0031-485 [I,A]; C07D0221-00 [I,C*];
C07D0221-26 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A];
C07D0405-00 [I,C*]; C07D0405-06 [I,A]; C07D0489-00 [I,C*];
C07D0489-00 [I,A]; C07D0489-08 [I,A]; C07D0489-10 [I,A];
C07D0491-00 [I,C*]; C07D0491-20 [I,A]; C07D0491-22 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 103 OF 155 USPATFULL on STN

Full Text

AN 2003:251687 USPATFULL
TI Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IN Barf, Tjeerd, Uppsala, SWEDEN
Nilsson, Marianne, Rimbo, SWEDEN
Vallgarda, Jerk, Uppsala, SWEDEN
Kurz, Guido, Stockholm, SWEDEN
PI US 2003176476 A1 20030918
US 7125900 B2 20061024
AI US 2003-276954 A1 20030218 (10)
WO 2001-SE1156 20010522
PRAI SE 2000-1899 20000522

DT Utility
FS APPLICATION
LN.CNT 1369
INCL INCLM: 514/370.000
INCLS: 548/193.000
NCL NCLM: 514/371.000; 514/370.000
NCLS: 548/194.000; 548/197.000; 548/193.000
IC [7]
ICM A61K031-426
ICS C07D277-38
IPCI A61K0031-426 [ICM,7]; C07D0277-38 [ICS,7]; C07D0277-00 [ICS,7,C*]
IPCI-2 C07D0277-52 [I,A]; C07D0277-00 [I,C*]; A61K0031-426 [I,A]
IPCR C07D0277-00 [I,C]; C07D0277-20 [I,A]; C07D0277-52 [I,A];
A61K0031-426 [I,C]; A61K0031-426 [I,A]; A61K0031-427 [I,C*];
A61K0031-427 [I,A]; A61K0031-428 [I,C*]; A61K0031-428 [I,A];
A61K0031-429 [I,C*]; A61K0031-429 [I,A]; A61K0031-4353 [I,C*];
A61K0031-437 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-472 [I,C*];
A61K0031-4725 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A];
A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-5375 [I,C*];
A61K0031-5377 [I,A]; A61K0031-541 [I,C*]; A61K0031-541 [I,A];
A61K0031-553 [I,C*]; A61K0031-553 [I,A]; A61P0003-00 [I,C*];
A61P0003-00 [I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A];
A61P0003-08 [I,A]; A61P0003-10 [I,A]; A61P0005-00 [I,C*];
A61P0005-48 [I,A]; A61P0009-00 [I,C*]; A61P0009-04 [I,A];
A61P0019-00 [I,C*]; A61P0019-10 [I,A]; A61P0025-00 [I,C*];
A61P0025-24 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
A61P0027-06 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A];
A61P0031-00 [I,C*]; A61P0031-06 [I,A]; A61P0031-12 [I,A];
A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0277-28 [I,A];
C07D0277-38 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A];
C07D0277-58 [I,A]; C07D0277-60 [I,A]; C07D0277-82 [I,A];
C07D0277-84 [I,A]; C07D0417-00 [I,C*]; C07D0417-04 [I,A];
C07D0417-06 [I,A]; C07D0417-12 [I,A]; C07D0417-14 [I,A];
C07D0491-00 [I,C*]; C07D0491-08 [I,A]; C07D0513-00 [I,C*];
C07D0513-04 [I,A]; C07D0521-00 [I,C*]; C07D0521-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 104 OF 155 USPATFULL on STN

Full Text

AN 2003:244997 USPATFULL
TI Amide derivatives as therapeutic agents
IN Kodra, Janos Tibor, Copenhagen, DENMARK
Lau, Jesper, Farum, DENMARK
Guzel, Mustafa, Jamestown, NC, UNITED STATES
Santhosh, Kalpathy Chidambareswaran, High Point, NC, UNITED STATES
Mjalli, Adnan M. M., Jamestown, NC, UNITED STATES
Andrews, Robert Carl, Jamestown, NC, UNITED STATES
Polisetti, Dharma Rao, Greensboro, NC, UNITED STATES
PI US 2003171411 A1 20030911
AI US 2002-323290 A1 20021219 (10)
PRAI EP 2002-388015 20020219
US 2001-386185P 20011221 (60)

DT Utility
FS APPLICATION
LN.CNT 5928
INCL INCLM: 514/357.000
INCLS: 514/408.000; 514/601.000; 514/625.000; 546/336.000; 548/561.000;
564/193.000; 564/080.000
NCL NCLM: 514/357.000
NCLS: 514/408.000; 514/601.000; 514/625.000; 546/336.000; 548/561.000;
564/080.000; 564/193.000
IC [7]
ICM C07D213-56
ICS A61K031-16; A61K031-18; C07D207-30
IPCI C07D0213-56 [ICM,7]; C07D0213-00 [ICM,7,C*]; A61K0031-16 [ICS,7];
A61K0031-18 [ICS,7]; C07D0207-30 [ICS,7]; C07D0207-00 [ICS,7,C*]
IPCR A61K0031-16 [I,C*]; A61K0031-16 [I,A]; A61K0031-18 [I,C*];
A61K0031-18 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 105 OF 155 USPATFULL on STN

Full Text

AN 2003:238531 USPATFULL
TI Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IN Kurz, Guido, Stockholm, SWEDEN
Nilsson, Marianne, Rimbo, SWEDEN
PI US 2003166689 A1 20030904
US 7132436 B2 20061107
AI US 2003-296552 A1 20030401 (10)
WO 2001-SE1158 20010522
PRAI SE 2000-1899 20000522
DT Utility
FS APPLICATION
LN.CNT 2542
INCL INCLM: 514/342.000
INCLS: 514/365.000; 548/205.000; 546/270.400
NCL NCLM: 514/366.000; 514/342.000
NCLS: 514/370.000; 548/150.000; 548/151.000; 548/197.000; 514/365.000;
546/270.400; 548/205.000
IC [7]
ICM C07D417-04
ICS C07D277-28; A61K031-4439; A61K031-426
IPCI C07D0417-04 [I,M,7]; C07D0417-00 [I,M,7,C*]; C07D0277-28 [I,M,7];
C07D0277-00 [I,M,7,C*]; A61K0031-4439 [I,M,7]; A61K0031-4427
[I,M,7,C*]; A61K0031-426 [I,M,7]
IPCI-2 C07D0277-52 [I,A]; C07D0277-00 [I,C*]; C07D0409-12 [I,A];
C07D0409-00 [I,C*]; A61K0031-426 [I,A]; A61K0031-427 [I,A]
IPCR C07D0277-00 [I,C]; C07D0277-20 [I,A]; C07D0277-52 [I,A];
A61K0031-426 [I,C]; A61K0031-426 [I,A]; A61K0031-427 [I,C];
A61K0031-427 [I,A]; A61K0031-428 [I,C*]; A61K0031-428 [I,A];
A61K0031-429 [I,C*]; A61K0031-429 [I,A]; A61K0031-4353 [I,C*];
A61K0031-437 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-472 [I,C*];
A61K0031-4725 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A];
A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-5375 [I,C*];
A61K0031-5377 [I,A]; A61K0031-541 [I,C*]; A61K0031-541 [I,A];
A61K0031-553 [I,C*]; A61K0031-553 [I,A]; A61P0003-00 [I,C*];
A61P0003-00 [I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A];
A61P0003-08 [I,A]; A61P0003-10 [I,A]; A61P0005-00 [I,C*];
A61P0005-48 [I,A]; A61P0009-00 [I,C*]; A61P0009-04 [I,A];
A61P0019-00 [I,C*]; A61P0019-10 [I,A]; A61P0025-00 [I,C*];
A61P0025-24 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
A61P0027-06 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A];
A61P0031-00 [I,C*]; A61P0031-06 [I,A]; A61P0031-12 [I,A];
A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07D0277-28 [I,A];
C07D0277-38 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A];
C07D0277-58 [I,A]; C07D0277-60 [I,A]; C07D0277-82 [I,A];
C07D0277-84 [I,A]; C07D0409-00 [I,C]; C07D0409-12 [I,A];
C07D0417-00 [I,C*]; C07D0417-04 [I,A]; C07D0417-06 [I,A];
C07D0417-12 [I,A]; C07D0417-14 [I,A]; C07D0491-00 [I,C*];
C07D0491-08 [I,A]; C07D0513-00 [I,C*]; C07D0513-04 [I,A];
C07D0521-00 [I,C*]; C07D0521-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 106 OF 155 USPATFULL on STN

Full Text

AN 2003:226389 USPATFULL
TI New compounds
IN Caldirola, Patrizia, Uppsala, SWEDEN
Johansson, Gary, Uppsala, SWEDEN
Mott, Andrew, Knivsta, SWEDEN
Beierlien, Katarina, Uppsala, SWEDEN
Thor, Markus, Knivsta, SWEDEN
Tedenborg, Lars, Uppsala, SWEDEN
Bremberg, Ulf, Uppsala, SWEDEN
Jensen, Annika Jenmalm, Uppsala, SWEDEN
PI US 2003158202 A1 20030821
US 7144883 B2 20061205
AI US 2002-167141 A1 20020611 (10)
PRAI SE 2001-2048 20010611
SE 2001-2386 20010703
SE 2001-3437 20011016
DT Utility

FS APPLICATION
LN.CNT 3624
INCL INCLM: 514/248.000
INCLS: 544/278.000; 544/280.000; 544/350.000; 544/238.000; 514/249.000;
514/260.100; 514/265.100
NCL NCLM: 514/254.110; 514/248.000
NCLS: 514/218.000; 514/249.000; 514/252.130; 514/253.060; 514/254.040;
514/254.060; 514/254.080; 514/254.090; 514/320.000; 514/321.000;
514/322.000; 514/323.000; 514/324.000; 514/367.000; 514/373.000;
514/375.000; 514/379.000; 514/393.000; 514/403.000; 514/414.000;
540/575.000; 544/349.000; 544/363.000; 544/368.000; 544/370.000;
544/371.000; 544/373.000; 544/376.000; 544/377.000; 546/196.000;
546/197.000; 546/198.000; 546/199.000; 546/201.000; 546/202.000;
514/260.100; 514/265.100; 544/238.000; 544/278.000; 544/280.000;
544/350.000
IC [7]
ICM A61K031-519
ICS C07D487-02; C07D491-02
IPCI A61K0031-519 [ICM,7]; C07D0487-02 [ICS,7]; C07D0487-00
[ICS,7,C*]; C07D0491-02 [ICS,7]; C07D0491-00 [ICS,7,C*]
IPCI-2 A61P0003-04 [I,A]; A61P0003-00 [I,C*]; A61P0007-00 [I,A];
A61K0031-42 [I,A]; A61K0031-445 [I,A]; A61K0031-497 [I,A];
A61K0031-4965 [I,C*]
IPCR A61P0003-00 [I,C]; A61P0003-04 [I,A]; A61K0031-407 [I,C*];
A61K0031-407 [I,A]; A61K0031-42 [I,C]; A61K0031-42 [I,A];
A61K0031-4353 [I,C*]; A61K0031-437 [I,A]; A61K0031-4409 [I,C*];
A61K0031-4409 [I,A]; A61K0031-445 [I,C]; A61K0031-445 [I,A];
A61K0031-495 [I,C*]; A61K0031-495 [I,A]; A61K0031-496 [I,C*];
A61K0031-496 [I,A]; A61K0031-4965 [I,C]; A61K0031-4965 [I,A];
A61K0031-497 [I,A]; A61K0031-551 [I,C*]; A61K0031-551 [I,A];
A61P0003-10 [I,A]; A61P0007-00 [I,C]; A61P0007-00 [I,A];
A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0025-06 [I,A];
A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-18 [I,A];
A61P0025-20 [I,A]; A61P0025-22 [I,A]; A61P0025-24 [I,A];
A61P0025-28 [I,A]; A61P0025-30 [I,A]; A61P0043-00 [I,C*];
A61P0043-00 [I,A]; C07D0211-00 [I,C*]; C07D0211-70 [I,A];
C07D0215-00 [I,C*]; C07D0215-40 [I,A]; C07D0215-58 [I,A];
C07D0217-00 [I,C*]; C07D0217-22 [I,A]; C07D0231-00 [I,C*];
C07D0231-16 [I,A]; C07D0241-00 [I,C*]; C07D0241-04 [I,A];
C07D0243-00 [I,C*]; C07D0243-08 [I,A]; C07D0295-00 [I,C*];
C07D0295-096 [I,A]; C07D0295-12 [I,A]; C07D0295-135 [I,A];
C07D0307-00 [I,C*]; C07D0307-79 [I,A]; C07D0319-00 [I,C*];
C07D0319-18 [I,A]; C07D0333-00 [I,C*]; C07D0333-34 [I,A];
C07D0333-62 [I,A]; C07D0409-00 [I,C*]; C07D0409-12 [I,A];
C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0487-00 [I,C*];
C07D0487-04 [I,A]; C07D0487-08 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 107 OF 155 USPATFULL on STN

Full Text

AN 2003:214378 USPATFULL
TI Piperazine mono(dithio)carbamate ester compounds and analogs thereof:
preparation method and uses thereof
IN Li, Runtao, Beijing, CHINA
Cheng, Tieming, Beijing, CHINA
Cui, Jingrong, Beijing, CHINA
Wang, Tingmin, San Marcos, CA, UNITED STATES
PA Medinox, Inc. (non-U.S. corporation)
PI US 2003149021 A1 20030807
AI US 2002-157733 A1 20020528 (10)
PRAI CN 2001-118399 20010529
DT Utility
FS APPLICATION
LN.CNT 1249
INCL INCLM: 514/211.010
INCLS: 514/217.110; 514/218.000; 514/227.500; 514/255.010; 514/238.800;
514/317.000; 514/365.000; 514/374.000; 514/385.000; 540/544.000;
540/575.000; 544/059.000; 540/607.000; 546/226.000; 544/386.000;
544/170.000
NCL NCLM: 514/211.010
NCLS: 514/217.110; 514/218.000; 514/227.500; 514/238.800; 514/255.010;
514/317.000; 514/365.000; 514/374.000; 514/385.000; 540/544.000;

540/575.000; 540/607.000; 544/059.000; 544/170.000; 544/386.000;
546/226.000

IC [7]
ICM C07D279-12
ICS C07D265-32; A61K031-55; A61K031-553; A61K031-554; A61K031-551;
A61K031-54; A61K031-537; A61K031-495
IPCI C07D0279-12 [ICM,7]; C07D0279-00 [ICM,7,C*]; C07D0265-32 [ICS,7];
C07D0265-00 [ICS,7,C*]; A61K0031-55 [ICS,7]; A61K0031-553
[ICS,7]; A61K0031-554 [ICS,7]; A61K0031-551 [ICS,7]; A61K0031-54
[ICS,7]; A61K0031-537 [ICS,7]; A61K0031-495 [ICS,7]
IPCR C07D0215-00 [I,C*]; C07D0215-22 [I,A]; C07D0295-00 [I,C*];
C07D0295-194 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 108 OF 155 USPATFULL on STN

Full Text

AN 2003:214377 USPATFULL
TI New compounds
IN Bremberg, Ulf, Uppsala, SWEDEN
Caldirola, Patrizia, Uppsala, SWEDEN
Jensen, Annika J., Uppsala, SWEDEN
Johansson, Gary, Uppsala, SWEDEN
Mott, Andrew, Knivsta, SWEDEN
Sutin, Lori, Knivsta, SWEDEN
Tejbrant, Jan, Enskede, SWEDEN
PI US 2003149020 A1 20030807
US 6969710 B2 20051129
AI US 2002-144677 A1 20020513 (10)
PRAI SE 2001-1659 20010511
SE 2001-1660 20010511
US 2001-294102P 20010529 (60)
US 2001-294132P 20010529 (60)
DT Utility
FS APPLICATION
LN.CNT 3229
INCL INCLM: 514/211.010
INCLS: 514/217.120; 514/217.110; 514/218.000; 514/227.500; 514/238.200;
514/255.020; 514/255.010; 514/317.000; 514/369.000; 514/370.000;
514/374.000; 514/397.000; 514/398.000; 514/603.000; 514/424.000;
540/544.000; 540/575.000; 540/604.000; 540/605.000; 544/059.000;
544/162.000; 544/158.000; 544/384.000; 546/223.000; 548/541.000;
548/316.400; 548/225.000; 548/182.000; 564/086.000
NCL NCLM: 514/218.000; 514/211.010
NCLS: 540/575.000; 514/217.110; 514/217.120; 514/227.500; 514/238.200;
514/255.010; 514/255.020; 514/317.000; 514/369.000; 514/370.000;
514/374.000; 514/397.000; 514/398.000; 514/424.000; 514/603.000;
540/544.000; 540/604.000; 540/605.000; 544/059.000; 544/158.000;
544/162.000; 544/384.000; 546/223.000; 548/182.000; 548/225.000;
548/316.400; 548/541.000; 564/086.000

IC [7]
ICM C07D279-12
ICS A61K031-551; A61K031-54; A61K031-537; A61K031-495; A61K031-445;
A61K031-426; A61K031-421; A61K031-4015
IPCI C07D0279-12 [ICM,7]; C07D0279-00 [ICM,7,C*]; A61K0031-551
[ICS,7]; A61K0031-54 [ICS,7]; A61K0031-537 [ICS,7]; A61K0031-495
[ICS,7]; A61K0031-445 [ICS,7]; A61K0031-426 [ICS,7]; A61K0031-421
[ICS,7]; A61K0031-4015 [ICS,7]
IPCI-2 C07D0295-04 [ICM,7]; C07D0295-00 [ICM,7,C*]; C07D0241-04 [ICS,7];
C07D0241-00 [ICS,7,C*]; C07D0211-46 [ICS,7]; C07D0211-00
[ICS,7,C*]; C07D0233-56 [ICS,7]; C07D0233-00 [ICS,7,C*];
A61K0031-495 [ICS,7]
IPCR C07D0215-00 [I,C*]; C07D0215-36 [I,A]; C07D0243-00 [I,C*];
C07D0243-08 [I,A]; C07D0261-00 [I,C*]; C07D0261-10 [I,A];
C07D0295-00 [I,C*]; C07D0295-135 [I,A]; C07D0401-00 [I,C*];
C07D0401-12 [I,A]; C07D0409-00 [I,C*]; C07D0409-14 [I,A];
C07D0413-00 [I,C*]; C07D0413-12 [I,A]; C07D0487-00 [I,C*];
C07D0487-04 [I,A]; C07D0487-08 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 109 OF 155 USPATFULL on STN

Full Text

AN 2003:214376 USPATFULL

TI New compounds
 IN Bremberg, Ulf, Uppsala, SWEDEN
 Caldirola, Patrizia, Uppsala, SWEDEN
 Jensen, Annika J., Uppsala, SWEDEN
 Johansson, Gary, Uppsala, SWEDEN
 Sutin, Lori, Knivsta, SWEDEN
 Mott, Andrew, Knivsta, SWEDEN
 Tejbrant, Jan, Enskede, SWEDEN
 PI US 2003149019 A1 20030807
 US 7173035 B2 20070206
 AI US 2002-143335 A1 20020510 (10)
 PRAI SE 2001-1659 20010511
 SE 2001-1660 20010511
 US 2001-294102P 20010529 (60)
 US 2001-294132P 20010529 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3179
 INCL INCLM: 514/211.010
 INCLS: 514/212.010; 514/227.500; 514/238.800; 514/255.020; 514/317.000;
 514/424.000; 514/603.000
 NCL NCLM: 514/253.060; 514/211.010
 NCLS: 514/254.040; 514/255.030; 544/363.000; 544/367.000; 544/395.000;
 514/212.010; 514/227.500; 514/238.800; 514/255.020; 514/317.000;
 514/424.000; 514/603.000
 IC [7]
 ICM A61K031-55
 ICS A61K031-553; A61K031-554; A61K031-54; A61K031-535; A61K031-496;
 A61K031-4015
 IPCI A61K0031-55 [ICM,7]; A61K0031-553 [ICS,7]; A61K0031-554 [ICS,7];
 A61K0031-54 [ICS,7]; A61K0031-535 [ICS,7]; A61K0031-496 [ICS,7];
 A61K0031-4015 [ICS,7]
 IPCI-2 A61P0025-00 [I,A]; A61K0031-497 [I,A]; A61K0031-4965 [I,A];
 C07D0401-00 [I,A]; C07D0241-00 [I,A]
 IPCR A61P0025-00 [I,C]; A61P0025-00 [I,A]; A61K0031-4965 [I,C];
 A61K0031-4965 [I,A]; A61K0031-497 [I,A]; C07D0215-00 [I,C*];
 C07D0215-36 [I,A]; C07D0241-00 [I,C]; C07D0241-00 [I,A];
 C07D0243-00 [I,C*]; C07D0243-08 [I,A]; C07D0261-00 [I,C*];
 C07D0261-10 [I,A]; C07D0295-00 [I,C*]; C07D0295-135 [I,A];
 C07D0401-00 [I,C]; C07D0401-00 [I,A]; C07D0401-12 [I,A];
 C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0413-00 [I,C*];
 C07D0413-12 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
 C07D0487-08 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 110 OF 155 USPATFULL on STN

Full Text

AN 2003:207989 USPATFULL
 TI Fat accumulation-modulation compounds
 IN Stevenson, Michael John, Haverhill, MA, UNITED STATES
 Leighton, Harrison Jefferson, Boston, MA, UNITED STATES
 PA AdipoGenix, Inc., Boston, MA, 02118 (U.S. corporation)
 PI US 2003144350 A1 20030731
 AI US 2002-201588 A1 20020722 (10)
 PRAI US 2001-306837P 20010720 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2344
 INCL INCLM: 514/485.000
 INCLS: 514/602.000; 514/558.000; 514/617.000
 NCL NCLM: 514/485.000
 NCLS: 514/558.000; 514/602.000; 514/617.000
 IC [7]
 ICM A61K031-325
 ICS A61K031-20; A61K031-18; A61K031-165
 IPCI A61K0031-325 [ICM,7]; A61K0031-20 [ICS,7]; A61K0031-185
 [ICS,7,C*]; A61K0031-18 [ICS,7]; A61K0031-165 [ICS,7]
 IPCR A61K0031-165 [I,C*]; A61K0031-165 [I,A]; A61K0031-18 [I,C*];
 A61K0031-18 [I,A]; A61K0031-185 [I,C*]; A61K0031-20 [I,A];
 A61K0031-325 [I,C*]; A61K0031-325 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 111 OF 155 USPATFULL on STN

Full Text

AN 2003:195048 USPATFULL
TI PPAR-gamma modulator
IN Amemiya, Yoshiya, Yokohama-shi, JAPAN
Wakabayashi, Kenji, Urayasu-shi, JAPAN
Takaishi, Sachiko, Ohta-ku, JAPAN
Fukuda, Chie, Shinagawa-ku, JAPAN
PA SANKYO COMPANY, LIMITED, Tokyo, JAPAN (non-U.S. corporation)
PI US 2003134859 A1 20030717
AI US 2002-278387 A1 20021023 (10)
RLI Continuation-in-part of Ser. No. WO 2001-JP3655, filed on 26 Apr 2001,
UNKNOWN
PRAI JP 2000-129565 20000428
JP 2001-60366 20010305
DT Utility
FS APPLICATION
LN.CNT 6541
INCL INCLM: 514/247.000
INCLS: 514/252.010; 514/255.050; 514/255.060; 514/256.000; 514/340.000;
514/365.000; 514/374.000; 514/375.000; 514/372.000; 514/415.000;
514/416.000; 514/406.000; 514/619.000; 514/616.000; 514/603.000;
514/471.000; 514/310.000; 514/314.000; 514/459.000; 514/457.000;
544/238.000; 544/333.000; 544/295.000; 544/405.000; 546/268.100;
548/146.000; 548/152.000; 548/217.000; 548/207.000; 548/241.000
NCL NCLM: 514/247.000
NCLS: 514/252.010; 514/255.050; 514/255.060; 514/256.000; 514/310.000;
514/314.000; 514/340.000; 514/365.000; 514/372.000; 514/374.000;
514/375.000; 514/406.000; 514/415.000; 514/416.000; 514/457.000;
514/459.000; 514/471.000; 514/603.000; 514/616.000; 514/619.000;
544/238.000; 544/295.000; 544/333.000; 544/405.000; 546/268.100;
548/146.000; 548/152.000; 548/207.000; 548/217.000; 548/241.000
IC [7]
ICM A61K031-506
ICS A61K031-501; A61K031-497; A61K031-4439; A61K031-427; A61K031-422;
A61K031-4035; A61K031-404; A61K031-4709; A61K031-366
IPCI A61K0031-506 [ICM,7]; A61K0031-501 [ICS,7]; A61K0031-497 [ICS,7];
A61K0031-4965 [ICS,7,C*]; A61K0031-4439 [ICS,7]; A61K0031-4427
[ICS,7,C*]; A61K0031-427 [ICS,7]; A61K0031-422 [ICS,7];
A61K0031-4035 [ICS,7]; A61K0031-404 [ICS,7]; A61K0031-403
[ICS,7,C*]; A61K0031-4709 [ICS,7]; A61K0031-366 [ICS,7]
IPCR C07C0233-00 [I,C*]; C07C0233-65 [I,A]; C07C0233-66 [I,A];
C07C0233-75 [I,A]; C07C0233-80 [I,A]; C07C0233-81 [I,A];
C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07C0271-00 [I,C*];
C07C0271-28 [I,A]; C07C0275-00 [I,C*]; C07C0275-14 [I,A];
C07C0275-28 [I,A]; C07C0275-40 [I,A]; C07C0275-50 [I,A];
C07C0311-00 [I,C*]; C07C0311-08 [I,A]; C07C0311-21 [I,A];
C07C0311-46 [I,A]; C07C0311-48 [I,A]; C07C0311-58 [I,A];
C07C0311-64 [I,A]; C07C0335-00 [I,C*]; C07C0335-16 [I,A];
C07C0335-20 [I,A]; C07C0335-26 [I,A]; C07C0335-28 [I,A];
C07D0207-00 [I,C*]; C07D0207-325 [I,A]; C07D0213-00 [I,C*];
C07D0213-40 [I,A]; C07D0213-75 [I,A]; C07D0213-76 [I,A];
C07D0213-82 [I,A]; C07D0215-00 [I,C*]; C07D0215-38 [I,A];
C07D0215-40 [I,A]; C07D0217-00 [I,C*]; C07D0217-22 [I,A];
C07D0231-00 [I,C*]; C07D0231-14 [I,A]; C07D0231-40 [I,A];
C07D0231-42 [I,A]; C07D0231-56 [I,A]; C07D0235-00 [I,C*];
C07D0235-30 [I,A]; C07D0237-00 [I,C*]; C07D0237-20 [I,A];
C07D0239-00 [I,C*]; C07D0239-42 [I,A]; C07D0239-46 [I,A];
C07D0239-545 [I,A]; C07D0241-00 [I,C*]; C07D0241-20 [I,A];
C07D0241-26 [I,A]; C07D0243-00 [I,C*]; C07D0243-38 [I,A];
C07D0261-00 [I,C*]; C07D0261-16 [I,A]; C07D0263-00 [I,C*];
C07D0263-50 [I,A]; C07D0263-58 [I,A]; C07D0277-00 [I,C*];
C07D0277-40 [I,A]; C07D0277-46 [I,A]; C07D0277-50 [I,A];
C07D0277-66 [I,A]; C07D0277-82 [I,A]; C07D0285-00 [I,C*];
C07D0285-135 [I,A]; C07D0285-14 [I,A]; C07D0295-00 [I,C*];
C07D0295-135 [I,A]; C07D0295-185 [I,A]; C07D0295-192 [I,A];
C07D0295-205 [I,A]; C07D0295-215 [I,A]; C07D0295-26 [I,A];
C07D0295-32 [I,A]; C07D0311-00 [I,C*]; C07D0311-24 [I,A];
C07D0333-00 [I,C*]; C07D0333-38 [I,A]; C07D0333-68 [I,A];
C07D0417-00 [I,C*]; C07D0417-04 [I,A]; C07D0471-00 [I,C*];
C07D0471-04 [I,A]; C07D0521-00 [I,C*]; C07D0521-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 112 OF 155 USPATFULL on STN

Full Text

AN 2003:188525 USPATFULL
TI Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IN Barf, Tjeerd, Uppsala, SWEDEN
Emond, Rikard, Saltsjobaden, SWEDEN
Kurz, Guido, Stockholm, SWEDEN
Nilsson, Marianne, Rimbo, SWEDEN
Vallgarda, Jerk, Uppsala, SWEDEN
Zhang, Lian, Sodertalje, SWEDEN
PI US 2003130318 A1 20030710
US 7094792 B2 20060822
AI US 2002-302036 A1 20021122 (10)
PRAI SE 2001-3911 20011122
US 2002-348617P 20020114 (60)
DT Utility
FS APPLICATION
LN.CNT 2475
INCL INCLM: 514/342.000
INCLS: 514/370.000; 546/269.700; 548/181.000; 548/190.000
NCL NCLM: 514/365.000; 514/342.000
NCLS: 548/204.000; 514/370.000; 546/269.700; 548/181.000; 548/190.000
IC [7]
ICM A61K031-4439
ICS A61K031-427; C07D417-02; C07D277-38
IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0031-427
[ICS,7]; C07D0417-02 [ICS,7]; C07D0417-00 [ICS,7,C*]; C07D0277-38
[ICS,7]; C07D0277-00 [ICS,7,C*]
IPCI-2 A61K0031-426 [I,A]; C07D0277-52 [I,A]; C07D0277-00 [I,C*]
IPCR C07D0277-00 [I,C*]; C07D0277-38 [I,A]; C07D0277-52 [I,A];
C07D0417-00 [I,C*]; C07D0417-06 [I,A]; C07D0417-12 [I,A];
C07D0417-14 [I,A]; C07D0521-00 [I,C*]; C07D0521-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 113 OF 155 USPATFULL on STN

Full Text

AN 2003:188486 USPATFULL
TI Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IN Kurz, Guido, Stockholm, SWEDEN
Nilsson, Marianne, Rimbo, SWEDEN
Vallgarda, Jerk, Uppsala, SWEDEN
Williams, Meredith, Uppsala, SWEDEN
PI US 2003130279 A1 20030710
AI US 2002-303158 A1 20021122 (10)
PRAI SE 2001-3913 20011122
SE 2001-4051 20011130
SE 2001-3915 20011122
US 2002-348468P 20020114 (60)
US 2002-348340P 20020114 (60)
DT Utility
FS APPLICATION
LN.CNT 2779
INCL INCLM: 514/232.200
INCLS: 514/252.130; 514/414.000; 514/326.000; 514/422.000; 514/336.000;
514/444.000; 544/145.000; 544/374.000; 546/207.000; 546/280.400;
548/465.000; 548/527.000; 549/059.000; 549/060.000; 514/151.000
NCL NCLM: 514/232.200
NCLS: 514/151.000; 514/252.130; 514/326.000; 514/336.000; 514/414.000;
514/422.000; 514/444.000; 544/145.000; 544/374.000; 546/207.000;
546/280.400; 548/465.000; 548/527.000; 549/059.000; 549/060.000
IC [7]
ICM C07D049-02
ICS C07D413-02; A61K031-5377; A61K031-496; A61K031-453; A61K031-405;
A61K031-4025; A61K031-381
IPCI C07D0049-02 [ICM,7]; C07D0413-02 [ICS,7]; C07D0413-00 [ICS,7,C*];
A61K0031-5377 [ICS,7]; A61K0031-5375 [ICS,7,C*]; A61K0031-496
[ICS,7]; A61K0031-453 [ICS,7]; A61K0031-4523 [ICS,7,C*];
A61K0031-405 [ICS,7]; A61K0031-403 [ICS,7,C*]; A61K0031-4025
[ICS,7]; A61K0031-381 [ICS,7]
IPCR A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-433 [I,C*];
A61K0031-433 [I,A]; A61P0003-00 [I,C*]; A61P0003-00 [I,A];

A61P0009-00 [I,C*]; A61P0009-12 [I,A]; A61P0019-00 [I,C*];
A61P0019-10 [I,A]; A61P0025-00 [I,C*]; A61P0025-00 [I,A];
A61P0027-00 [I,C*]; A61P0027-06 [I,A]; A61P0029-00 [I,C*];
A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-00 [I,A];
C07D0285-00 [I,C*]; C07D0285-08 [I,A]; C07D0285-135 [I,A];
C07D0333-00 [I,C*]; C07D0333-36 [I,A]; C07D0409-00 [I,C*];
C07D0409-12 [I,A]; C07D0409-14 [I,A]; C07D0417-00 [I,C*];
C07D0417-04 [I,A]; C07D0417-06 [I,A]; C07D0417-12 [I,A];
C07D0417-14 [I,A]; C07D0521-00 [I,C*]; C07D0521-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 114 OF 155 USPATFULL on STN

Full Text

AN 2003:188467 USPATFULL
TI Aryl fused azapolycyclic compounds
IN Coe, Jotham Wadsworth, Niantic, CT, UNITED STATES
Brooks, Paige Roanne Palmer, North Stonington, CT, UNITED STATES
PI US 2003130260 A1 20030710
US 7144882 B2 20061205
AI US 2003-336532 A1 20030103 (10)
RLI Continuation of Ser. No. US 2000-514002, filed on 25 Feb 2000, PENDING
Continuation-in-part of Ser. No. US 1999-402010, filed on 28 Sep 1999,
GRANTED, Pat. No. US 6410550 A 371 of International Ser. No. WO
1998-IB1813, filed on 13 Nov 1998, UNKNOWN
PRAI US 1997-70245P 19971231 (60)
DT Utility
FS APPLICATION
LN.CNT 4151
INCL INCLM: 514/212.050
INCLS: 514/214.030; 540/579.000
NCL NCLM: 514/250.000; 514/212.050
NCLS: 514/286.000; 514/295.000; 544/343.000; 546/063.000; 546/097.000;
514/214.030; 540/579.000
IC [7]
ICM A61K031-55
ICS C07D487-04
IPCI A61K0031-55 [ICM,7]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
IPCI-2 A61P0025-30 [I,A]; A61P0025-00 [I,C*]; A61K0031-495 [I,A];
A61K0031-44 [I,A]; C07D0241-36 [I,A]; C07D0241-00 [I,C*];
C07D0221-22 [I,A]; C07D0221-00 [I,C*]
IPCR A61P0025-00 [I,C]; A61P0025-30 [I,A]; A61K0031-44 [I,C];
A61K0031-44 [I,A]; A61K0031-495 [I,C]; A61K0031-495 [I,A];
C07D0221-00 [I,C]; C07D0221-22 [I,A]; C07D0221-24 [I,A];
C07D0241-00 [I,C]; C07D0241-36 [I,A]; C07D0413-00 [I,C*];
C07D0413-04 [I,A]; C07D0471-00 [I,C*]; C07D0471-08 [I,A];
C07D0498-00 [I,C*]; C07D0498-08 [I,A]; C07D0513-00 [I,C*];
C07D0513-08 [I,A]; C07D0521-00 [I,C*]; C07D0521-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 115 OF 155 USPATFULL on STN

Full Text

AN 2003:188465 USPATFULL
TI Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IN Kurz, Guido, Stockholm, SWEDEN
Nilsson, Marianne, Rimbo, SWEDEN
Vallgarda, Jerk, Uppsala, SWEDEN
Williams, Meredith, Uppsala, SWEDEN
PI US 2003130258 A1 20030710
US 7074788 B2 20060711
AI US 2002-302329 A1 20021122 (10)
PRAI SE 2001-3913 20011122
SE 2001-4051 20011130
US 2002-348468P 20020114 (60)
DT Utility
FS APPLICATION
LN.CNT 3006
INCL INCLM: 514/211.150
INCLS: 514/227.800; 514/235.800; 514/254.030; 514/326.000; 514/362.000;
514/363.000; 540/544.000; 544/060.000; 544/134.000; 544/366.000;
546/209.000; 548/133.000; 548/138.000
NCL NCLM: 514/236.200; 514/211.150
NCLS: 544/134.000; 514/227.800; 514/235.800; 514/254.030; 514/326.000;

514/362.000; 514/363.000; 540/544.000; 544/060.000; 544/366.000;
546/209.000; 548/133.000; 548/138.000

IC [7]
ICM A61K031-553
ICS A61K031-541; A61K031-5377; A61K031-496; A61K031-454; A61K031-433;
C07D417-02
IPCI A61K0031-553 [ICM,7]; A61K0031-541 [ICS,7]; A61K0031-5377
[ICS,7]; A61K0031-5375 [ICS,7,C*]; A61K0031-496 [ICS,7];
A61K0031-454 [ICS,7]; A61K0031-4523 [ICS,7,C*]; A61K0031-433
[ICS,7]; C07D0417-02 [ICS,7]; C07D0417-00 [ICS,7,C*]
IPCI-2 C07D0417-06 [I,A]; C07D0417-00 [I,C*]; A61K0031-5377 [I,A];
A61K0031-5375 [I,C*]
IPCR A61K0031-381 [I,C*]; A61K0031-381 [I,A]; A61K0031-433 [I,C*];
A61K0031-433 [I,A]; C07D0285-00 [I,C*]; C07D0285-08 [I,A];
C07D0285-135 [I,A]; C07D0333-00 [I,C*]; C07D0333-36 [I,A];
C07D0409-00 [I,C*]; C07D0409-14 [I,A]; C07D0417-00 [I,C*];
C07D0417-04 [I,A]; C07D0417-06 [I,A]; C07D0417-12 [I,A];
C07D0417-14 [I,A]; C07D0521-00 [I,C*]; C07D0521-00 [I,A];
C07D0417-00 [I,C]; C07D0417-06 [I,A]; A61K0031-5375 [I,C];
A61K0031-5377 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 116 OF 155 USPATFULL on STN

Full Text

AN 2003:174225 USPATFULL
TI Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine
phosphatases
IN Seto, Christopher T., Barrington, RI, UNITED STATES
PI US 2003120073 A1 20030626
AI US 2002-117699 A1 20020405 (10)
PRAI US 2001-286740P 20010425 (60)
DT Utility
FS APPLICATION
LN.CNT 1704
INCL INCLM: 546/014.000
INCLS: 546/335.000; 546/290.000; 546/304.000; 546/314.000; 552/007.000;
558/414.000; 562/430.000; 560/358.000; 556/437.000
NCL NCLM: 546/014.000
NCLS: 546/290.000; 546/304.000; 546/314.000; 546/335.000; 552/007.000;
556/437.000; 558/414.000; 560/358.000; 562/430.000
IC [7]
ICM C07F007-02
ICS C07D213-63; C07D213-72; C07D213-70
IPCI C07F0007-02 [ICM,7]; C07F0007-00 [ICM,7,C*]; C07D0213-63 [ICS,7];
C07D0213-72 [ICS,7]; C07D0213-70 [ICS,7]; C07D0213-00 [ICS,7,C*]
IPCR C07C0059-00 [I,C*]; C07C0059-84 [I,A]; C07C0059-88 [I,A];
C07C0059-90 [I,A]; C07C0069-00 [I,C*]; C07C0069-738 [I,A];
C07C0069-76 [I,A]; C07C0227-00 [I,C*]; C07C0227-16 [I,A];
C07D0209-00 [I,C*]; C07D0209-18 [I,A]; C07D0307-00 [I,C*];
C07D0307-54 [I,A]; C07D0333-00 [I,C*]; C07D0333-24 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 117 OF 155 USPATFULL on STN

Full Text

AN 2003:127896 USPATFULL
TI Protected forms of pharmacologically active agents and uses therefor
IN Lai, Ching-San, Encinitas, CA, UNITED STATES
Wang, Tingmin, San Marcos, CA, UNITED STATES
PA Medinox, Inc. (U.S. corporation)
PI US 2003088111 A1 20030508
AI US 2002-97197 A1 20020312 (10)
RLI Continuation of Ser. No. US 2000-602688, filed on 23 Jun 2000, GRANTED,
Pat. No. US 6355666
DT Utility
FS APPLICATION
LN.CNT 1211
INCL INCLM: 548/494.000
INCLS: 560/011.000; 560/012.000; 558/044.000
NCL NCLM: 548/494.000
NCLS: 558/044.000; 560/011.000; 560/012.000
IC [7]
ICM C07D209-18

ICS C07C039-70
IPCI C07D0209-18 [ICM,7]; C07D0209-00 [ICM,7,C*]; C07C0039-70 [ICS,7]
IPCR A61K0047-48 [I,C*]; A61K0047-48 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 118 OF 155 USPATFULL on STN

Full Text

AN 2003:93646 USPATFULL
TI NK1 receptor antagonists
IN Creswell, Mark Wallace, Chelsea, MI, UNITED STATES
Higginbottom, Michael, Cambridgeshire, UNITED KINGDOM
Horwell, David Christopher, Cambridge, UNITED KINGDOM
Lewthwaite, Russel Andrew, Cambridge, UNITED KINGDOM
Pritchard, Martyn Clive, Cambridgeshire, UNITED KINGDOM
Raphy, Jennifer, Herts, UNITED KINGDOM
PI US 2003065007 A1 20030403
AI US 2002-267477 A1 20021009 (10)
RLI Division of Ser. No. US 2001-868449, filed on 18 Jun 2001, GRANTED, Pat.
No. US 6472418 A 371 of International Ser. No. WO 1999-US29592, filed on
14 Dec 1999, PENDING
PRAI US 1998-112725P 19981218 (60)
DT Utility
FS APPLICATION
LN.CNT 2656
INCL INCLM: 514/307.000
INCLS: 514/357.000; 514/375.000; 514/311.000; 514/406.000; 514/394.000;
514/438.000; 514/415.000; 514/443.000; 514/469.000; 514/471.000;
514/563.000; 514/617.000; 546/146.000; 546/175.000; 546/336.000;
548/217.000; 548/309.700; 548/375.100; 548/494.000; 548/567.000;
549/049.000; 549/076.000; 549/467.000; 562/455.000; 564/161.000;
514/408.000
NCL NCLM: 514/307.000
NCLS: 514/311.000; 514/357.000; 514/375.000; 514/394.000; 514/406.000;
514/408.000; 514/415.000; 514/438.000; 514/443.000; 514/469.000;
514/471.000; 514/563.000; 514/617.000; 546/146.000; 546/175.000;
546/336.000; 548/217.000; 548/309.700; 548/375.100; 548/494.000;
548/567.000; 549/049.000; 549/076.000; 549/467.000; 562/455.000;
564/161.000
IC [7]
ICM C07D333-52
ICS C07D333-22; C07D217-06; C07D217-12
IPCI C07D0333-52 [ICM,7]; C07D0333-22 [ICS,7]; C07D0333-00 [ICS,7,C*];
C07D0217-06 [ICS,7]; C07D0217-12 [ICS,7]; C07D0217-00 [ICS,7,C*]
IPCR C07D0209-00 [I,C*]; C07D0209-20 [I,A]; C07D0401-00 [I,C*];
C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12 [I,A];
C07D0405-00 [I,C*]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
C07D0409-00 [I,C*]; C07D0409-12 [I,A]; C07D0409-14 [I,A];
C07D0413-00 [I,C*]; C07D0413-14 [I,A]; C07D0487-00 [I,C*];
C07D0487-18 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 119 OF 155 USPATFULL on STN

Full Text

AN 2003:33485 USPATFULL
TI Methods of modulating tyrosine protein kinase function with indolinone
compounds
IN Tang, Peng Cho, Moraga, CA, United States
Sun, Li, Foster City, CA, United States
PA Sugen, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6514981 B1 20030204
AI US 1999-283657 19990401 (9)
PRAI US 1998-80422P 19980402 (60)
DT Utility
FS GRANTED
LN.CNT 4145
INCL INCLM: 514/267.000
INCLS: 514/291.000; 514/292.000; 514/293.000; 514/411.000; 514/413.000;
544/250.000; 544/251.000; 546/080.000; 546/081.000; 546/082.000;
546/083.000; 546/085.000; 546/089.000; 548/439.000; 548/440.000;
548/441.000; 548/452.000
NCL NCLM: 514/267.000
NCLS: 514/291.000; 514/292.000; 514/293.000; 514/411.000; 514/413.000;

544/250.000; 544/251.000; 546/080.000; 546/081.000; 546/082.000;
546/083.000; 546/085.000; 546/089.000; 548/439.000; 548/440.000;
548/441.000; 548/452.000

IC [7]
ICM A61K031-404
ICS C07D209-34; C07D403-06; C07D409-06
IPCI A61K0031-404 [ICM,7]; A61K0031-403 [ICM,7,C*]; C07D0209-34
[ICS,7]; C07D0209-00 [ICS,7,C*]; C07D0403-06 [ICS,7]; C07D0403-00
[ICS,7,C*]; C07D0409-06 [ICS,7]; C07D0409-00 [ICS,7,C*]
IPCR C07D0209-00 [I,C*]; C07D0209-34 [I,A]; C07D0209-86 [I,A];
C07D0403-00 [I,C*]; C07D0403-06 [I,A]; C07D0409-00 [I,C*];
C07D0409-06 [I,A]
EXF 544/250; 544/251; 546/80; 546/81; 546/82; 546/83; 546/85; 546/89;
548/439; 548/440; 548/441; 548/452; 514/267; 514/291; 514/292; 514/293;
514/411; 514/414

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 120 OF 155 USPATFULL on STN

Full Text

AN 2002:323195 USPATFULL
TI Methods of modulating protein tyrosine kinase function with substituted
indolinone compounds
IN Tang, Peng Cho, Moraga, CA, UNITED STATES
PA SUGEN, Inc. (U.S. corporation)
PI US 2002183364 A1 20021205
US 6680335 B2 20040120
AI US 2001-13944 A1 20011213 (10)
RLI Continuation of Ser. No. US 1999-407164, filed on 28 Sep 1999, PENDING
PRAI US 1998-102178P 19980928 (60)
DT Utility
FS APPLICATION
LN.CNT 2961
INCL INCLM: 514/339.000
INCLS: 514/414.000; 548/455.000; 546/277.400
NCL NCLM: 514/414.000; 514/339.000
NCLS: 548/455.000; 546/277.400

IC [7]
ICM A61K031-4439
ICS A61K031-404; C07D043-14; C07D043-02
IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0031-404
[ICS,7]; A61K0031-403 [ICS,7,C*]; C07D0043-14 [ICS,7];
C07D0043-02 [ICS,7]
IPCI-2 A61K0031-404 [ICM,7]; A61K0031-403 [ICM,7,C*]; C07D0403-06
[ICS,7]; C07D0403-00 [ICS,7,C*]
IPCR C07D0209-00 [I,C*]; C07D0209-34 [I,A]; C07D0401-00 [I,C*];
C07D0401-10 [I,A]; C07D0403-00 [I,C*]; C07D0403-06 [I,A];
C07D0405-00 [I,C*]; C07D0405-06 [I,A]; C07D0409-00 [I,C*];
C07D0409-10 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 121 OF 155 USPATFULL on STN

Full Text

AN 2002:283298 USPATFULL
TI Non-peptide NK1 receptors antagonists
IN Creswell, Mark Wallace, Chelsea, MI, United States
Higginbottom, Michael, Cambridgeshire, UNITED KINGDOM
Horwell, David Christopher, Cambridge, UNITED KINGDOM
Lewthwaite, Russel Andrew, Cambridge, UNITED KINGDOM
Pritchard, Martyn Clive, Cambridgeshire, UNITED KINGDOM
Raphy, Jennifer, Herts, UNITED KINGDOM
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S.
corporation)
PI US 6472418 B1 20021029
WO 2000037462 20000629
AI US 2001-868449 20010618 (9)
WO 1999-US29592 19991214
20010618 PCT 371 date
PRAI US 1998-112725P 19981218 (60)
DT Utility
FS GRANTED
LN.CNT 2408
INCL INCLM: 514/422.000

INCLS: 548/467.000; 548/490.000; 548/494.000
NCLM: 514/422.000
NCLS: 548/467.000; 548/490.000; 548/494.000
IC [7]
ICM A61K031-404
ICS C07D209-40; C07D209-42
IPCI A61K0031-404 [ICM,7]; A61K0031-403 [ICM,7,C*]; C07D0209-40 [ICS,7]; C07D0209-42 [ICS,7]; C07D0209-00 [ICS,7,C*]
IPCR C07D0209-00 [I,C*]; C07D0209-20 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C*]; C07D0409-12 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C*]; C07D0413-14 [I,A]; C07D0487-00 [I,C*]; C07D0487-18 [I,A]
EXF 548/452; 548/454; 548/469; 548/490; 548/494; 514/414; 514/415; 514/419; 514/422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 122 OF 155 USPATFULL on STN

Full Text

AN 2002:251972 USPATFULL
TI 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
IN Bannani, Yousseff L., Shaker Heights, OH, UNITED STATES
Faghih, Ramin, Lake Forest, IL, UNITED STATES
Dwight, Wesley J., San Diego, CA, UNITED STATES
Vasudevan, Anil, Gurnee, IL, UNITED STATES
Conner, Scott E., Elizabethtown, IN, UNITED STATES
PI US 2002137931 A1 20020926
US 6620839 B2 20030916
AI US 2002-44471 A1 20020111 (10)
RLI Continuation-in-part of Ser. No. US 2001-902925, filed on 11 Jul 2001, PENDING
PRAI US 2000-218084P 20000713 (60)
DT Utility
FS APPLICATION
LN.CNT 5299
INCL INCLM: 544/060.000
INCLS: 544/132.000; 544/139.000; 544/370.000; 544/372.000; 546/210.000; 546/208.000; 548/314.700; 548/570.000
NCL NCLM: 514/426.000; 544/060.000
NCLS: 548/557.000; 544/132.000; 544/139.000; 544/370.000; 544/372.000; 546/208.000; 546/210.000; 548/314.700; 548/570.000
IC [7]
ICM C07D417-14
ICS C07D413-14; C07D043-14; C07D043-02
IPCI C07D0417-14 [ICM,7]; C07D0417-00 [ICM,7,C*]; C07D0413-14 [ICS,7]; C07D0413-00 [ICS,7,C*]; C07D0043-14 [ICS,7]; C07D0043-02 [ICS,7]
IPCI-2 C07D0207-04 [ICM,7]; C07D0207-00 [ICM,7,C*]; A61K0031-40 [ICS,7]
IPCR C07D0207-00 [I,C*]; C07D0207-12 [I,A]; C07D0207-14 [I,A]; C07D0207-24 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0403-00 [I,C*]; C07D0403-04 [I,A]; C07D0403-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-12 [I,A]; C07D0409-00 [I,C*]; C07D0409-12 [I,A]; C07D0417-00 [I,C*]; C07D0417-12 [I,A]; C07D0417-14 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 123 OF 155 USPATFULL on STN

Full Text

AN 2002:236049 USPATFULL
TI Beta3 agonists and uses thereof
IN Dow, Robert L., Waterford, CT, UNITED STATES
Paight, Ernest S., Pawcatuck, CT, UNITED STATES
PI US 2002128247 A1 20020912
US 6939867 B2 20050906
AI US 2002-86588 A1 20020228 (10)
PRAI US 2001-272681P 20010301 (60)
DT Utility
FS APPLICATION
LN.CNT 3087
INCL INCLM: 514/183.000
INCLS: 514/210.010; 514/212.010; 514/316.000; 514/424.000; 514/520.000;

514/603.000; 540/604.000; 546/236.000; 548/542.000; 548/950.000;
 548/965.000; 564/082.000
 NCL NCLM: 514/063.000; 514/183.000
 NCLS: 514/217.040; 514/235.500; 514/253.010; 514/278.000; 514/295.000;
 514/309.000; 514/318.000; 514/326.000; 514/331.000; 514/336.000;
 514/339.000; 514/343.000; 514/357.000; 514/376.000; 514/600.000;
 540/597.000; 544/131.000; 544/360.000; 546/014.000; 546/017.000;
 546/097.000; 546/141.000; 546/194.000; 546/209.000; 546/232.000;
 546/276.700; 546/279.100; 546/283.400; 546/334.000; 548/229.000;
 564/079.000; 514/210.010; 514/212.010; 514/316.000; 514/424.000;
 514/520.000; 514/603.000; 540/604.000; 546/236.000; 548/542.000;
 548/950.000; 548/965.000; 564/082.000
 IC [7]
 ICM A61K031-55
 ICS A61K031-445; A61K031-4015; C07D223-06; C07D211-54; C07D027-36
 IPCI A61K0031-55 [ICM,7]; A61K0031-445 [ICS,7]; A61K0031-4015 [ICS,7];
 C07D0223-06 [ICS,7]; C07D0223-00 [ICS,7,C*]; C07D0211-54 [ICS,7];
 C07D0211-00 [ICS,7,C*]; C07D0027-36 [ICS,7]
 IPCI-2 A61P0001-00 [ICM,7]; A61P0025-00 [ICS,7]; A61K0031-55 [ICS,7];
 A61K0031-535 [ICS,7]; A61K0031-44 [ICS,7]; A61K0031-42 [ICS,7];
 C07D0401-00 [ICS,7]; C07D0413-00 [ICS,7]; C07D0221-22 [ICS,7];
 C07D0221-00 [ICS,7,C*]; C07D0263-00 [ICS,7]
 IPCR C07C0307-00 [I,C*]; C07C0307-10 [I,A]; C07D0209-00 [I,C*];
 C07D0209-52 [I,A]; C07D0213-00 [I,C*]; C07D0213-42 [I,A];
 C07D0295-00 [I,C*]; C07D0295-26 [I,A]; C07D0401-00 [I,C*];
 C07D0401-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-12 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 124 OF 155 USPATFULL on STN

Full Text

AN 2002:194898 USPATFULL
 TI Modified forms of pharmacologically active agents and uses therefor
 IN Lai, Ching-San, Encinitas, CA, United States
 Wang, Tingmin, San Marcos, CA, United States
 PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
 PI US 6429223 B1 20020806
 AI US 2000-715767 20001117 (9)
 RLI Continuation-in-part of Ser. No. US 2000-602688, filed on 23 Jun 2000
 DT Utility
 FS GRANTED
 LN.CNT 1781
 INCL INCLM: 514/411.000
 INCLS: 514/415.000; 514/424.000; 514/517.000; 514/532.000; 514/533.000;
 514/534.000
 NCL NCLM: 514/411.000
 NCLS: 514/415.000; 514/424.000; 514/517.000; 514/532.000; 514/533.000;
 514/534.000
 IC [7]
 ICM A61K031-48
 ICS A61K031-405; A61K031-255; A61K031-40; A61K037-34
 IPCI A61K0031-48 [ICM,7]; A61K0031-405 [ICS,7]; A61K0031-403
 [ICS,7,C*]; A61K0031-255 [ICS,7]; A61K0031-21 [ICS,7,C*];
 A61K0031-40 [ICS,7]; A61K0037-34 [ICS,7]
 IPCR A61K0047-48 [I,C*]; A61K0047-48 [I,A]
 EXF 548/366.7; 514/424; 514/411; 514/415; 514/517; 514/532; 514/533; 514/534
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 125 OF 155 USPATFULL on STN

Full Text

AN 2002:99491 USPATFULL
 TI Beta3 adrenergic receptor agonists and uses thereof
 IN Day, Robert F., Groton, CT, UNITED STATES
 Lafontaine, Jennifer A., Mystic, CT, UNITED STATES
 PI US 2002052392 A1 20020502
 US 6566377 B2 20030520
 AI US 2001-981551 A1 20011017 (9)
 PRAI US 2000-242274P 20001020 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3410
 INCL INCLM: 514/345.000
 INCLS: 514/357.000; 514/365.000; 514/374.000; 514/653.000; 546/329.000;

546/300.000; 548/235.000; 548/205.000; 514/553.000; 514/603.000;
514/520.000; 514/534.000
NCL NCLM: 514/340.000; 514/345.000
NCLS: 514/341.000; 546/269.100; 546/269.700; 546/271.400; 546/272.100;
546/272.400; 546/275.100; 546/275.400; 514/357.000; 514/365.000;
514/374.000; 514/520.000; 514/534.000; 514/553.000; 514/603.000;
514/653.000; 546/300.000; 546/329.000; 548/205.000; 548/235.000
IC [7]
ICM C07D277-28
ICS C07D263-30; C07D213-78
IPCI C07D0277-28 [ICM,7]; C07D0277-00 [ICM,7,C*]; C07D0263-30 [ICS,7];
C07D0263-00 [ICS,7,C*]; C07D0213-78 [ICS,7]; C07D0213-00
[ICS,7,C*]
IPCI-2 A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; C07D0403-10
[ICS,7]; C07D0403-00 [ICS,7,C*]
IPCR C07D0231-00 [I,C*]; C07D0231-12 [I,A]; C07D0233-00 [I,C*];
C07D0233-54 [I,A]; C07D0263-00 [I,C*]; C07D0263-32 [I,A];
C07D0271-00 [I,C*]; C07D0271-06 [I,A]; C07D0271-10 [I,A];
C07D0277-00 [I,C*]; C07D0277-24 [I,A]; C07D0277-28 [I,A];
C07D0285-00 [I,C*]; C07D0285-06 [I,A]; C07D0401-00 [I,C*];
C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0409-00 [I,C*];
C07D0409-14 [I,A]; C07D0413-00 [I,C*]; C07D0413-12 [I,A];
C07D0417-00 [I,C*]; C07D0417-04 [I,A]; C07D0417-12 [I,A];
C07D0417-14 [I,A]; C07D0521-00 [I,C*]; C07D0521-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 126 OF 155 USPATFULL on STN

Full Text

AN 2002:99447 USPATFULL
TI Compounds having reversible inhibiting activity of carnitine
palmitoyl-transferase
IN Giannessi, Fabio, Pomezia (RM), ITALY
Marzi, Mauro, Rome, ITALY
Minetti, Patrizia, Rome, ITALY
De Angelis, Francesco, Rome, ITALY
Tinti, Maria Ornella, Roma, ITALY
Chiodi, Piero, Ciampino, ITALY
Arduini, Arduino, Rome, ITALY
PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (non-U.S. corporation)
PI US 2002052348 A1 20020502
US 6444701 B2 20020903
AI US 2001-986327 A1 20011108 (9)
RLI Division of Ser. No. US 2000-677328, filed on 2 Oct. 2000, PENDING
PRAI IT 1998-MI1075 19980515
WO 1999-IT126 19990511
DT Utility
FS APPLICATION
LN.CNT 2386
INCL INCLM: 514/105.000
INCLS: 514/114.000; 514/120.000; 514/331.000; 514/478.000; 514/561.000;
514/563.000
NCL NCLM: 514/476.000; 514/105.000
NCLS: 514/381.000; 514/546.000; 548/252.000; 548/254.000; 560/129.000;
560/157.000; 562/020.000; 514/114.000; 514/120.000; 514/331.000;
514/478.000; 514/561.000; 514/563.000
IC [7]
ICM A61K031-66
ICS A61K031-445; A61K031-195
IPCI A61K0031-66 [ICM,7]; A61K0031-445 [ICS,7]; A61K0031-195 [ICS,7];
A61K0031-185 [ICS,7,C*]
IPCI-2 A61K0031-195 [ICM,7]; A61K0031-185 [ICM,7,C*]; A61K0031-41
[ICS,7]; C07C0229-22 [ICS,7]; C07C0229-00 [ICS,7,C*]; C07D0257-04
[ICS,7]; C07D0257-00 [ICS,7,C*]
IPCR C07C0229-00 [I,C*]; C07C0229-22 [I,A]; C07C0229-26 [I,A];
C07C0271-00 [I,C*]; C07C0271-12 [I,A]; C07C0271-22 [I,A];
C07C0275-00 [I,C*]; C07C0275-16 [I,A]; C07C0311-00 [I,C*];
C07C0311-06 [I,A]; C07C0335-00 [I,C*]; C07C0335-08 [I,A];
C07D0257-00 [I,C*]; C07D0257-04 [I,A]; C07D0295-00 [I,C*];
C07D0295-15 [I,A]; C07D0453-00 [I,C*]; C07D0453-02 [I,A];
C07F0009-00 [I,C*]; C07F0009-38 [I,A]; C07F0009-54 [I,A];
C07F0009-58 [I,A]; C07F0009-6561 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 127 OF 155 USPATFULL on STN

Full Text

AN 2002:92280 USPATFULL
TI Novel antioxidants
IN Avery, Mitchell Allen, Oxford, MS, UNITED STATES
Pershadsingh, Harrihar A., Bakersfield, CA, UNITED STATES
PI US 2002048798 A1 20020425
US 6664287 B2 20031216
AI US 2001-809518 A1 20010314 (9)
PRAI US 2000-189514P 20000315 (60)
DT Utility
FS APPLICATION
LN.CNT 4281
INCL INCLM: 435/183.000
INCLS: 536/008.000; 549/039.000
NCL NCLM: 514/436.000; 435/183.000
NCLS: 549/020.000; 549/021.000; 549/022.000; 536/008.000; 549/039.000
IC [7]
ICM C07H007-06
ICS C07D339-04; C12N009-00
IPCI C07H0007-06 [ICM,7]; C07H0007-00 [ICM,7,C*]; C07D0339-04 [ICS,7];
C07D0339-00 [ICS,7,C*]; C12N0009-00 [ICS,7]
IPCI-2 A61K0031-385 [ICM,7]; C07D0339-00 [ICS,7]
IPCR C07C0323-00 [I,C*]; C07C0323-52 [I,A]; C07C0327-00 [I,C*];
C07C0327-22 [I,A]; C07C0329-00 [I,C*]; C07C0329-06 [I,A];
C07D0339-00 [I,C*]; C07D0339-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 128 OF 155 USPATFULL on STN

Full Text

AN 2002:81488 USPATFULL
TI 2,3,4,4A-tetrahydro-1H-pyrazino[1,2-A]quinoxalin-5(6H)one derivatives
IN Sabb, Annmarie L., Pennington, NJ, United States
Welmaker, Gregory S., Jackson, NJ, United States
Nelson, James A., Washington Crossing, PA, United States
PA American Home Products Corporation, Madison, NJ, United States (U.S.
corporation)
PI US 6372745 B1 20020416
AI US 1999-455220 19991206 (9)
DT Utility
FS GRANTED
LN.CNT 1078
INCL INCLM: 514/250.000
NCL NCLM: 514/250.000
IC [7]
ICM A61K031-5025
IPCI A61K0031-5025 [ICM,7]
IPCR A61K0031-4985 [I,C*]; A61K0031-4985 [I,A]; C07D0487-00 [I,C*];
C07D0487-04 [I,A]

EXF 544/346; 544/388; 544/389; 514/293; 514/255; 514/250

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 129 OF 155 USPATFULL on STN

Full Text

AN 2002:75447 USPATFULL
TI Compounds having reversible inhibiting activity of carnitine
palmitoyl-transferase
IN Giannessi, Fabio, Pomezia, ITALY
Marzi, Mauro, Rome, ITALY
Minetti, Patrizia, Rome, ITALY
De Angelis, Francesco, Rome, ITALY
Tinti, Maria Ornella, Rome, ITALY
Chiodi, Piero, Ciampino, ITALY
Arduini, Arduino, Rome, ITALY
PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Rome, ITALY (non-U.S.
corporation)
PI US 6369073 B1 20020409
AI US 2000-677328 20001002 (9)
RLI Continuation of Ser. No. WO 1999-IT126, filed on 11 May 1999
DT Utility
FS GRANTED

LN.CNT 2083
 INCL INCLM: 514/305.000
 INCLS: 546/133.000; 546/022.000; 548/252.000; 564/017.000; 564/032.000;
 564/047.000; 564/063.000; 564/079.000; 564/095.000; 514/357.000;
 514/381.000; 514/476.000; 514/588.000; 514/600.000
 NCL NCLM: 514/305.000
 NCLS: 514/357.000; 514/381.000; 514/476.000; 514/588.000; 514/600.000;
 546/022.000; 546/133.000; 548/252.000; 564/017.000; 564/032.000;
 564/047.000; 564/063.000; 564/079.000; 564/095.000
 IC [7]
 ICM A61K031-46
 ICS C07D453-02
 IPCI A61K0031-46 [ICM,7]; C07D0453-02 [ICS,7]; C07D0453-00 [ICS,7,C*]
 IPCR A61K0031-185 [I,C*]; A61K0031-197 [I,A]; A61K0031-41 [I,C*];
 A61K0031-41 [I,A]; A61K0031-66 [I,C*]; A61K0031-66 [I,A];
 A61P0003-00 [I,C*]; A61P0003-04 [I,A]; A61P0003-06 [I,A];
 A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
 A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07C0229-00 [I,C*];
 C07C0229-22 [I,A]; C07C0229-26 [I,A]; C07C0271-00 [I,C*];
 C07C0271-12 [I,A]; C07C0271-22 [I,A]; C07C0275-00 [I,C*];
 C07C0275-16 [I,A]; C07C0307-00 [I,C*]; C07C0307-06 [I,A];
 C07C0311-00 [I,C*]; C07C0311-06 [I,A]; C07C0311-13 [I,A];
 C07C0335-00 [I,C*]; C07C0335-08 [I,A]; C07D0257-00 [I,C*];
 C07D0257-04 [I,A]; C07D0295-00 [I,C*]; C07D0295-15 [I,A];
 C07D0453-00 [I,C*]; C07D0453-02 [I,A]; C07F0009-00 [I,C*];
 C07F0009-38 [I,A]; C07F0009-54 [I,A]; C07F0009-576 [I,A];
 C07F0009-58 [I,A]; C07F0009-6561 [I,A]
 EXF 514/305; 514/357; 514/358; 514/381; 514/476; 514/512; 514/580; 514/588;
 514/600; 514/601; 546/133; 546/22; 548/252; 560/155; 560/179; 564/32;
 564/47; 564/63; 564/17; 564/79; 564/95
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 130 OF 155 USPATFULL on STN

Full Text

AN 2002:61267 USPATFULL
 TI 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3
 receptor ligands and their therapeutic applications
 IN Bennani, Youssef L., Lake Bluff, IL, UNITED STATES
 Faghih, Ramin, Lake Forest, IL, UNITED STATES
 Dwight, Wesley J., San Diego, CA, UNITED STATES
 Vasudevan, Anil, Gurnee, IL, UNITED STATES
 Conner, Scott E., Elizabethtown, IN, UNITED STATES
 PI US 2002035103 A1 20020321
 US 6515013 B2 20030204
 AI US 2001-902925 A1 20010711 (9)
 PRAI US 2000-218084P 20000713 (60)
 DT Utility
 FS APPLICATION

LN.CNT 4659

INCL INCLM: 514/210.180
 INCLS: 514/428.000; 548/574.000
 NCL NCLM: 514/426.000; 514/210.180
 NCLS: 548/557.000; 514/428.000; 548/574.000
 IC [7]
 ICM A61K031-40
 ICS C07D207-04
 IPCI A61K0031-40 [ICM,7]; C07D0207-04 [ICS,7]; C07D0207-00 [ICS,7,C*]
 IPCI-2 C07D0207-04 [ICM,7]; C07D0207-00 [ICM,7,C*]; A61K0031-4025
 [ICS,7]
 IPCR C07D0207-00 [I,C*]; C07D0207-12 [I,A]; C07D0207-14 [I,A];
 C07D0207-24 [I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A];
 C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0403-00 [I,C*];
 C07D0403-04 [I,A]; C07D0403-12 [I,A]; C07D0405-00 [I,C*];
 C07D0405-12 [I,A]; C07D0409-00 [I,C*]; C07D0409-12 [I,A];
 C07D0417-00 [I,C*]; C07D0417-12 [I,A]; C07D0417-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 131 OF 155 USPATFULL on STN

Full Text

AN 2002:50997 USPATFULL
 TI Protected forms of pharmacologically active agents and uses therefor
 IN Lai, Ching-San, Encinitas, United States

Wang, Tingmin, San Marcos, both of, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 635566 B1 20020312
AI US 2000-602688 20000623 (9)
DT Utility
FS GRANTED
LN.CNT 1234
INCL INCLM: 514/411.000
INCLS: 514/415.000; 514/424.000; 514/517.000; 514/532.000; 514/533.000;
514/534.000; 548/366.700; 548/367.100; 548/449.000; 548/486.000;
558/052.000; 558/066.000; 560/060.000; 560/073.000; 564/092.000;
564/167.000; 564/168.000
NCL NCLM: 514/411.000
NCLS: 514/415.000; 514/424.000; 514/517.000; 514/532.000; 514/533.000;
514/534.000; 548/366.700; 548/367.100; 548/449.000; 548/486.000;
558/052.000; 558/056.000; 560/060.000; 560/073.000; 564/092.000;
564/167.000; 564/168.000
IC [7]
ICM A61K031-48
ICS A61K031-405; A61K031-255; A61K031-40; A61K037-34
IPCI A61K0031-48 [ICM,7]; A61K0031-405 [ICS,7]; A61K0031-403
[ICS,7,C*]; A61K0031-255 [ICS,7]; A61K0031-21 [ICS,7,C*];
A61K0031-40 [ICS,7]; A61K0037-34 [ICS,7]
IPCR A61K0047-48 [I,C*]; A61K0047-48 [I,A]
EXF 548/366.7; 548/367.1; 548/486; 548/449; 514/424; 514/532; 514/533;
514/534; 514/411; 514/415; 514/517; 514/575; 558/52; 558/56; 560/60;
560/73; 564/92; 564/160; 564/163
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 132 OF 155 USPATFULL on STN

Full Text

AN 2002:43695 USPATFULL
TI 2-hydroxy-3 - (4-hydroxy-3-sulfonamidophenyl) - propylamines useful as
beta 3 adrenergic agonists
IN Sher, Philip M., Plainsboro, NJ, UNITED STATES
Washburn, William N., Titusville, NJ, UNITED STATES
Godfrey, Jollie D., JR., Trenton, NJ, UNITED STATES
PI US 2002026065 A1 20020228
US 6436914 B2 20020820
AI US 2001-912778 A1 20010725 (9)
RLI Continuation of Ser. No. US 1999-338996, filed on 24 Jun 1999, PENDING
PRAI US 1998-91192P 19980630 (60)
DT Utility
FS APPLICATION
LN.CNT 1683
INCL INCLM: 558/166.000
INCLS: 558/413.000; 560/013.000; 564/090.000; 564/097.000
NCL NCLM: 514/114.000; 558/166.000
NCLS: 514/456.000; 514/466.000; 514/524.000; 514/604.000; 549/351.000;
549/357.000; 549/366.000; 549/443.000; 564/099.000; 558/413.000;
560/013.000; 564/090.000; 564/097.000
IC [7]
ICM C07F009-38
ICS C07C311-08
IPCI C07F0009-38 [ICM,7]; C07F0009-00 [ICM,7,C*]; C07C0311-08 [ICS,7];
C07C0311-00 [ICS,7,C*]
IPCI-2 A61K0031-66 [ICM,7]; A61K0031-18 [ICS,7]; C07D0319-14 [ICS,7];
C07D0319-00 [ICS,7,C*]
IPCR C07C0311-00 [I,C*]; C07C0311-08 [I,A]; C07D0317-00 [I,C*];
C07D0317-62 [I,A]; C07D0317-64 [I,A]; C07D0319-00 [I,C*];
C07D0319-18 [I,A]; C07D0323-00 [I,C*]; C07D0323-00 [I,A];
C07F0009-00 [I,C*]; C07F0009-40 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 133 OF 155 USPATFULL on STN

Full Text

AN 2001:52074 USPATFULL
TI Modulators of peroxisome proliferator activated receptor-gamma, and
methods for the use thereof
IN Evans, Ronald M., La Jolla, CA, United States
Forman, Barry M., La Jolla, CA, United States
PA The Salk Institute for Biological Studies, La Jolla, CA, United States

(U.S. corporation)
 PI US 6214850 B1 20010410
 AI US 1999-255392 19990222 (9)
 RLI Division of Ser. No. US 1995-477493, filed on 7 Jun 1995, now patented,
 Pat. No. US 5939442
 DT Utility
 FS Granted
 LN.CNT 962
 INCL INCLM: 514/357.000
 INCLS: 514/365.000; 514/367.000; 514/222.200; 514/223.200; 514/226.500;
 514/227.500; 514/228.800; 514/241.000; 514/254.000; 514/257.000;
 514/909.000
 NCL NCLM: 514/357.000
 NCLS: 514/222.200; 514/223.200; 514/226.500; 514/227.500; 514/228.800;
 514/241.000; 514/252.100; 514/255.060; 514/257.000; 514/365.000;
 514/367.000; 514/909.000
 IC [7]
 ICM A61K031-44
 ICS A61K031-425; A61K031-54; A61K031-53; A61K031-505
 IPCI A61K0031-44 [ICM,7]; A61K0031-425 [ICS,7]; A61K0031-54 [ICS,7];
 A61K0031-53 [ICS,7]; A61K0031-505 [ICS,7]
 IPCR A61K0031-41 [I,A]; A61K0031-41 [I,C*]; A61K0031-425 [I,A];
 A61K0031-425 [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*];
 A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-53 [I,A];
 A61K0031-53 [I,C*]; A61K0031-54 [I,A]; A61K0031-54 [I,C*]
 EXF 514/357; 514/365; 514/367; 514/222.2; 514/223.2; 514/226.5; 514/227.5;
 514/228.8; 514/241; 514/254; 514/257; 514/909
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 134 OF 155 USPATFULL on STN

Full Text

AN 2001:4758 USPATFULL
 TI Quinoline-indole antimicrobial agents, uses and compositions related
 thereto
 IN Cuny, Gregory D., Hudson, MA, United States
 Hauske, James R., Hopkington, MA, United States
 Heefner, Donald L., Hudson, MA, United States
 Hoemann, Michael Z., Marlborough, MA, United States
 Kumaravel, Gnanasambandam, North Andover, MA, United States
 Melikian-Badalian, Anita, Watertown, MA, United States
 Rossi, Richard F., Norton, MA, United States
 PA Sepracor, Inc., Marlborough, MA, United States (U.S. corporation)
 PI US 6172084 B1 20010109
 AI US 1998-99640 19980618 (9)
 RLI Continuation-in-part of Ser. No. US 1998-45051, filed on 19 Mar 1998
 Continuation-in-part of Ser. No. US 1997-878781, filed on 19 Jun 1997,
 now abandoned
 DT Patent
 FS Granted
 LN.CNT 4837
 INCL INCLM: 514/312.000
 INCLS: 514/313.000; 514/314.000; 546/154.000; 546/159.000; 546/162.000;
 546/167.000
 NCL NCLM: 514/312.000
 NCLS: 514/313.000; 514/314.000; 546/154.000; 546/159.000; 546/162.000;
 546/167.000
 IC [7]
 ICM A61K031-47
 ICS C07D215-38; C07D215-16; C07D215-20; C07D215-36
 IPCI A61K0031-47 [ICM,7]; C07D0215-38 [ICS,7]; C07D0215-16 [ICS,7];
 C07D0215-20 [ICS,7]; C07D0215-36 [ICS,7]; C07D0215-00 [ICS,7,C*]
 IPCR C07D0209-00 [I,C*]; C07D0209-12 [I,A]; C07D0209-14 [I,A];
 C07D0215-00 [I,C*]; C07D0215-52 [I,A]; C07D0401-00 [I,C*];
 C07D0401-04 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C*];
 C07D0405-04 [I,A]; C07D0409-00 [I,C*]; C07D0409-04 [I,A];
 C07D0471-00 [I,C*]; C07D0471-04 [I,A]; C07D0491-00 [I,C*];
 C07D0491-04 [I,A]
 EXF 514/312; 514/313; 514/314; 546/154; 546/159; 546/162; 546/167
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 135 OF 155 USPATFULL on STN

Full Text

AN 1999:75651 USPATFULL
TI Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide
derivatives, their preparation and their use as inhibitors of microsomal
triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
IN Chang, George, Ivoryton, CT, United States
Dorff, Peter H., Norwich, CT, United States
Quallich, George J., North Stonington, CT, United States
PA Pfizer INC., New York, NY, United States (U.S. corporation)
PI US 5919795 19990706
WO 9640640 19961219
AI US 1997-952507 19971128 (8)
WO 1995-IB448 19950607
19971128 PCT 371 date
19971128 PCT 102(e) date
DT Utility
FS Granted
LN.CNT 2439
INCL INCLM: 514/310.000
INCLS: 546/143.000
NCL NCLM: 514/310.000
NCLS: 546/143.000
IC [6]
ICM C07D217-04
ICS C07D401-06; A61K031-47; A61K031-495
IPCI C07D0217-04 [ICM,6]; C07D0217-00 [ICM,6,C*]; C07D0401-06 [ICS,6];
C07D0401-00 [ICS,6,C*]; A61K0031-47 [ICS,6]; A61K0031-495 [ICS,6]
IPCR C07D0217-00 [I,C*]; C07D0217-04 [I,A]; C07D0217-06 [I,A];
C07D0401-00 [I,C*]; C07D0401-06 [I,A]; C07D0401-10 [I,A];
C07D0405-00 [I,C*]; C07D0405-06 [I,A]; C07D0409-00 [I,C*];
C07D0409-06 [I,A]; C07D0413-00 [I,C*]; C07D0413-06 [I,A];
C07D0417-00 [I,C*]; C07D0417-06 [I,A]
EXF 546/143; 514/310
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 136 OF 155 USPATFULL on STN
Full Text

AN 1998:150974 USPATFULL
TI Heterocyclic β -adrenergic agonists
IN Dow, Robert L., Groton, CT, United States
Wright, Stephen W., Groton, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 5843972 19981201
AI US 1997-827289 19970328 (8)
PRAI US 1996-15216P 19960409 (60)
DT Utility
FS Granted
LN.CNT 2356
INCL INCLM: 514/367.000
INCLS: 514/443.000; 514/444.000; 514/469.000; 514/255.000; 514/256.000;
514/258.000; 514/365.000; 514/372.000; 514/373.000; 514/374.000;
514/375.000; 514/415.000; 544/253.000; 548/152.000; 548/217.000;
548/237.000; 549/049.000; 549/058.000; 549/491.000; 549/492.000
NCL NCLM: 514/367.000
NCLS: 514/256.000; 514/365.000; 514/372.000; 514/373.000; 514/374.000;
514/375.000; 514/415.000; 514/443.000; 514/444.000; 514/469.000;
544/253.000; 548/152.000; 548/217.000; 548/237.000; 549/049.000;
549/058.000; 549/491.000; 549/492.000
IC [6]
ICM A61K031-38
ICS A61K031-425; C07D307-02; C07D277-60
IPCI A61K0031-38 [ICM,6]; A61K0031-425 [ICS,6]; C07D0307-02 [ICS,6];
C07D0307-00 [ICS,6,C*]; C07D0277-60 [ICS,6]; C07D0277-00
[ICS,6,C*]
IPCR C07D0209-00 [I,C*]; C07D0209-42 [I,A]; C07D0213-00 [I,C*];
C07D0213-40 [I,A]; C07D0215-00 [I,C*]; C07D0215-48 [I,A];
C07D0307-00 [I,C*]; C07D0307-85 [I,A]; C07D0311-00 [I,C*];
C07D0311-66 [I,A]
EXF 544/253; 548/152; 548/217; 548/237; 549/49; 549/58; 549/491; 549/492;
549/495; 514/443; 514/444; 514/469; 514/255; 514/256; 514/258; 514/365;
514/367; 514/372; 514/373; 514/374; 514/375; 514/415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 137 OF 155 USPATFULL on STN

Full Text

AN 1998:7070 USPATFULL
TI Benzoazine derivative or salt thereof and pharmaceutical composition comprising the same
IN Nagao, Yoshihiro, Narita, Japan
Ito, Yoshikuni, Narita, Japan
Kotake, Jiro, Ichikawa, Japan
Kouda, Tadayuki, Narita, Japan
Honda, Haruyoshi, Tomisato-machi, Japan
Sato, Susumu, Narita, Japan
Matsuda, Hideaki, Abiko, Japan
PA SS Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 5710152 19980120
AI US 1997-791269 19970130 (8)
PRAI JP 1996-14898 19960131
DT Utility
FS Granted
LN.CNT 1080
INCL INCLM: 514/225.200
NCL NCLM: 514/225.200
NCLS: 514/230.500; 514/266.200; 544/050.000; 544/092.000; 544/287.000
IC [6]
ICM C07D417-12
ICS A61K031-54; A61K031-535; A61K031-505
IPCI C07D0417-12 [ICM,6]; C07D0417-00 [ICM,6,C*]; A61K0031-54 [ICS,6]; A61K0031-535 [ICS,6]; A61K0031-505 [ICS,6]
IPCR C07D0417-00 [I,C*]; C07D0417-12 [I,A]
EXF 544/50; 544/92; 544/287; 514/225.2; 514/230.5; 514/254
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 138 OF 155 USPATFULL on STN

Full Text

AN 95:84474 USPATFULL
TI Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
IN Fisher, Michael H., Ringoes, NJ, United States
Mathvink, Robert J., Jersey City, NJ, United States
Ok, Hyun O., Edison, NJ, United States
Parmee, Emma R., Hoboken, NJ, United States
Weber, Ann E., Scotch Plains, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5451677 19950919
AI US 1993-168105 19931215 (8)
RLI Continuation-in-part of Ser. No. US 1993-15689, filed on 9 Feb 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2259
INCL INCLM: 546/138.000
INCLS: 546/290.000; 548/316.400; 548/469.000; 548/541.000; 549/033.000; 549/416.000; 549/475.000; 564/080.000; 564/082.000; 564/083.000; 564/084.000; 564/085.000; 564/086.000; 564/087.000; 564/088.000; 564/089.000; 564/090.000; 564/092.000; 564/096.000; 564/099.000
NCL NCLM: 546/138.000
NCLS: 546/290.000; 548/316.400; 548/469.000; 548/541.000; 549/033.000; 549/416.000; 549/475.000; 564/080.000; 564/082.000; 564/083.000; 564/084.000; 564/085.000; 564/086.000; 564/087.000; 564/088.000; 564/089.000; 564/090.000; 564/092.000; 564/096.000; 564/099.000
IC [6]
ICM C07D455-00
ICS C07D307-10; C07C311-01
IPCI C07D0455-00 [ICM,6]; C07D0307-10 [ICS,6]; C07D0307-00 [ICS,6,C*]; C07C0311-01 [ICS,6]; C07C0311-00 [ICS,6,C*]
IPCR C07C0311-00 [I,C*]; C07C0311-13 [I,A]; C07C0311-14 [I,A]; C07C0311-21 [I,A]; C07C0311-29 [I,A]; C07C0311-44 [I,A]; C07C0311-46 [I,A]; C07C0311-47 [I,A]; C07D0209-00 [I,C*]; C07D0209-08 [I,A]; C07D0209-12 [I,A]; C07D0209-34 [I,A]; C07D0213-00 [I,C*]; C07D0213-65 [I,A]; C07D0213-71 [I,A]; C07D0213-73 [I,A]; C07D0215-00 [I,C*]; C07D0215-36 [I,A]; C07D0261-00 [I,C*]; C07D0261-20 [I,A]; C07D0277-00 [I,C*]; C07D0277-74 [I,A]; C07D0285-00 [I,C*]; C07D0285-14 [I,A];

C07D0307-00 [I,C*]; C07D0307-79 [I,A]; C07D0307-82 [I,A];
C07D0311-00 [I,C*]; C07D0311-08 [I,A]; C07D0317-00 [I,C*];
C07D0317-62 [I,A]; C07D0319-00 [I,C*]; C07D0319-18 [I,A];
C07D0333-00 [I,C*]; C07D0333-34 [I,A]; C07D0333-54 [I,A];
C07D0333-62 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A];
C07D0405-00 [I,C*]; C07D0405-12 [I,A]; C07D0409-00 [I,C*];
C07D0409-04 [I,A]; C07D0409-12 [I,A]; C07D0413-00 [I,C*];
C07D0413-12 [I,A]; C07D0417-00 [I,C*]; C07D0417-12 [I,A];
EXF 514/604; 514/605; 564/80; 564/82; 564/83; 564/84; 564/85; 564/86;
564/87; 564/88; 564/89; 564/90; 564/92; 564/96; 564/99; 546/290;
546/138; 548/469; 548/541; 548/316.4; 549/33; 549/475; 549/416
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 139 OF 155 USPAT2 on STN

Full Text

AN 2006:54662 USPAT2
TI PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS
IN Satyam, Apparao, Nicholas Piramal Research Centre, 1 Nirlon Complex,
Near NSE, Goregaon East, Mumbai, INDIA 400063
PA Nicholas Piramal India Ltd., Mumbai, INDIA, 400013 (non-U.S.
corporation)
PI US 2006205674 A2 20060914
AI US 2005-213396 A1 20050826 (11)
RLI A substitute for Ser. No. US 2005-213396, filed on 26 Aug 2005, Pending
PRAI IN 2005-7792005 20050701
DT Utility
FS APPLICATION
LN.CNT 4851
INCL INCLM: 514/019.000
INCLS: 514/242.000; 514/355.000; 514/476.000; 514/255.040; 514/049.000;
514/510.000; 514/396.000; 514/397.000; 514/172.000; 514/378.000;
514/406.000; 514/394.000; 514/338.000; 514/327.000; 514/419.000;
514/509.000
NCL NCLM: 514/019.000
NCLS: 514/049.000; 514/172.000; 514/242.000; 514/255.040; 514/327.000;
514/338.000; 514/355.000; 514/378.000; 514/394.000; 514/396.000;
514/397.000; 514/406.000; 514/419.000; 514/476.000; 514/509.000;
514/510.000
IC IPCI A61K0038-04 [I,A]; A61K0031-7072 [I,A]; A61K0031-7042 [I,C*];
A61K0031-455 [I,A]; A61K0031-53 [I,A]; A61K0031-4172 [I,A];
A61K0031-4178 [I,A]; A61K0031-4164 [I,C*]; A61K0031-337 [I,A];
A61K0031-21 [I,A]
IPCI-2 A61K0038-04 [I,A]; A61K0031-7072 [I,A]; A61K0031-7042 [I,C*];
A61K0031-455 [I,A]; A61K0031-53 [I,A]; A61K0031-4172 [I,A];
A61K0031-4178 [I,A]; A61K0031-4164 [I,C*]; A61K0031-337 [I,A];
A61K0031-21 [I,A]
IPCR A61K0038-04 [I,C]; A61K0038-04 [I,A]; A61K0031-21 [I,C];
A61K0031-21 [I,A]; A61K0031-337 [I,C]; A61K0031-337 [I,A];
A61K0031-4164 [I,C]; A61K0031-4172 [I,A]; A61K0031-4178 [I,A];
A61K0031-455 [I,C]; A61K0031-455 [I,A]; A61K0031-53 [I,C];
A61K0031-53 [I,A]; A61K0031-7042 [I,C]; A61K0031-7072 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 140 OF 155 USPAT2 on STN

Full Text

AN 2005:313144 USPAT2
TI Substituted furo[2,3-b]pyridine derivatives
IN Toupenca, Richard B., South Plainfield, NJ, UNITED STATES
Debenham, John S., Scotch Plains, NJ, UNITED STATES
Goulet, Mark T., Westfield, NJ, UNITED STATES
Madsen-Duggan, Christina B., Scotch Plains, NJ, UNITED STATES
Walsh, Thomas F., Watchung, NJ, UNITED STATES
Shah, Shrenik K., Metuchen, NJ, UNITED STATES
PA Merck & Co., Inc., Rahway, NJ, UNITED STATES (U.S. corporation)
PI US 7091216 B2 20060815
WO 2004012671 20040212
AI US 2003-521821 20030801 (10)
WO 2003-US24280 20030801
20050121 PCT 371 date
PRAI US 2003-456332P 20030320 (60)
US 2002-400852P 20020802 (60)
DT Utility

FS GRANTED
LN.CNT 6267
INCL INCLM: 514/302.000
INCLS: 546/115.000
NCL NCLM: 514/302.000
NCLS: 546/115.000
IC IPCI C07D0491-02 [ICM,7]; C07D0491-00 [ICM,7,C*]; A61K0031-4741
[ICS,7]; A61K0031-4738 [ICS,7,C*]
IPCI-2 A61K0031-44 [I,A]; C07D0409-02 [I,A]; C07D0409-00 [I,C*]
IPCR A61K0031-4738 [I,C*]; A61K0031-4741 [I,A]; C07D0491-00 [I,C*];
C07D0491-02 [I,A]
EXF 514/302; 546/115
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d an ti in pi kwic 136 138

L20 ANSWER 136 OF 155 USPATFULL on STN

Full Text

AN 1998:150974 USPATFULL
TI Heterocyclic β -adrenergic agonists
IN Dow, Robert L., Groton, CT, United States
Wright, Stephen W., Groton, CT, United States
PI US 5843972 19981201
CLM What is claimed is:
. one to three substituents, each substituent is independently selected
from the group consisting of hydroxy, fluoro, chloro, iodo, bromo,
CF.sub.3, **sulfonamide**, (C.sub.1 -C.sub.4)alkyl, (C.sub.1
-C.sub.4)alkoxy, carboxy, hydroxyalkyl, (C.sub.1 -
C.sub.4)alkoxycarbonyl, (C.sub.1 -C.sub.4)thioalkyl, sulfonyl, sulfinyl,
amino, --NH--CO--(CH.sub.2).sub.a -(phenyl), --NH--CO--(C.sub.1
-C.sub.10)alkyl, --NH--SO.sub.2 --(CH.sub.2).sub.a -(phenyl).
substituted with one to three substituents, each independently selected
form the group consisting of hydroxy, fluoro, chloro, iodo, bromo,
CF.sub.3, **sulfonamide**, (C.sub.1 -C.sub.4)alkyl, (C.sub.1
-C.sub.4)alkoxy, carboxy, hydroxyalkyl, (C.sub.1 -
C.sub.4)alkoxycarbonyl, (C.sub.1 -C.sub.4)thioalkyl, sulfonyl, sulfinyl,
amino, --NH--CO--(CH.sub.2).sub.a -(phenyl), --NH--CO--(C.sub.1
-C.sub.10)allyl, --NH--SO.sub.2 --(CH.sub.2).sub.a -(phenyl).
8. A method of treating a condition selected from the group consisting
of diabetes, hyperglycemia and **obesity** in a mammal, comprising
administering to a mammal in need of such treatment an amount of a
compound of formula.

L20 ANSWER 138 OF 155 USPATFULL on STN

Full Text

AN 95:84474 USPATFULL
TI Substituted phenyl sulfonamides as selective β 3 agonists for the
treatment of diabetes and obesity
IN Fisher, Michael H., Ringoes, NJ, United States
Mathvink, Robert J., Jersey City, NJ, United States
Ok, Hyun O., Edison, NJ, United States
Parmee, Emma R., Hoboken, NJ, United States
Weber, Ann E., Scotch Plains, NJ, United States
PI US 5451677 19950919
CLM What is claimed is:
8. A compound of claim 1 which is N-[4-[2-[[2-hydroxy-3-(4-
hydroxyphenoxy)propyl]amino]ethyl]phenyl]benzenesulfonamide
N-[4-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-4-
iodobenzenesulfonamide N-[4-[2-[[2-hydroxy-3-(4-
hydroxyphenoxy)propyl]amino]ethyl]phenyl]-2-naphthalenesulfonamide
N-[4-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-4-
(benzo-2,1,3-thiadiazole)sulfonamide N-[4-[2-[[2-hydroxy-3-(4-
hydroxyphenoxy)propyl]amino]ethyl]phenyl]-2phenylethanesulfonamide
N-[4-[2-[[3-(4-fluorophenoxy)-2-hydroxypropyl]amino]ethyl]phenyl]-4-
benzenesulfonamide N-[4-[2-[[3-[(2-amino-5-pyridinyl)oxy]-2-
hydroxypropyl]amino]ethyl]phenyl]-2-naphthalenesulfonamide
N-[4-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-3-
quinolinesulfonamide N-[4-[2-[[2-hydroxy-3-(4-
hydroxyphenoxy)propyl]amino]ethyl]phenyl]4-[(5-
methoxycarbonyl)pentanoyl]amino]benzenesulfonamide N-[4-[2-[[2-hydroxy-3-
(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-4-[(5-

hydroxycarbonyl)pentanoyl]amino]benzenesulfonamide N-[4-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-4-(hexylaminocarbonylamino)benzenesulfonamide N-[4-[2-[[2-hydroxy-3-phenoxypropyl]amino]ethyl]phenyl]-4-chlorobenzenesulfonamide N-[4-[2-[[2-hydroxy-3-(3-cyanophenoxy)propyl]amino]ethyl]phenyl]-3quinolinesulfonamide N-[4-[2-[[3-(4-amino-3-cyanophenoxy)-2-hydroxypropyl]amino]ethyl]phenyl]-3-quinolinesulfonamide N-[4-[2-[[2-hydroxy-3-[(3-hydroxymethyl)phenoxy]propyl]amino]ethyl]phenyl]-3-quinolinesulfonamide N-[4-[2-[[2-hydroxy-3-(3-pyridyloxy)propyl]amino]ethyl]phenyl]-3-quinolinesulfonamide N-[4-[2-[[2-hydroxy-3-(3-pyridyloxy)propyl]amino]ethyl]phenyl]-4-iodobenzenesulfonamide N-[4-[2-[[3-[(2-amino-5-pyridinyl)oxy]-2-hydroxypropyl]amino]ethyl]phenyl]-4-isopropylbenzenesulfonamide.

12. A method for the treatment of **obesity** which comprises administering to an **obese** patient an effective amount of a compound of claim 1.

18. A composition for the treatment of diabetes or **obesity** or for lowering triglyceride or cholesterol levels or increasing high density lipoprotein levels or for decreasing gut motility or for.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

56.23

128.73

STN INTERNATIONAL LOGOFF AT 00:52:42 ON 06 AUG 2007